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SUMMARY OF THESIS 
The application of Solid-Phase Extraction (SPE) and Supercritical Fluid Extraction 
(SFE) were evaluated for the determination of various drugs of abuse analyzed in the 
field of forensic toxicology. Three biological matrices (blood, urine and hair) were 
investigated for the recovery of various commonly abused drugs. 
The current SPE method used in the routine laboratory was optimized for the 
extraction of benzodiazepines in whole blood and applied to authentic forensic case 
samples. The optimized method and the routine method were then compared using 
authentic forensic samples. . Successful methodology developed provided an 
efficient, less time consuming, reproducible and more robust alternative to the 
current routine method. 
The use of SFE was applied to blood and urine samples for the extraction of cocaine 
and its metabolites, benzoylecgonine and ecgonine methyl ester. The method 
developed showed that the drugs can be successfully extracted from various 
biological matrices such as blood and urine with comparable results to SPE methods. 
Forensic case samples positive for morphine were extracted using SFE and SPE 
techniques and the results compared. A good correlation was observed between the 
two methods rendering them compatible for the detection of morphine in whole 
blood. 
Hair analysis was investigated using both SPE and SFE techniques. A study was 
carried out to determine whether a correlation existed between self-report data and 
hair analysis for five amphetamines (metamphetamine, amphetamine methylene-
Summary iii 
dioxyamphetamine, methylenedioxyethylamphetamine and methylenedioxymeth-
amphetamine). SPE methods developed proved that all five amphetamines could be 
extracted from human hair. However, a correlation did not exist between self-report 
and hair analysis data. Inter-laboratory studies carried out between two laboratories 
showed that both produced similar results for case samples containing 
amphetamines. 
For the extraction of amphetamines (MDA, MDMA and MDEA) and cocaine and its 
metabolite from hair, developed SFE methods were applied. Amphetamines in hair 
were successfully extracted from spiked and authentic hair samples thought to 
contain amphetamines using developed SFE methods. Cocaine and ecgonine methyl 
ester were also successfully extracted from spiked human hair. 
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Chapter One: Supercritical Fluids 
1. SUPERCRITICAL FLUIDS 
1.1 LITERATURE REVIEW 
1.1.1 INTRODUCTION 
page 1 
Over the past decade, there has been a growmg interest 111 supercritical fluid 
extraction (SFE) as an alternative to conventional sample preparation techniques. 
SFE is a relatively new analytical technique based on the use of supercritical fluids 
(SF) for the isolation of analytes from various matrices. It is attracting great interest 
because of the increasing need for a simple, rapid, environmentally friendly, 
automated and selective extraction method.' 
The principal goal of analytical chromatography is to provide precise, accurate, rapid 
and inexpensive measurements of unknown and target chemical species in complex 
samples.2 Although research to improve the sensitivity, selectivity, speed, and 
separating capabilities of analytical techniques has increased, less attention has been 
focused on the preparation of the sample before introduction into the 
chromatographic system. 
The identity or concentration of a compound is determined through chromatographic 
analysis and extraction of the target analytes from the matrix is necessary for 
preparation of the sample prior to the chromatographic process. Ideally, the 
extraction and preparation should yield quantitative and high recoveries of the target 
analyte, at low cost and risk to the environment. 
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The above criteria for ideal extraction and sample preparation resulted in the 
implementation of SF as a replacement for liquid solvents in the extraction process. 
Its combined gas-like mass transfer and liquid-like solvating characteristics first led 
analytical chemists to use them as chromatographic mobile phases and later as fluids 
capable of removing compounds from solid samples. 
1.1.2 HISTORY 
Supercritical fluid technology essentially involves the exploitation of the unusual 
variations in solubility with pressure and temperature immediately above the critical 
point of a volatile solvent. Supercritical fluids (SF) were first researched in 1822 by 
Baron Charles Cagniard de ia Tour.' He discovered the critical point of a substance 
by sealing a liquid and a flint ball into a cannon barrel, heating and rocking it, while 
listening for changes in the sound of the rolling ball or sound changes made when the 
barrel was tapped. Discontinuities in the sound led him to describe the point known 
then as the "Cagniard de la Tour" point. which today is known as the critical point. 
By the mid to late 1800s, Dr Thomas Andrews4 carried out a series of investigations 
on the phase behaviour of CO2• Later in his famous Bakerian Lecture in 1809 he 
described his experimental apparatus and observations of the critical properties of 
CO2• Andrews reported that when carbonic acid is partially liquefied by pressure, 
while simultaneously raising the temperature gradually to 88 of, the line of the 
liquid-gas demarcation surface fades, loses its curvature and then disappears to exist 
as a homogenous fluid. 
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Decreasing the pressure or slightly lowering the temperature of the extraction 
apparatus, cause the appearance of t1icking striae throughout the entire mass of the 
fluid. Temperatures above 88°F, showed no apparent liquefaction of the carbonic 
acid and no separation of the two distinct forms of matter, could be effected, even 
when a pressure of 300 or 400 atmospheres was applied. The critical point of CO2 
was reported by Andrews as 30.92°e and 73.0 atm, which is in close agreement to 
presently accepted values of 31.1 °C and 72.8 atm. 
The ability of a SF to dissolve low vapour pressure solid materials using methyl 
halides in supercritical ethanol whik increasing the pressure, was first reported by 
Hannay and Hogarth in 1879.5 They modified the experimental apparatus used by 
Andrews 7 for an experiment carried out in a small-diameter glass tube, to monitor 
the effect of pressure changes which resulted in inorganic salts dissolving in or 
precipitating from ethanol at a temperature above its critical temperature. 
In the same year, Amagat described a method of compressing gases to 400 atm using 
mercury columns extending to the bottom of a mine shaft.6 This was followed by 
Cailletet in 1891, who described the generation of high pressure with a mercury 
column reaching to the top of the Eiffel Tower. 7 
The earliest published work on liquid CO2 as a solvent was by Gore in 1861.8 He 
found naphthalene and camphor to be soluble in liquid CO2, but conclude that CO2 
was a very feeble solvent of substances in general, after testing a small number of 
organic compounds. In 1896, Villard described SF ability of methane, ethylene, CO2 
and nitrous oxide to dissolve numerous liquid and solid hydrocarbons.9 Several years 
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later, Buchner carried out qualitative studies on SFs over a wide temperature range to 
observe cloud points, melting points, freezing points and the number of phases 
present for solubility determination. lu 
Researchers of the late 1800s and early 1900s met and overcame many obstacles 
found in carrying out their studies. By the early 1960s, the solubility of naphthalene 
and a variety of other gases were studied. Studies of SFs have continued over the 
decades to the present day, with numerous researchers contributing to this new 
application. 
In 1962, Kelps et at first reported the use of a SF as a chromatographic mobile phase 
by using difluoromethane and monochlorodifluoromethane to separate nickel 
porphyrin isomers. II Sie e/ ai investigated the lIse of carbon dioxide isopropanol, n-
pentane and other materials as mobile phases with packed columns. 12-14 Giddings et 
al demonstrated the migration of carotenoids, sugars, amino acids, nucleotides, 
various polymers and other solutes using high pressure gas chromatography with 
CO2 or ammonia as the mobile phase.
15
-
16 Their work showed great potential for this 
application of SFs. 
Numerous applications of the use of SFs have been developed which include food, 
oils, coffee, tobacco and spices. This led to the building of the first large-scale 
production plant in 1979 by Hag, using SFE. It was used for the removal of caffeine 
from green coffee beans.17 By the 1980s, SFE as an independent sample preparation 
technique became attractive to the analytical chemist and is still at the forefront of 
technology today. 
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1.1.3 DEFINITION OF A SUPERCRITICAL FLUID 
By definition, a SF is a substance that at a temperature and pressure greater than its 
critical temperature (Tc) and pressure (Pc), is a gas-like, compressible fluid that takes 
the shape of and fills its container. It is not a liquid but has liquid-like densities (0.1 
to Ig/mL) and solvating power. IS 
1.1.3.1 Supercritical Fluids 
SFs are usually used at temperatures and pressures significantly higher than their 
critical values. Therefore, choosing an ideal SF, depends on the polarity and thermal 
stability of the analyte(s), the solvent strength and selectivity of extracted 
components at adequate operating temperatures and the limitations of the analysis 
instrumentation associated with high critical pressures required for some SFs.19 The 
critical pressure determines the importance of the solvent power of the fluid, hence 
fluids with high critical pressures arc more likely to dissolve polar components than 
fluids with lower critical pressures. Hence, critical temperature of a SF is influenced 
by the stability of the component to be extracted. 
A wide range of SFs have been used in SFE covering a range of critical temperatures 
and pressures, molecular sizes and polarities. Among these, carbon dioxide seems to 
be the most widely used because of its moderate critical pressure (73.8 atm) and low 
critical temperature (31.1 0c). 
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Table 1.1 Critical Parameters of commonly used SFs.2u 
Fluid Critical Temp Critical Pressure Solubility 
(OC) (atm) Parameters 
CO2 31 73 10.7 
N20 36 72 10.6 
NHJ I"') ..l_ 112 13.2 
MEOH 240 78 14.4 
CCIFJ 29 38 7.8 
Ethane 32 48 6.6 
Ethylene 10 51 6.6 
1.1.3.2 Carbon Dioxide 
An SF such as CO2 has a hydrocarbon like solvent strength at typical conditions, so it 
is an appropriate solvent for lipophillic substances. 21 Among the fluids shown in 
Table 1.1, CO2 is the most frequently used for SFE for the following reasons. I 
• Easy temperature and pressure manipulation (31°C and 73.8 atm) 
• Good solvent strength and miscibility with most solvents 
• Compatible temperature with the thermal stability of solutes 
• Low surface tension and viscosity 
• Odourless, non-toxic, non-flammable and non-corrosive 
• Readily available in high purity 
• High diffusivity 
• Economical (inexpensive) 
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1.1.3.3 SF Modifiers 
Supercritical CO2 has been the choice for most SFE studies, because of these 
attractive practical characteristics. It is an excellent extraction medium for nonpolar 
species and is reasonably good for moderately polar species. However, one of the 
disadvantages is that it is less useful for more polar compounds. One way to increase 
the polarity of a SF is to add small amounts of polar liquid solvents (e.g. methanol, 
acetonitrile or water) to optimise analyte recovery during SFE. These polar liquid 
solvents are known as cosolvent, moderators, modifiers or entrainers. '7•22 
SFE modifier can have dramatic effects on the analytes and matrices. They are a 
rapidly developing area of study in SFE technology in which new permutations and 
combinations are virtually unlimited. Most modifiers have solvent parameters 
greater than CO2 so they are used to enhance the solubility properties and increase 
the yield or decrease the pressure and solvent requirements in the extraction of polar 
molecules. 
The modifier exerts its effect by interacting with the analyte or matrix complex to 
promote rapid desorption into the SF.23 The addition of minute amounts of modifier 
to a SF, can dramatically increase the solubility and critical properties and increase 
the solvent strength while maintaining its adjustably.17 This increase can only be 
observed with the use of solvents with polar chemical functions. Yang et ai, 
demonstrated that the combination of modifier and high temperature is highly 
effective.24 
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The use of different extraction pressures, entrainers and fluids with varying polarity 
is valuable in allowing class selective extraction methods to be developed for various 
compounds. 2o•25 The modifier can be either added to the sample in the extraction cell 
prior to SFE, so that the modifier is swept directly from the cell when the SF starts to 
circulate through the sample or mixed with the CO2 where it is continuously passed 
through the matrix. 
1.1.3.4 SF Properties 
SFs have numerous advantages necessary to meet the criteria for adequate extraction 
and preparation techniques. 15. 26·28 Some of these are listed below: 
• Solvent strengths approaching those of liquid solvents, with low viscosity and high 
solute diffusivity, thus better mass transfer characteristics than liquids and faster 
extractions. 
• Increase in pressure, results in an increased density which optimises the extraction 
conditions for the target analyte by changing the extraction pressure or temperature. 
• Class-selective extractions of particular compound classes are possible with the 
extraction of the same sample at different pressures 
• Relatively inert, pure and non-toxic 
• Inexpensive per extraction 
• Selective by adjusting pressure, temperature and degree of modifier 
• Diffusion properties permit rapid penetration and extraction from the sample 
• CO2 has a relatively low critical temperature that allows good stability of thermally 
unstable components 
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• Reduction or elimination of liquid solvents waste being generated and toxic 
solvent exposure in the laboratory 
1.1.4 THERMODYNAMIC PROPERTIES 
The thermodynamic state of a pure component is determined by the pressure (P), 
volume (V) and temperature (T). 17.29.30 This combination of variables is known as 
the state equation represented by a surface in the three dimensional plotting ofP,V,T. 
Depending on the value of these parameters, a pure component will be either a solid, 
liquid or gas. 
The phase diagram in Figure 1.1 shows the three phase transitions of a solid, liquid 
and gas boundaries. These transitions are accompanied by physical properties of 
increased pressure and temperature th'1t move along the gas liquid boundary. Due to 
thermal expansion, the liquid becomes less dense and the gas becomes denser 
because of increased pressure.31 When the critical point (Cpt) of a substance is 
reached, the densities of the two phases are identical and the distinction between the 
gas and liquid phase is absent. The substance now is no longer a gas or a liquid but 
described as a fluid. 
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Figure 1.1 Schematic phase diagram of a single substance. 
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A supercritical state is obtained at temperatures and pressures superior to those of 
critical temperature (T c) and pressure (Pc). The Cpt or Cst corresponding to the T c, 
Pc and critical density (Pc) is represented as C, which acts as an intermediate state 
between a liquid and a gas. Another important parameter is the critical volume eVc) 
for one mole of substance. With an increase of temperature and pressure above a 
substances critical parameters, it becomes known as the supercritical state. If one of 
the parameters falls under its critical value while the other remains superior to its 
critical value, the substance is in a subcritical state. The critical parameters of 
various substances used as SF during analysis is listed in Table 1.2. The most 
commonly used substance is Carbon dioxide (C02), due to its convenient 
supercritical properties.29 
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1.1.5 PHYSICOCHEMICAL PROPERTIES 
SFs possess physical properties intermediate between those having gas-like transfer 
and liquid-like solvating characteristics. These properties demonstrate favourable 
behaviour for the transportation of a solute and are int1ucnced by diffusion, viscosity, 
density and solubility.l~ Table 1.2 shows physical parameters were SFs have densities 
comparable to liquids, viscosities comparable to gases and diffusivities comparable 
between liquid and gases. 
Table 1.2 Physical parameters for Gas, SFs and a liquid.J2 
PHASE DENSITY (g/ml) VISCOSITY DIFFUSION (m2. s) 
Gas 0.001 0.00005-0.00035 0.01-1.0 
Supercritical fluid 0.2-0.9 0.0002-0.001 0.00033-0.00001 
Liquid 0.8-1.0 0.003-0.24 0.000005-0.00002 
Having these properties have led analytical chemists to use SF as a chromatographic 
mobile phase that is demonstrated in SFC and its use as an extractant which is 
demonstrated in SFE.33 The most important factor to consider in both techniques is 
the solubility of the analytes of interest. Regardless of the extraction conditions, the 
solvent strength of a liquid is essentially constant. However, the solvent strength of a 
SF is dependent on the temperature and pressure used for the extraction.34 
1.1.5.1 Viscosity 
SFs are slightly viscous with viscosities higher than those of gases despite of their 
high densities. This property causes a pronounced viscosity during SFE, which 
causes an obvious pressure drop in an extraction cell.I The viscosity of a SF 
increases with pressure, but approaches that of a liquid less rapidly than the density. 
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Fluids in a supercritical state have viscosities inferior to that of a liquid even if very 
high pressures are used. 
1.1.5.2 Density 
Solvating power, diffusion and viscosity are all functions of density. Therefore, 
altering the density of the fluid, alters the properties of the fluid from gas-like to 
liquid-like form without crossing the gas/liquid equilibrium line. In addition, large 
changes in SF densities and solvating power effect small changes in pressure because 
the compressibility of a SF is largely above the TC. IJ·21 The density is directly related 
to the solvent strength of a SF hence, the SF solvating ability can easily be modified 
for a particular species by changing the extraction pressure and temperature. 17. 22. 26 
1.1.5.3 Solubility 
The solvent strength of a liquid is essentially constant regardless of the extraction 
conditions, but the solvent strength of a SF depends on the pressure and temperature 
used for the extraction. 34 At constant temperatures, extraction at lower pressures will 
favour less polar analytes, while extraction at higher pressures will favour more polar 
and higher molecular weight analytes. 35 This allows the extraction to be optimised 
for a particular compound class by changing the pressure and to a lesser extent, the 
temperature, of the extraction. This solvent strength variation is demonstrated by the 
Hildebrand solubility parameter on temperature and pressure for carbon dioxide in 
Figure 1.2. 
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Figure 1.2 Dependence of the Hildebrand solubility parameter on temperature and 
pressure for supercritical CO/5 
10.U-t---:;;;;;;::::------------=---____ ---. 
9. Pressure (atm) 
8. 
t::! 5 . 
..,.... 
730 r"l E40 
u' 
::::. 
COl 
U 440 
~3. 
III 
I-
~ 
-~ 290 E f! 2.0 
COl 
c.. • 
.f' • 
• :c • ~I.O • 
r.n • 145 
0.9 • 
• 
0.8 • 
·_Tc 100 
0.7 • 
• 
0.6 • 80 
• 
0.5 20 60 180 220 
The choice of SFE conditions are pressure and temperature based, so that the target 
analytes have the highest solubility in SF.35 The optimum conditions can be 
approximated if the solubility parameter of the analytes and the correlations are 
known; like the one proposed by Giddings ls : 
8 = 1.25 p/~ (p '/p ,I) 
Where: the Hildebrand solubility parameter is 8 = (cal cm,3) Yz, pc is the critical 
pressure of the fluid (atm), p rg is the density of the gas and P rI is the density of the 
liquid. This equation also indicates that the polarity of the SF depends on its state by 
the relationship P rjp rI and on its nature (chemical efTect from the term 1.25 PCYz).1 
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By using the above equation, the choice of which supercritical fluid is suitable and at 
what density for a given solute can be determined. Therefore, solubility parameters 
of the fluid and the solute should be identical at maximum solubility. 
1.1.5.4 Solvent Strength 
As mentioned earlier, the solvent strength of a SF is directly related to its density and 
may be changed using the pressure and or the temperature to adjust the reaction rates 
involved in the extraction process. This can be done by small changes in pressure 
and temperature producing relatively large changes in the density at the critical point. 
As pressure increases, the solvent power or fluid density increases at a given 
temperature. At a constant pressure, temperature increases lead to a decrease in 
solvent density. This strong pressure dependency of the SF solvating power is a key 
factor in SFE and is exhibited by all solid and many liquid solutes as long as the 
solute is not intinitely miscible with the solvent. Ju 
In a SF, the efTect of temperature on the solubility of a substance changes with 
pressure. Increases in temperature at a pressure close to the critical point (Cpt) lead 
to a decrease in the solute concentration in the supercritical phase. However, at a 
high pressure, an increase in temperature causes an increase in solubility leads to a 
simultaneous decrease in gas density thus increasing the vapour pressure of the 
solute. 3D This gas density reduction caused by the rise in temperature, is less 
pronounced at a higher pressure than a lower pressure. Therefore, the increase in the 
solute's vapour pressure overcomes the decrease in the gas density and leads to a 
higher concentration in the supercritical region:l() 
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1.1.6 CLASSIFICATION OF FLUID PHASE BEHAVIOUR'7 
Interpreting high pressure phase behaviour data can be very difficult for a given 
practical application of SF technology. This can be explained by the mixture 
components varying in molecular size, shape, structure and even polarity. The 
diversity of a mixture's components and the amount can also contribute to the 
complexity of the phase behaviour. 
The binary phase behaviour system is greatly varied and more complex than a single 
component system, but these too can be very complicated. The addition of polar 
modifiers to the SF can enhance SF -C02 solubility properties and influence the 
analyte or matrix complex causing rapid desorption into the SF. 
This section is a review of vapour-liquid equilibria of binary mixtures. Generally of 
the different systems, the simplest is with a single solvent SF binary mixture with a 
single solute.37 Although process mixtures are generally quite complex, it is 
instructive to study the phase diagrams of binary mixtures.3o Useful detailed 
discussions of the thermodynamic behaviour of the various types of mixtures, with 
specific examples are provided by Rawlinson and Swinton 38, Streett 37 and McHugh 
and Krukonis. 17 
The currently accepted scheme for classitication of binary mixture phase diagrams 
was described in 1970 by van Konynenberg and Scott.39 They observed five classes 
of binary phase diagrams that could be qualitatively described using the van der 
Waals equation of state. There are tive distinct phases that were derived according to 
this scheme, as shown in Figure 1.3. 
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Figure 1.3 The five classifications for binary mixture phase diagrams. 17 
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An understanding of the phase equilibrium principles of the phase diagrams above is 
crucial during SF solvent extraction of mixtures. Demonstrated in two dimensional 
p-T plots for simplicity, Figure 1.3 a is the simplest of the binary phase diagrams. 
The critical points are represented by component one (C I) and component two (C2), 
where mixture at its critical state runs continuously from the critical point of the 
heavier component to the lighter component forming the critical-mixture curve. In 
Figures 1.3 b-e, like Figure 1.3 a, the critical-curve of the binary mixture is 
represented by dashed lines connecting C 1 to C2, with open triangles depicting the 
critical end points. 
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In general, the three-dimensional P-T -x diagram for type 1 binary mixtures, as shown 
in Figure 1.4, show that they can be constructt:d by compiling numerous isothermal 
P-x plots, as shown in Figures 1.4 c and d. In the P-T-x, P denotes pressure, T 
temperature and x the composition of the heavy component. 
Figure 1.4 Diagrams for a type-l Binary Mixture P-T-x (a), P-T (b), P-x (C).17 
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Temperature, which is below critical temperature of both components, is 
demonstrated as P-x at temperature T, in Figure 1.4 c. A familiar vapour-liquid 
envelope is observed which intercepts the pressure axis at the vapour pressure of pure 
component 1 and 2. The overall fixed composition denoted by x* in this figure, 
consists of a single vapour phase existing at low pressures. By isothermally 
increasing these pressures, the two-phase vapour-liquid envelope is intersected and a 
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dew or liquid phase now appears. The two phase vapour liquid is separated from the 
one phase vapour region by a locus of points called the "dew point curve". Within 
the two-phase boundary of the vapour-liquid envelope, the equilibrium vapour and 
liquid phase concentration is determined by a horizontal tie line as depicted in this 
figure. 17 
Further increasing the pressure increases the liquid phase mixture while decreasing 
the vapour phase, leaving only a small bubble of vapour. Increasing the pressure 
further, as the vapour liquid envelope is finally crossed the bubble of vapour 
disappears leaving a single liquid phase. The "bubble-point curve" is the name 
depicted for the locus of points that separate the two-phase vapour-liquid region for 
the one phase liquid region described in Figure 1.4 a. 
Demonstrated in Figure 1.4 d, is the behaviour caused by increasing the temperature 
above the critical temperature of the component I (Tel). Although the vapour-liquid 
envelope is similar to that in Figure 1.4 c, the envelope intersects the pressure axis at 
the vapour pressure of component 2 only. Since the temperature is greater than (Tel)' 
the vapour-liquid envelope on the left-hand side does not touch the pressure axis, 
because the vapour-liquid line for component I is never crossed. 
Experimentally, at an overall composition equal to x** (shown in Figure 1.4 d), the 
vapour-liquid envelope is first intercepted along the dew-point curve at low 
pressures. It is then intercepted at its highest pressure, which corresponds to the 
critical mixture point for this temperature and composition. If the overall 
composition of the mixture is to the right of x** and the pressure is increased, a 
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bubble-point is observed; ifit is slightly to the left ofx**, a dew point is observed if 
the pressure is increased. This vapour-liquid envelope at T2 is shown in the P-T-x 
diagram in Figure 1.4 a. 
As a function of pressure and composition, critical mixture points are determined and 
P-x diagrams are determined at higher and higher temperatures to create a critical 
curve. Assembling these P-x diagrams to form three dimensional P-T-x 
representation (shown in Figure l.4a), the critical mixture curve is obtained, shown 
by a dashed line though the locus of critical mixture points. Finally, if this P-T-x 
diagram is represented as a two dimensional P-T diagram, a continuous critical-
mixture curve, (shown in Figure 1.4 b) is observed. 
1.1.7 SUPERCRITICAL FLUID EXTRACTION 
Supercritical fluid extraction (SFE) is an independent sample preparation method, 
whose extracts can be analysed using various appropriate techniques. The 
widespread interest paid to the process of SFE is due to its unique solvent 
characteristics. It is especially useful for separating substances with low volatilities 
that decompose before reaching normal boiling points.21 The phenomenon of SFE is 
based on the process where the dissolving power of a solvent; as a first 
approximation, changes greatly with its density.21 
The solvent power of the SF is controlled by its density in the Cpt vicinity where 
slight pressure or temperature changes can produce large density changes. The SF 
density is typically 100 to 1000 times greater than that of the gas and solvating 
characteristics approaching those of a liquid are imparted.J6 However, the diffusion 
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coefficient and viscosity of the fluid remain intermediate between the gas and liquid 
phases at moderate densities, allowing rapid mass transfer of the solute compared 
with the liquid. 
These liquid-like solvent powers and rapid mass transfer properties provide the 
potential for a more rapid extraction rate and a more efficient extraction than would 
be obtained with liquid due to better penetration into the matrix. Another advantage 
of using a SF as a solvent is its high ditTusivity and low viscosity. This allows the 
SF to be able to penetrate into a polymer phase more etTectively than a liquid solvent. 
In addition, the separation of the solute from the solvent can be achieved by the 
reduction in pressure and/ or cooling, thus making a very selective and efficient 
fractionation possible. 
1.1.7.1 A Typical SFE Process 
At the start of a SFE, the extraction t1uid that is at or above its Pc is supplied by a 
pump to the extraction cell, which is placed in an oven at maintained temperatures at 
or above Tc. During the extraction, a preheat zone in front of the extraction cell 
helps to maintain the Tc, Pc and density conditions for soluble analytes to be 
partitioned from the sample matrix and incorporated into the SF. The analytes are 
then swept from the extraction cell at a t10w rate and a time period empirically 
determined during the method development stage.40 After passing through the cell, 
the SF containing extracted analytes flow through a restrictor and are depressurised 
into a collection vial containing an appropriate collection liquid. 
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The extraction can be carried out in two extraction modes, dynamic and static.35 The 
dynamic mode (continuous mode), uses a continuous flow of SF through the 
extraction cell for continuous recovery of the analyte. The valve is opened allowing 
pressure to be maintained through the flow restrictor and cell allowing 
depressurisation into a collecting device. The static mode is carried out by closing 
the outlet flow of the SF allowing the cell to pressurise for a while, then the valve is 
opened (dynamic mode) allowing the analytes to be swept into the collection device. 
Figure 1.5 shows the schematics for Rbeodyne dynamic and static extraction modes. 
Figure 1.5 Rbeodyne schematic of dynamic and static extraction modes. 
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Extraction valve 
Sample 
Collection 
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As demonstrated in Figure 1.5, when the first (top) Rheodyne valve is at the load 
(equilibrate) position, the flow is passed from position 2 to position 3, bypassing the 
second Rbeodyne valve which is set in inject (continuous) mode. By setting the first 
valve to the inject (extract) position, the flow is diverted from position 2 to position 
1, down to position 2 on the bottom valve. To perform a static extraction, the bottom 
valve is set to the inject position until the extraction cell is pressurised. 
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Once the required pressure is reached, the bottom valve in switched from the inject 
position to the load (static) position, diverting flow back to position 4 in the first 
valve via position 3 and out through the pressure regulator. Once the required time 
has elapsed during static extraction, the second valve is switched to the inject 
position and the analytes of interest along with the supercritical fluid are flushed out 
and depressurised through the restictor into the sample collection vial. 
1.1.8 SFE INSTRUMENTATION 
The main components in a SFE instrumentation are, the C02 source, the pump, the 
extraction cell, the restrictor, the oven and the anaiyte collection device. Generally, 
commercial extraction units will vary depending on the distributor, but all will 
consist of these major parts. Figure 1.6 demonstrates the schematics of the 
components consisted in a typical SFE system. 
Figure 1.6 Schematics of a typical SFE instrumentation. 
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1.1.8.1 SF-Carbon Dioxide 
High purity CO2 is generally required for most SFE applications, so the analytes and 
their impurities, especially those with high boiling points, are collected during 
extraction. It is provided as a liquid-gas mixture in a 25-kg tank and at room 
temperature has a substantial vapour pressure that helps to displace the liquid to the 
pump. CO2 is very dense, therefore a full length dip tube is installed which makes it 
more accessible and can be drained from the bottom of the tank easily. In addition, 
high purity CO2 is better for certain detectors that can not tolerate impurities. 
1.1.8.2 The Pump 
The pump is used to pump liquid CO2 at high pressure, to transport reproducible 
volumes, pump the moditier through with the SF and supply a constant fluid flow 
throughout the extraction. The constant How rate provides a measure of the retention 
time of the separated analytes being collected for a tinite time before further analysis. 
Therefore, the total SF passed through the extraction cell is of great importance. 
There are two types of pumps used in SFE that meet the flow and pressure 
requirements are the syringe pump and the reciprocating pump. 18 
The reciprocating pump supplies a continuous now and has an infinite reservoir. Its 
main disadvantage is that the pump head must be cooled constantly to allow the 
pumping of the liquid CO2, The syringe pump can provide pulseless flow, is easily 
filled with CO2 and does not require to be cooled because the CO2 is liquefied by 
pressure not temperature. IS Howewr, because of their limited volume, syringe 
pumps need to be tilled and repressurised when the pump cylinder is emptied and 
thoroughly flushed when changing modifiers to prevent carryover. Fluid can be 
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pumped at flow rates of 0,5 to 4mLlmin that enable faster flow rates to reduce 
extraction time, 
1.1.8.3 The Extraction Cell 
The extraction cell is generally a simple stainless steel tube, 100fli to 50ml in 
capacity with auto-sealing or compressed end fittings, They are placed inside the 
oven that controls the surrounding temperatures and must be able to withstand 
temperatures generated by the oven as well as the pressures generated by the pump, 
1.1.8.4 Restrictor 
In order for the system to reach a supercritical state during the extraction, the 
extraction cell is under pressure, which is incurred by usmg a fixed or variable 
restrictor, Fixed restrictors are commonly used during an extraction and consist of a 
piece of capillary tubing with an initial diam~ter and length inductive to produce 
appropriate backpressure, Varying the flow rate through the restrictor may change 
the SF density, Thus, fixed restictors must be changed between extractions because 
of the complex temperature, pressure, density and flow rate relationship, to vary the 
system pressure and change the density at a constant flow rate,lS 
Variable restrictors are more complex than fixed restrictors. but do not have to be 
changed during extractions, They regulate pressure independent of the flow rate by 
mechanically regulating the size of a small opening, allowing the de-coupling of 
pressure and flow rate, 
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1.1.8.5 Analyte Collection 
After SFE has been completed, the trapping/collection efficiencies of the product 
analyte(s) are important for further analysis. Three ways of recuperating the analyte 
after depressurisation of the SF are by thermal, sorbent or solvent trapping.! Thermal 
trapping is where the SF is depressurised into a cooled vial. However, the high gas 
flows at the SFE outlet can cause volatile components to be lost, only retaining non-
volatile components. Sorbent trapping is where the SF is depressurised, absorbing 
volatile and non-volatile components onto a solid support, that are eluted with a 
solvent after SFE is finished. 
The simplest and quickest of the three is solvent trapping, where the SF is 
depressurised into a liquid solvent. It does not otTer the selectivity of sorbent 
trapping, but is efficient for SFE, with optional collection solvent selectivity. Two 
major concerns in SFE for optimal analyte recoveries are, that the analyte of interest 
must be extractable from the matrix and the system used must be able to efficiently 
collect the analyte of interest. 
1.1.9 SFE METHOD DEVELOPMENT 
Analytical sample preparation techniques such as SPE have been widely used for a 
variety of matrices, compared to SFE, which is relatively new. During SFE method 
development, the appropriate conditions are often chosen by trial and error. The 
analytes that are contained in a solid matrix mllst be solubilzed in a SF in order to be 
extracted. Therefore, the relative affinities of the analyte for the SF and to the solid 
matrix have to be understood. 
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1.1.9.1 Analyte and M~'trix Properties 
Under SF conditions there are numerous analyte and matrix parameters that need to 
be considered to be adequate for sample preparation. The chemical properties of an 
analyte must be considered when selecting the starting conditions. The molecular 
weight, functional groups, polarity, solubility, volatility, pKa, thermal stability and 
concentration are all considerable parameters. Equally, matrix characteristics such 
as, the particle size, homogeneity. volume, porosity, composition, solubility, density 
and immobility are important for SFE. These parameters are all taken into 
consideration for SFE preparation to prevent the matrix from dissolving in the SF or 
the analyte being strongly retained during the extraction. 
The morphology and physical form of the matrix can have an enormous influence on 
the transport of the analyte into the SF and this can effect quantitative recovery 
during SFE. If the matrix is in bulk form (e.g. solid polymeric pellets or hard soils), 
preliminary sample preparations such as grinding, sieving, drying or wetting may be 
used. The porosity and relative size of the matrix, smaller being better, effects the 
speed and efficiency of the extraction. This is due to the short internal distance the 
solute has to cover to attain the core of the SF solution. 
In some cases, the geometrical form of the matrix used can influence the rate and 
efficiency of the extraction in the same way as the porosity of a matrix effects a 
solid-liquid extractions:2,43 The lise of solid supports such as diatomaceous earth, 
filter paper or a drying agent can be used for the application of a liquid sample to 
facilitate the extraction and at the same time preventing the matrix from being swept 
through the extraction cell. 
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The adjustment of pH or addition of solvent to the extraction cell can also aid in the 
SFE process for optimal recovery of the analyte of interest. Other parameters such as 
controlling the density, temperature, sample composition, flow rate and time can 
affect the reproducibility of SFE. Increased density increases solvent strength, thus, 
more polar analytes are removed. Controlling these parameters during SFE aids the 
selective fractionation of analytes into one or more fractions while leaving behind 
impurities in another fraction.J5 This results in fewer interferences due to impurities 
in the final analytical analysis. 
The flow rate of the SF can also dTect the extraction process. An increase in flow 
rate can accelerate analyte elution when optimum conditions are obtained. The other 
important parameter mentioned is the length of time needed to complete an 
extraction. Moditiers, as mentioned earlier, can be used to decrease the extraction 
time where most SFE can take 20 to 30 minutes depending on the type of sample. 
1.1.10 COLLECTION TECHNIQUES 
1.1.10.1 Off-line and On-line SFE Techniques 
Sample preparation and extraction is often more dit1icult and time consuming than 
the actual analysis procedure and can lead to relatively inefficient analyte recoveries. 
Two types of extraction collection techniques that provide an alternative to 
conventional extraction techniques are by off-line and on-line SFE collection 
methods. 
Off-line SFE is relatively simple to carry out. The analytes are collected into a 
collection device as described earlier. for subsequent analysis after extraction is 
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completed. The collected extracts may be analysed by a variety of appropriate 
analysis techniques (e.g. SFC~~·~7, GC2.20.4S, HPLC~'), TLC5u, GC/MSS' ). 
During off-line SFE, the analytes are depressurised and usually collected into a few 
millilitres of a liquid solvent. The vial is cooled by expansion of the SF that prevents 
rapid evaporation of the collection solvent due to the high gas t1ows. SFE eluents 
have been collected ii'om numerous sorbents that aid analyte collection. Silica, 
bonded-phase packing and various forms of diatomaceous earth can be used to aid 
the analyte to be eluted successfully with a liquid solvent for subsequent analysis 
without interference. 
1.1.10.2 On-line SFE 
On-line SFE techniques can be directly coupled with an analysis technique such as 
SFC, GC, GC/MS, HPLC and TLC. The advantages of on-line SFE are that it 
eliminates sample handling and its associated errors and in most cases maximises 
sensitivity to yield high analyte recovery. A disadvantage of direct coupling of SFE 
is that the sample extracts are not viable for analysis using another method. On-line 
SFE coupled systems must be selected based on chromatographic techniques suitable 
to the analyte being extracted.J5 
1.1.11 SFE COUPLED TECHNIQUES 
The direct coupling of SFE with various analysis techniques has been investigated 
and reported over the years. Stahl and Schilz in 1976, reported the use of a 
microextractor with TLC. 50 The coupling of SFE to HPLC was described by Unger 
and Roumeliotis with more recent developments of SFE coupled with SFC and aC.n 
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1.11.1 SFE-TLC 
The coupling of on-line SFE to TLC has lead to the development of an extraction 
apparatus for the purpose of extracting a wide range of naturally occurring materials 
(e.g. coffee, dye-mix leaves etc.).22 The extracts from this coupled technique are 
directly deposited onto the TLC plute, resulting in a static process being carried out. 
The components can be isolated ti·om or detected on the support material in one or 
two dimensional chromatograms that can aid further analysis. 
Although on-line SFE-TLC provides a rapid and simple insight into the extraction 
performance, it its not without its limitations. Quantification is difficult and there are 
problems with calculation of concentration levels, low resolution and high pressures 
that can cause instability of the support medium. 
1.11.2 SFE-HPLC 
There are numerous investigations reported for the application of off-line SFE-
HPLC. For example, the technique was applied for the extraction of caffeine from 
roasted coffee beans using supcn:ritical CO2, the extraction of vitamin K, from 
commercial soy and milk based infant formulas, extracting polymer additives from 
polyethylene and polypropylene and for the isolation of morphine and quinine from 
various plant materials. 22 
The first coupled on-line SFE-HPLC device was described by Unger and 
Roumeliotis in 1983.22 This system consisted of a connected series of two high-
pressure sample-injection valves. The tirst valve serves as a switching valve to the 
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loop and pressure controller over a packed microbore column, while the second valve 
is operated as an injector for the normal-phase HPLC column. 
1.1.11.3 SFE-GC 
Selection of a chromatographic technique coupled with on-line SFE is based on 
choosing one that best fits the analyte of interest. The most commonly used SFs are 
gases under certain conditions, which make the coupling of SFE with capillary GC 
an appropriate analytical technique. On-line SFE-GC can be coupled either by direct 
depressurisation of the SF inside a conventional split or splitless injection port or via 
a capillary column with an extraction cell restrictor inserted through the on-column 
injection port. 35 
During SFE the analytes are cryogenically focused in the GC column stationary 
phase and the analysis is carried out as normal. On-line SFE-GC yields maximum 
sensitivity using smaller samples than off-line SFE-GC, because of the direct 
coupling of the extracted analytes onto capillary GC. For larger samples and a 
broader range of matrices, the use of split GC/MS can be used. IS 
1.1.11.4 SFE-SFC 
The direct coupling of SFE with SFC has greater advantages for drug analysis than 
with the other coupled techniques, simply because both methods use SFs. Successful 
coupling can be attributed to the injection solvent being the same as the mobile phase 
and interfering components insoluble in the mobile phase will not be introduced onto 
the column following extraction. 
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During the coupling of on-line SFE-SFC, the analyte extracted is swept from the 
extraction cell and collected either into an accumulator trap containing a solvent 
material or thermally trapped at the head of the SFE column. After SFE, the 
extracted analytes are swept from the accumulation device by the mobile phase onto 
the SFE column. The analysis is then carried out under the appropriate conditions 
and chromatographic parameters. 
On-line SFE-SFC involves three types of SFC techniques. 19 
• Conventional packed columns 
• Capillary columns 
• Packed capillary columns 
Packed column SFC has a few advantages in companson with capillary and 
conventional packed columns. It has a higher loading option and shorter analysis 
times, while capillary columns have the advantage of a lower pressure drop, higher 
efficiency and lower flow rates resulting in easy FID or MS interfacing. 
1.1.12 SFE INSTRUMENTION SET-UP 
The SFE system used was manuLlctured by Gilson and consisted of all the necessary 
components. The system consisted of the following: 
• CO2 cylinder titted with a full length dip-tube (7.2 kg of CO2) 
• A SFEC3 refrigeration chiller unit 
• Two Gilson 10SC pumps (306 and 308) with built-in an automated programming 
system supplied via the GSIOe (Gilson Serial Input Output Channel) 308 pump 
• A Gilson 811 B dynamic mixer 
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• A 7125 Rheodyne (equilibrate/ extract valve (A)) 
• A second valve for static and dynamic extraction (B) 
• Open! close valve for extractions (C) 
• A Gilson 821 pressure regulator 
• A Rheodyne 7037 back-pressure regulator (inside oven) 
• Gilson 831 temperature regulator (oven) 
Figure 1.7 SFE instrumentation described above used in research laboratory 
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Polyvinyldifluoride (PYDF) check valves were placed in the C02-10SC 308 
pumphead giving it more resistance for hot and cold temperatures. This pumphead 
was chilled using the CFC3 chiller unit. The second pumphead (306) contained 
polytetrafluoroethylene (PTFE) check valves and was used to pump the modifier. 
The pressure, CO2 amount, modifier and flow rate were all measured USIng the 
Gilson 308 "master" pump, which controls the 306 "slave" pump. The slave pump 
delivers organic modifier solvent to the 811 B which is mixed with C02. The 821 
pressure regulator is controlled by the 308 pump that controls the operation of the 
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pressure regulation valve indicated by P2 and PIon the program. P2 maintains the 
required pressure levels at the outlet and P I is used to implement the flow rate 
accuracy corrections and ensures that the system pressure is not above or below the 
limits entered in the program. 
The HPLC 7125 Rheodyne valVi.' (A), was placed in-line between the 811B mixer 
and the extraction cell, which was housed inside the oven, for the application of the 
gas and modifier to the cell. It would have been more ideal to have the Rheodyne 
inside the oven so that supercritical conditions are applied directly to the matrix 
containing the analytes, but with the initial set up used, this was not mechanically 
feasible. 
To prevent deposits from the CO2 cylinder that would contaminate the system, an 
HPLC stainless steel column (4.6 mm id. x 10 cm) loosely packed with lichoprep 60 
was placed in the system between the CO2 cylinder and the CO2 pump head. The 
extraction cells were made from stainless steel empty HPLC columns. The 
dimensions were 3.4 cm x 4.6mm id and 7 cm in length. 
This system described was used for method development throughout the course of 
research. Moditications that were made to the system will be discussed further 
through the course of this study. 
1.1.13 CONCLUSION 
Supercritical fluids as a medium for selectively separating components from a 
complex mixture via extraction and or coupling with chromatographic techniques are 
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currently being actively studied world wide. In an effort to effectively deal with 
thermally liable and non-volatile compounds (e.g. drugs, pharmaceuticals, foods, 
pesticides) analytical chemists have facilitated the use of SFs (e.g. CO2) for adequate 
extraction and sample preparation techniques. This is mainly because of the 
advantages that SFs have over conventional liquid solvent techniques in the areas of 
efficiency, method development, cost and environmental consequences. 
SFE utilises the properties of SFs for selective extractions of specific classes of 
solutes from complex matrices and can be used as an alternative to time- consuming 
solvent extractions for sample preparation. In addition, the incorporation of SF 
technology with analytical chromatography presents great potential towards 
quantitative or qualitative determinations of specific solutes in complex matrices. 
SFs are finding wide acceptance in a number of analytical disciplines as umque 
solvating media, with the attributes of SFE well documented. 52 There are many areas 
in which the technology can and must improve, therefore, with the continued 
addition of new research, these improvements will be made. 
Chapter Two: Cocaine 
2. COCAINE 
2.1 LITERATURE REVIE\V 
2.1.1 INTRODUCTION 
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Over the past few decades, there has been rapid growth of illicit, medical and non-
medical abuse of psychoactive drugs, one of which is cocaine. Cocaine is by no 
means a new drug. For over 3000 years, cocaine and cocaine-containing substances 
have been used in a custom known as coca chewing by the Native Indians in South 
America. 53 
Coca chewing can be done in two principle ways. First, toasted coca leaves are 
combined with an alkaline material and held in the mouth between the gum and 
cheek, this is known as a quid or wad. 54 This quid is re-chewed and the juice 
swallowed. It is kept in the cheeks for continuous low concentrations of cocaine to 
be released, because the effects of coca chewing are not long lasting. 
A second method of coca chewing contains a tine powder made from ground dried 
coca leaves mixed with ashes. Small amounts of the quid are held between the cheek 
and gum as in the first method, with the juice and powder swallowed over several 
hours. The lime and ash combined with the coca leaves is used to facilitate drug 
absorption, as some of the cocaine is inadvertently swallowed while also being 
absorbed though membranes of the mouth. 5.1•54 
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2.1.2 HISTORY 
Controlled under the Misuse of Drugs Act (1971) Schedule II, cocaine is a highly 
lipophillic class A drug. It has been highly abused for decades as a topical anesthesia 
because of its properties. It is a natural alkaloid found in the leaves Erythoxylon 
coca and Erythroxylum Norgranatense, a plant indigenous to South America.55 There 
are at least eighteen alkaloids contained in the leaves with the principle component 
cocaine, which represents 0.2-1 % by dry weight of the leae3. 56 
This pure alkaloid was first isolated in 1860 by Albert Niemann. 57 In 1884, Koller 
introduced cocaine into clinical practice as a topical anesthetic for ophthalmologic 
surgery, that later extended to dental, oral and urethral applications.58 This stimulant 
of the central nervous system, had the potential to act as a local anesthetic and a 
sympathomimetic, increasing blood pn:ssure, heart rate and body temperature. The 
earliest case of cocaine poisoning was reported in 1888 where a pharmacist made a 
deliberate suicide attempt by taking an overdose of the drug. 57,58 
In addition, up until 1894 all other t~ltalities were accidental consequences because of 
cocaine usage for surgical applications. \~ This predominate accidental poisoning from 
cocaine usage, prompted the synthesis of synthetic substitutes such as procaine 
(Novocaine) by Einhorn in 1905.57 This substance was less toxic and lacked the 
central effects caused by cocaine, because of its block anesthesia by hypodermic 
infiltration. However, in spite the dangers associated with cocaine hydrochloride, it 
was still used as an efTective local anesthetic, mostly onto direct mucous membrane 
surfaces. 
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The use of cocaine has been available since the 1850s, when its addictive properties 
were appreciated. 54 The most widely used agents today are procaine, lidocaine, 
bupivacaine and tetracaine. Cocaine is now a commonly lIsed addictive drug because 
of its psychoactive properties. 
2.1.3 PHARMACOLOGY 
The reinforcing effects of COCaine and its analogs correlate best with their 
effectiveness 111 blocking the dopamine transporter, leading to increased 
dopaminergic stimulation at critical brain sites. However, cocaine also blocks 
norepinephrine (NE) and serotonin (5-HT) reuptake. The clinical use of cocaine has 
steadily declined, mainly because of its toxic effects and abuse potential. The 
blockage of catecholamine uptake in the central and peripheral nervous systems is 
due to the high toxicity of cocaine, while euphoric properties are due to the inhibition 
of catecholamine uptake (primarily dopamine) at the central nervous system 
synapses. Other local anesthetics do not block the uptake of NE or produce the 
stimulus to catecholamines. vasoconstriction or mydriasis characteristics of cocaine. 
2.1.4 PHARMACOKINETICS 
The conversion of cocaine to metabolites begins to occur soon after absorption.46 
Cocaine absorption is very variable, resulting in a wide spread of values for the time 
to peak concentration, peak concentration and half-life. Half-life varies with the 
individual with estimates ranging from 16-90 minutes (intranasal mean t1l2 75 
minutes; intravenous, mean t1l2 54 minutes: oral, mean tl/2 48 minutes).59.60 In 
urine, excretion of cocaine depends on the pHD) with approximately 1-9% of cocaine 
unchanged and detectable for only a few hourS.62 Therefore, for the detection of the 
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presence of cocaine in bodily fluids, more persistent urinary metabolites are looked 
at. however, cocaine itselfis relatively stable in hair. 
1.1.5 CHEMICAL STRUcrURE 
The chemical structure of cocaine below in Figure 2.1 is referred to as a boat shaped 
structure that contains a methyl group attached to a nitrogen group, Rt which is a 
methyl ester group, R2 which is benzoyl group and a hydrogen. 
Figure 2.1 Chemical structure of cocaine 
CH3 
N 
R1 
/ 
1.1.6 MET ABOLISIM 
Metabolism of cocaine begins almost immediately after absorption with hydrolysis of 
the ester to give the two m.yor metabolites of cocaine, benzoylecgonine 61.063, that is 
detected in most immunoassays and ecgonine methyl ester.64-66 By the chemical 
hydrolysis of cocaine, benzoylecgonine is rapidly fonned in biological fluids, while 
cbolinesterases in serum or plasma and liver are responsible for the hydrolysis to 
ecgonine methyl ester. The plasma enzyme is less abundant, with a higher affinity 
than the liver, but the contribution of the two are similar except in users with 
cholinesterase." Further hydrolysis of the two products leads to ecgonine. 
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Figure 2.2 Metabolic route of cocaine 
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Eleven metabolites of cocaine have be identified in unne including ecgonine66, 
ecgonidine methyl ester67, benzoylnorecgonineUI and norcocaine68, with the latter 
being found in only trace amounts. Arylhydroxl'> and arylhydroxymethoxy70. 71 
metabolites and their ethyl ester analogues have also been found7l , with the latter 
formed with the simultaneous combination of ethyl alcohol. Norcocaine is the only 
active metabolite found in small concentration in urine up to 4 hours after a lOOmg 
intravenous dose of cocaine.C,7 
With the simultaneous combination of alcohol and COCaIne, trans-esterification of 
cocame occurs changing it to ethyl benzoylecgonine (cocaethylene).72. 73 Coca-
ethylene is an analyte with pharmacological activity similar to cocame. The 
detection of cocaethylene is toxicologically important because of its frequent use 
with alcohol, its longer half-life than cocaine and prolongs the action of cocaine and 
is often present in similar or greater concentration than cocaine. 73 It can also be 
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hydrolyzed to benzoylecgonine and ecgonine ethyl ester through similar pathways as 
cocaine.56 In addition, for the detection of cocaine in hair, the detection of 
cocaethylene can confirm the use of cocaine rather than accidental exogenous 
contamination. 
2.1.7 COCAINE PREPARATION 
Cocaine (benzomethylecgonine) being an aromatic residue, an intermediate chain and 
an amino, share common characteristics with other local anaesthetics. 58 It is an 
extract from the leaves of the plant with the use of an organic solvent such as paraffin 
and or petrol and sulfuric acid creating a coca paste ( cocaine sulfate). S4 The paste is 
then treated with hydrochloric acid to reline and remove impurities, becoming a 
hydrochloric salt. The result is a pure white crystalline powder known as cocaine 
hydrochloride. 
Cocaine hydrochloride can be administered intravenously, intranasally (orally) or by 
smoking. 54, 60, 74, 75 It has a melting point of 195°C and decomposes on heating, 
therefore, it can not be smoked and the hydrochloride must be removed. It is 
frequently reconverted into cocaine freebase or "crack" by a process known as 
freebasing. This process occurs when cocaine hydrochloride is mixed with sodium 
bicarbonate (baking soda), or water and ammonium hydroxide. Ether or a fast drying 
solvent can then be added to free the cocaine from the water, becoming an insoluble 
freebase form of cocaine.54 It is then more volatile than cocaine hydrochloride and 
amenable to be ingested by smoking because the low melting point (98°C). 
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2.1.8 ROUTES OF ADMINISTRATION 
Following administration, cocaine rapidly penetrates all body tluids and tissue. It is 
readily absorbed into the bloodstream and mucous areas depending on whether it is 
intravenously, orally or intranasally administered. Acute administration of cocaine 
through these routes, can cause mood elevation, euphoria, increased energy and self-
esteem, alertness and can lead to a decrease in appetite and sexual interest.56 
Tolerance can be built up to the euphoria by chronic use of cocaine. Frequency of 
use increases anxiety, paranoia, hallucination and perceptual changes.54 Respiratory 
arrest and convulsions can be experienced by an overdose and may be followed by 
death. 
2.1.8.1 Intranasal administration 
Intranasal administration or "snorting" is the most commonly used route of 
administering cocaine. Cocaine hydrochloride is ground tinely and snorted into the 
nasal cavity using a small piece of tubing. Within seconds of snorting the cocaine, a 
numbing sensation is experienced which lasts up to five minutes. As the high 
commences, euphoria and an increase in energy is experienced. A peak high is 
reached within 10-20 minutes, subsiding within an hour. 54 
2.1.8.2 Intravenous administnttion 
Cocaine is converted into a solution for Intravenous administration and then a 
tourniquet or belt is used to help swell the veins for easier access when injected. This 
produces an instant high. The same euphoric high is experience with intranasal 
usage. However, there is more of an intense and t~lster rush within minutes of 
intravenous administration. This usually wears otT within about thirty minutes. 54 In 
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addition, intravenous use can cause hazardous problems such as overdose and 
transfer of infectious diseases such as AIDS or hepatitis. 
2.1.8.3 Smoking 
The most expensive and common form of cocaine is cocaine-freebase.58 When 
cocaine hydrochloride is converted into cocaine-freebase the freebase is smoked 
through a water pipe to produce an intense rush and a euphoric like high. During this 
process, much of the cocaine is lost through condensation and escaped smoke, 
therefore, only 5-6 % of the drug gets through the pipe.56 
One reason for freebasing being a common use of drug abuse today is because it 
produces increased craving for another dose, energy, and pleasure than the other 
routes of administration. In addition, because of the flammable solvents incorporated 
in cocaine freebase, it can damage the lungs. 
2.1.9 DRUG INTERACTION 
Sometimes drug combinations can be ingested inadvertently, because the user is not 
knowledgeable or concerned about drug interactions. The ingestion of two or more 
drugs, can produce various unpredictable effects greater or less than the effects of 
one of the consumed drugs or an effect unrelated to any of the drugs alone. Cocaine 
users tend to take other drugs such as benzodiazepines, barbiturates, marijuana or 
alcohol in combination with cocaine, thus having toxic effects. A common 
combination is with the use of heroin with cocaine known as a "speedball", that can 
have toxic effects resulting in death. 
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2.1.10 EFFECTS OF COCAINE 
The psychological effects of cocaine are complex and influenced by the environment, 
the dose, the route of administration and the characteristics and experience of the 
user. The general transition of nerve impulses are blocked by cocaine in various 
nerve fibers. It has a profound prominent stimulatory effect on the central nervous 
system at the cortical level. This results in a heighten euphoric, physical and mental 
effect and the feeling of increased energy and in most cases hallucinogenic and 
paranoia effects. Doses of 25 mg produce euphoria within 2 minutes by intravenous 
injection or with in 3-5 minutes when taken intranasally.74. 75 This initial euphoria is 
followed by a marked depression described by abusers as a "crash". This marked 
depression often leads to a prompt to experience the high over again every 10 to 30 
minutes. 58 
2.1.11 STABILITY OF COCAINE 
Cocaine is hygroscopic and benzoylecgonine forms a tetrahydrate, therefore, the 
stability and storage of cocaine and its metabolites is important to ensure proper 
preparation and preservation of the drug when in biological specimens and in solid or 
liquid forms.76 Cocaine is most stable in aqueous solutions at pH 3-4, with stability of 
pH < 4 for over 24 days at 24°C. 76 The base if stored in methanol at -15°C, is 
stable indefinitely. Benzoylecgonine is most stable at pH 1.8 and in urine at pH 5-9 
at 4°C up to 200 days.n. 7S However, leaving benzoylecgonine in methanol for long 
storage periods leads to the formation of its methyl ester. At room temperature, vial 
to vial transfer, during transport or at pH 9, the loss of cocaine and its metabolites 
can be up to 50% over a 20-30 day period. N 
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To minimize the loss of the drug, a number of options may be taken. Evaporating the 
organic extracts to dryness can minimize the loss. Silanization of glassware or pre-
treat auto-sample vials with 0.1 % ethylene diamine tetra acetic acid (EDTA) can 
increase recovery and prevent tertiary amines forming complexes with metal ions in 
the glass. 80. 81 
2.1.12 CHROMATOGRAPHIC ANALYSIS 
2.1.12.1 TLC ANALYSIS 
For the detection of drugs of abuse, TLC can be used as a presumptive test. Cocaine 
has a relatively high Rf value on most solvent systems, while benzoylecgonine often 
remains at the origin. 76 For good separation of cocaine and its metabolites, suitable 
solvents are chloroform, methanol and ammonia. Dragendorff reagent is the most 
sensitive spray reagent used with TLC. For improved sensitivity this may be 
followed by over spraying with 20 %v/v sulfuric acid or by exposure to iodine vapors 
for 60-90 sec. 80 
2.1.12.2 GC and GC/MS ANALYSIS 
The use of GC and GC/MS are more contirmatory methods for analysis. The 
specimen requires evaporation before being analyzed because of their volatility 
followed by derivatisation of its carboxyl groups to improve chromatography. Most 
methods in GC/MS lise EI at 70-75 eV for the analysis of cocaine82 alone or with nor-
cocaine83 with benzoylecgonineS4 , or with benzoylecgonine and ecgonine methyl 
ester.62 
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2.1.12.3 HPLC ANALYSIS 
The high water solubility of the amphoteric benzoylecgonine makes this a good 
candidate for estimation by HPLC without the need to derivatise. A loss of benzoic 
acid to form ecgonine methyl ester and ecgonine can occur and these compounds 
have poor UV absorbance. However, electrochemical detection at 1-2V over the 
limited pH range of 6-8 will detect cocaine, benzoylecgonine and ecgonine.85 
UV absorbance for cocaine and its metabolites is monitored at wavelengths of 232-
235 nm and occasionally at 200nm to increase sensitivty.H6 Reverse phase C I8 
columns are predominately used during HPLC analysis, however, phenyl and C8 
columns have also be used occasionally. Generally, methanol and or acetonitrile or 
acid buffer (pH 2-3) mobile phases combined with an amine modifier87 , sodium 
chloride88, EDTA 89 or an ion-pair agent90 , are used during HPLC analysis of cocaine 
and its metabolites. 
2.1.12.4 IMMUNOASSAY ANALYSIS 
Relatively specific immunoassay techniques such as RIA (radioimmunoassay) and 
EMIT (enzyme multiplied immunoassay technique) are designed to detect 
benzoylecgonine. However. relative cross reactivity of cocaine can be observed, but 
not much research has been recorded for cross reactivity for ecgonine methyl ester. 
Low, medium and high known concentration level calibrators are supplied by 
manufactures. with cut-off levds or 300pg/L for benzoylecgonine. with levels lower 
than this considered negatiw. 7u 
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2.1.13 SFE ANALYSIS 
Although the extraction of cocaine and its metabolites using SPE and LLE are well 
documented for biological tluids, there is no literature on the use of SFE for cocaine 
and metabolites from biological tluids. More recently, SFE has been applied for the 
extraction of cocaine from huir, but there has not been literature published on the use 
of SFE for cocaine and its metabolites in blood or urine. 
2.1.14 CONCLUSION 
The late twentieth century has seen the rapid growth of both the legitimate medical 
use and the illicit, non-medical abuse of an increasing number of drugs which alter 
ones state of mind. The widespread usc and abuse of cocaine has led to a search for 
rapid and easy solutions to the problems of addiction. Cocaine continues to be one of 
the most popular and common drugs of abuse on the streets today. 
Although treatment for the use or cocaine is on an increase, it can take a long time 
before a real cure is found. Even then it is unlikely that a single approach will be 
successful for all drug users seeking treatment, because the seriousness of the 
individual differs tremendously. Therefore, it is important that the specific needs of a 
patient are carefully evaluated, before a particular treatment is decided on. 
2.2 CURRENT METHODOLOGY 
Initially, a literature review on SPE methods was carried Ollt to tind Ollt what types of 
solvent combination cocaine and its metabolites were extracted with, because there 
was no literature published for SFE. 
Chapter Two: Cocaine page 47 
The worldwide monitoring SPE method used currently in routine work was used as a 
reference for the extraction of cocaine and its metabolites. 
• Blood sample pre-lrealmel1l: To a viall ml of blood, 4 ml of de-ionized water and 
100 III of internal standard (d,-cocaine) were added. pH was adjusted to 6 +1- 0.5 
with mono or di-basic phosphate, mixed or vortexed and left for 5 minutes. 
• Urine sample pre-lrealJ1lel1l: To a vial 1 ml of urine, 2 ml of 0.1 M phosphate 
buffer pH 6 and 100 III of internal standard were added. 
• Column condilioning: The column was conditioned with 3 ml of MeOH. 3 ml of 
de-ionized and 1 ml buffer. The sample was added to the column and pulled through 
• Column wash: The column was washed with 2 ml de-ionized water, 2 ml O.IM 
HCL and 3 ml MeOH and dried (5 min at ~ 1 Oinches Hg). 
• Elution: The analytes were duted with 3 ml of dichloromethane: isopropyl 
alcohol: ammonium hydroxide (7g:20:2 v/v) which was prepared daily. 
The eluent containing the drugs was evaporated to dryness at 40°C. The vial was 
sealed and derivatise with 50 ~tl of BSTF A for 20 min at 70°C. It was removed from 
heat source until cool and 1 ~tl was injeckd into the GC/MS for analysis. 
2.2.1 GC/MS Pammeters 
GCIMS for cocaine, benzoylecgonine and ecgonine methyl ester was carried out 
using a Fisons GC 8000 series gas chromatography with a mass detector MD 800. 
The OC was titted with an HP I capillary column (30 m x 0.25 mm x 0.25 11m film 
thickness). The GC/MS was operated in single ion monitoring mode (SIR) with an 
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injector temperature set at 250 0 C. The initial temperature was 100 0 C with an oven 
rise of 10 °C Iminute and the final temperature was 300 0 C which was held for 2 
minutes. 
The mass to charge ratios (mlz) detected were 303, 182* for cocaine, 240* and 361 
for benzoylecgonine, 182 and 82* for ecgonine methyl ester and for the internal 
standard deuterated cocaine (d3-cocaine) the 185* ion was llsed for quantification. (* 
indicates the ion used for quantification). 
Figure 2.3 GC/MS trace of cocaine, benzoylecgonine and ecgonine methyl ester. 
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The initial SFE set-up is described in section one of supercritical fluids. There are 
several startup checks to follow for tLlrning on the system. Below is a list of steps: 
Initial set-up: 
• The Chiller unit is switched on first and left to cool the pump head 
• Turn on the oven, 821 pressure regulator, both pumps and the mixer if needed 
Chapter Two: Cocaine page 49 
• Open the CO2 cylinder so the gas can now through the system 
• Once the chiller unit is cold. the now rate program can be initiated and the oven 
temperature set 
• When the pressure is above 1.070 psi the selected pressure can be programmed 
• Edit the method development parameter for the initial run 
• Pack the sample into the extraction cell and connect it onto the on-line tubing 
which is housed in the own 
• Switch the valve from equilibrate to extract and immediately start the program 
• Collect the sample analytes which will depressurize into a vial containing a 
solvent 
• Analyze using GC/MS 
At the end of an extraction: 
• Switch the valve from extract to equilibrate 
• Remove collection vial 
• Dry and derivatise for analysis 
Switching off the system: 
• Go to the program and edit a program to depressurize the system 
• If done manually, set the t10w to 1500 psi which is the pressure limit for the back 
pressure regulator 
• Once at this pressure, set it again to zero and set the t10w rate to zero 
• Turn off the CO2, the oven, pressure regulator, both pumps and unplug the chiller 
unit. 
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2.4 METHOD DEVELOPMENT 
Cocaine, benzoylecgonine and ecgonine methyl ester were all investigated by SFE 
from whole blood and urine matrices. Currently there is not a method for the SFE of 
cocaine and its metabolites ii'om blood or urine. Therefore, an initial outline for a 
method had to be devised and then optimized. 
2.4.1 CLEANING GLASSWARE 
Glassware (e.g. Hypovials"') used throughout laboratory research were washed by 
hand using Oecon 90. Oecon 90 is a surface active cleaning agent and or radioactive 
decontaminant for laboratory use. It is biodegradable, phosphate-free, non-
flammable and rinsable. The formation is comprised of an emulsion of highest 
quality, ionic and non-ionic surface-active agents, stabilizing agents, alkalis, 
nonphosphorus detergent builders and sequestering agents in an aqueous base. For a 
sufficient wash, 2-5 % solution mixture in water was used. Glassware was soaked 
for 24 hours, rinsed twice with water, twice with MeOH, then placed in a drying 
oven till dry. 
2.4.2 EFFECTS OF TEMPERATURE 
2.4.2.1 Expcrimcnt~ll 
For the extraction of cocaine and its metabolites, approximately 0.13 g of plain 
Extrelut® was used as a sample matrix and extracted at temperatures ranging from 
40-100 °C without the presence of blood or urine. 
100 JlI of each drug with internal standard (d}-cocaine) was loaded onto the matrix 
and left to dry. Once dry the sample was loosely packed into the extraction cell. The 
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elution solvent DCM: IPA: NH1 (78:20:2 v/v) was prepared and 300 ~tl was added to 
the extraction cell containing the sample. The initial conditions used were 1.5 
ml/min flow rate, 2700 psi, 100 % CO2 and the temperature set at 40°C for the first 
four sets of matrices and then raised in increments of 10°C under the same conditions 
to 100 0c. 
The extraction was under static conditions for 10 minutes and dynamic for 20 
minutes for a total of 30 minute extraction time. The extracts were collected in 3 ml 
of MeOH at the now outlet, evaporated to dryness under N2 at 40°C and derivatised 
with 50 /.ll of BSTF A at 70°C for 20 minutes. Figure 2.4 shows the sample vial 
containing MeOH lIsed for the collection of the eluted analytes. The vial was sealed 
using a butyl rubber septa with a disposable needle inserted into the top. The needle 
was used as a pressure release during depressurization of the aerosol containing the 
analytes into the vial. Unextracted standards containing all three drugs and the 
internal standard were prepared and used as references. Samples were run under 
cocaine parameters lIsing GC/MS. 
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Figure 2.4 Collection vial used for SFE of cocaine and its metabolites 
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Analysis parameters for SFE were the same as set for SPE parameter for the analysis 
of cocaine and its metabolites discussed previously. The analysis parameters 
provided good results for this SFE methodology. 
2.4.2.3 Results and Discussion 
Out of all the san1ples extracted under these conditions, it was shown that only 40° C 
recovered cocaine and its metabolites but in low quantities using plain Extrelut® 
However, 80° C did recover cocaine, but not the two metabolites. The temperature 
that was selected was 40° C and optimization to improve the method is discussed 
further. 
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2.4.3 EFFECTS OF SUPPORT MATRIX 
2.4.3.1 Experimenhll 
page S3 
A collection of four matrices, cation exchange silica packing, Extrelut® washed with 
OCM, MeOH washed, and Extrdut® without being washed in solvent were 
investigated. It was thought that by washing the Extrelut® in a polar solvent, might 
decrease any possibility of the drug binding to the sample matrix and increase elution 
of the drug of interest. 
2.4.3.2 Results and Discussion 
The four support matrices gave positiw results for presence of the drugs at 40° C 
under parameters discussed earlier. However, out of the four, MeOH washed 
Extrelut® led to better recoveries of cocaine and benzoylecgonine more than the 
others. Shown in Figure 2.5 is a graph comparing the four support mediums 
determined by the peak an:a ratio. Extrelut® washed with MeOH, (a polar organic 
solvent), is thought to potentially enhance the extraction along with the modifier and 
makes it more sunicient. 
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Figure 2.5 Comparison of the four different sample matrices at 40°C. 
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The pressure used in SFE operates in combination with temperature that controls the 
density of the SF. As the pressure and density increase, the solvating power of the 
fluid increases. Thus, a chemical change occurs from adjusting the pressure and or 
temperature and the solvating power also adjusts. Now that the temperature and 
extraction matrix were chosen, the pressure and flow rate had to be optimized. The 
pressure was increased to 3500 psi and the flow rate to 2 ml Imin to see if this would 
make a difference in the quality of the extraction. 
2.4.4.2 Results and Discussion 
It was noted that by increasing the pressure at a constant temperature was more 
favorable for analytes that are more polar with higher analyte molecular weights. 
This with the inclusion of the modifier produced bigger peaks for all three drugs 
making them easier to quantify and elute the drugs at higher concentrations. The 
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making them easier to quantify and elute the drugs at higher concentrations. The 
flow rate was adjusted to 2 ml Imin because the higher the flow rate, the better and 
quicker the analytes will be extracted from the matrix and less time is needed during 
extraction. 
2.4.5 EFFECT OF THE MODIFIER 
2.4.5.1 Experimental 
The addition of a modifier incorporated directly to the sample enhances not only the 
polarity of the extraction, but increases the recovery of the drug of interest from the 
matrix while decreasing the extraction time. DCM: IPA: NH3 was chosen in a 
78:20:2 v/v ratio because of its polarity and its use in SPE as a potential eluent for 
cocaine and its metabolites. 
2.4.5.2 Results and Discussion 
This combination was chosen because of its characteristics and proved to be able to 
sufficiently elute cocaine, benzoyJecgonine and ecognine methyl ester. Small 
amounts of concentrated ammonia was used because of its high polarity and strong 
solvating power to give the solvent combination added enhancement. Recoveries 
were estimated to be relatively high for cocaine and ecgonine methyl ester, however 
relatively low recoveries were found for benzoylecgonine. 
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2.4.6 EFFECTS OF DERIV ATISA TION TIME 
2.4.6.1 Experimental 
The effects of derivatisation time on cocame, d3- cocame, benzoyl ecgonine and 
ecgonine methyl ester were investigated. Unextracted standards were prepared 
containing 50 III of a 10 Ilgl ml solution pipetled into a vial, evaporated to dryness 
and reconstituted with 50 III of BSTF A (1 % TMCS). Each standard was derivatised 
at various times from 20 minutes to 1 hour in intervals of 10 minutes at 70°C. 
2.4.6.2 Results and Discussion 
The results of the effects of derivatisation times is shown in Table 2.1 with peak 
areas of cocaine (m/z 182, 303), d3-cocaine (m/z 185), benzoyl ecgonine (mlz 240, 
361) and ecgonine methyl ester (m/z 82, 182). 
Table 2.1 Effects of derivatisation time 
Time m/z 185 mlz 182 mlz 303 m/z 240 m/z 361 m/z 82 m/z 182 
20 987642 2204723 1630202 224430704 99591216 5765876 723918 
30 287883 762050 287907 48802172 41070144 829800 46160 
40 I II 123 314443 1 1 1 154 4037605 6360242 361745 23710 
50 92961 304923 108933 2414641 3550462 1134521 78350 
60 203194 502818 196056 7612161 10698116 456558 20953 
Derivatisation at 20 minutes proved to be the best time to derivatise cocaine and 
metabolites and therefore was the starting time for derivatisation to take place. From 
these results, 20 minutes is confirmed to be the best time for derivatisation and 
produced higher peak areas for each drug compared to the other times. By 
derivatising for 30 minutes was seen to still be acceptable, however more than this 
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time lead to a decrease in the peak areas for cocaine, d}-cocaine, benzoylecgonine 
and ecgonine methyl ester 
2.4.7 EXTRACTION OF DRUGS INDIVDUALLY 
2.4.7.1 Experimenhd 
Since the method was found to elute the drugs of interest under supercritical 
temperatures, before it could be fully optimized each drug was extracted individually 
under the same conditions discussed to rule out possible hydrolysis. 100 III of each 
drug with 1 00 ~ll of internal standard was pipetted onto MeOH washed Extrelut® and 
dried. 300 III of modifier was added to the extraction cell and the extraction started. 
Blanks samples containing modifier were also run before and after extraction just to 
eliminate the possibly of carryover. 
2.4.7.2 Results and Discussion 
Results showed that each drug was successfully extracted fine individually and there 
were no indications of cocaine hydrolyzing to form benzoylecgoine and ecgonine 
methyl ester. They were also individually extracted without the problem of 
hydrolysis. Overall there was no carryover detected in the system. 
2.5 CONCLUSIONS FROM METHOD DEVELOPMENT 
The final extraction conditions developed for cocaine, benzoylecgoine and ecgonine 
methyl ester are as follows: 
• Flow Rate 2 ml Imin 
• Temperature 40°C 
• Pressure 3500 psi 
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• Support medium MeOH washed Extrelut® 
• 100 % CO2 
• Run time 10 min static, 20 min dynamic 
• Modifier 100 ~ll OCM: IPA: NH3 (78:20:2 v/v) 
Under these conditions, the SFE system was left to equilibrate while the sample was 
prepared. Approximately 0.13 g of MeOH washed Extrelut® was placed in a 
weighing boat with 1 00 ~d aliquot of d-:; internal standard (1 ~lg Im1) and a 200 III 
aliquot of sample blood or urine. The sample was left to dry at room temperature 
overnight or until a friable consistency was observed. The sample was loosely 
packed into the extraction cell with 1 00 ~d of modifier, OCM: IPA: NH, and placed 
inside the oven The Rheodyne valve was switched from the equilibrate to the extract 
position with the valve closed for static extraction and opened for 20 minutes for 
dynamic extraction. This allows the flow of the SF to pass through the extraction 
cell. The analytes are depressurized at the flow outlet into a glass Hypovia(" 
containing 3 ml of MeOH. 
2.6 METHOD VALIDATION 
In order to investigate whether or not the optimized method was suitable for sample 
extraction, it was applied to blood and urine samples which were pipetted onto the 
MeOH washed Extrelut® matrix. The extraction was under optimized conditions 
with pressures of 3500 psi, flow rate 2 mil min, temperature 40°C, 100 % CO2 and 
300 III of modifier added to the extraction cell for 10 minutes static and 20 minutes 
dynamic. 
Chapter Two: Cocaine page 59 
2.6.1 RECOVERY 
2.6.1.1 Experimental 
To determine the percentage recovery of each drug, several spiked blood and urine 
samples were prepared without the internal standard d-} cocaine. The internal 
standard was added at the end of the extraction to the eluent as a reference ion to 
calculate how much of each drug was being recovered from the extraction. 
2.6.1.2 Results and Discussion 
Along with the addition of the internal standard after elution, an unextracted standard 
of the same concentration was analyzed and used to calculate the recovery. 
Recoveries for cocaine in blood were better than 70 %, benzoylecgonine 40 % and 
ecgonine methyl ester 85 %. Recoveries for cocaine in urine were better than 75 %, 
benzoyl ecgonine 49 % and ecgonine methyl ester 90 %. It was observed that out of 
the three drugs, benzoylecgonine produced very low recoveries for blood and urine. 
Low recoveries of Benzoykcgonine may be due to poor analyte solubility and or a 
binding mechanism to the sample matrix that diners from cocaine and ecgonine 
methyl ester rendering the metabolite semi-extractable under these SFE conditions. 
Recoveries in urine were found to be a little higher than for blood. This could be 
explained partly because of the composition of the biological fluids and its affinity to 
adhere to the matrix. Urine is more lipophobic and is easier to extract than whole 
blood that forms a lipophilic bond with the proteins and drugs that can interfere with 
the extraction of the drug of interest. 
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2.6.2 REPRODUCIBILITY 
2.6.2.1 Experimental 
Several blood and urine blank samples were applied individually to several MeOH 
washed Extrelut® mediums. They were spiked with 1 00 ~d (1 ~lg Iml) for each drug, 
cocaine, benzoylecgoine and ecgonine methyl ester and d)-cocaine, which was 
pi petted onto the matrix, mixed and left to dry. Blanks were included during the run 
to observe any trace of carryover during the extractions. The extractions were 
carried out five times for blood and for urine at the selected parameters discussed 
earlier. 
2.6.2.2 Results and Discussion 
The following Figures 2.6 and 2.7 indicate the results obtained for the extraction of 
cocaine, benzoylecgonine, and ecgonine methyl ester at optimized conditions for 
urine and blood. As can be seen from these results, there was adequate run to run 
repeatability between each extraction (n = 5) indicating the accuracy of the method 
from run to run. 
Table 2.2 Method repeatability of cocaine. benzoylecgonine and ecgonine methyl 
ester for blood 
Blood COC m/z 182/185 BZE m/z 240/185 EME m/z 821185 
1 0.746 0.22 1.28 
2 0.849 0.278 1.30 
3 0.949 0.27 1.55 
4 0.876 0.251 1.43 
5 0.769 0.267 1.51 
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Figure 2.6 Chart showing run to run repeatability of cocaine and its metabolites in 
blood. 
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As shown in Figure 2.6 above, each spiked sample contained the same amount of 
drug concentration that was reproducible from run to run for each drug. The 
recovery varied for each drug with benzoylecgonine being the least recovered, 
however consistent within each run. 
Table 2.3 Method repeatability of cocame, benzoylecgonine and ecgonme 
methylester for urine. 
Urine COC m/z 182/185 BZE m/z 240/185 EME m/z 821185 
1 0.758 0.298 1.09 
2 0.675 0.316 1.31 
3 0.75 0.30 1.31 
4 0.81 0.28 1.32 
5 0.79 0.27 1.22 
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Figure 2.7 Chart showing run to run repeatability of cocaine and its metabolites in 
urme. 
Urine Run Repeatibility 
2 
---- ----~- --- ----
o 
2 3 4 
Number of Runs 
5 
• cae 
o BZE 
. EME 
As demonstrated in Figures 2.6, Figure 2.7 also produced similar findings from run 
to run for urine samples with benzoyl ecgonine being the least recovered of the three 
drugs. 
Table 2.4 summarises the method reproducibility of cocaine and its metabolites from 
both blood and urine. Overall, reproducibility from run to run for cocaine, 
benzoylecgonine and ecgonine methyl ester in blood and urine produced good 
standard deviations and relative standard deviations (% CV) . Methods producing 
RSDs of less than 10 % are reported to be acceptable for method validation of 
biological specimens.39 
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Table 2.4 Method validation of cocaine, benzoylecgonine and ecgonine methyl ester 
in blood and urine (n = 5) 
DRUG StdDev %RSD PAR %Recovery 
Me~lD 
BLOOD 
Cocaine 0.0823 9.8 0.837 70 
Benzoylecgonine 0.0229 8.9 0.257 40 
Ecgonine methyl ester 0.1213 8.5 1.41 85 
URINE 
Cocaine 0.0518 6.8 0.756 75 
Benzoylecgonine 0.0180 6.1 0.292 49 
Ecgonine methyl ester 0.098 7.8 1.25 90 
2.6.3 LINEAR CALIBRATION 
2.6.3.1 Experimental 
Taken at various concentration ranges, aliquots from a 1 pg Iml solution standard of 
cocaine, benzoylecgonine, ecgonine methyl ester and d-3 cocaine were pipetted onto 
a support matrix containing either 200 ~Ll of blood or urine. For a calibration curve, 
the concentration range was from 5 ng to 100 ng 1200 ~d for both blood and urine. 
The sample was treated, extracted and derivatised using the developed method. The 
derivatised samples were analyzed by GC/MS. 
2.6.3.2 Results and Discussion 
Three separate calibration curves were created for each drug for blood and urine 
listed below in Figures 2.8-2.10. The results for the various concentrations cocaine, 
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benzoylecgonine and ecgonine methyl ester are shown in Tables 2.5 and 2.6 listed 
with the mJz ratios for each concentration for linear calibration. 
Table 2.5 Linearity of cocaine, benzoylecgonine and ecgonine methyl ester in blood 
over a range from 5-100ng/200~d 
Cone" ng/,..ll CDC m/z 182/185 BZE m/z 240/185 EME m/z 82/185 
5 0.008 0.001 0.76 
10 0.032 0.006 0.97 
20 0.07 0.02 1.21 
40 0.19 0.03 1.52 
60 0.27 0.44 1.83 
80 0.42 0.068 1.97 
100 0.58 0.10 2.21 
Regression and slope were calculated for blood for all three drugs. Table 2.6 
summarizes concentration range for the calibration curves and the limit of detection 
(LOD) and quantitation (LOQ) for each drug. 
The LOD for cocaine, benzoylecgonine and ecgonine methyl ester was determined 
by using 200 ,.tl of blank blood spiked from a 1 pgl 1111 solution. For the three drugs, 
the LOD was 1 ng with a LOc...> of lOng in 200 ,.tl of blood. Figures 2.8-2.10 
demonstrate the calibration curve for each of the three drugs along a concentration of 
5 - lOOng as listed in Table 2.4 for blood. 
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Figure 2.8 Linearity of cocaine in blood 
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Figure 2.9 Linearity of benzoylecgonine in blood 
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Figure 2.10 Linearity of ecgonine methyl ester in blood 
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Table 2.6 Linearity of cocaine, benzoylecgonine and ecgonine methyl ester in urine 
over a range from 5 - I OOngl 200111 
Concn ng cac m/z 182/185 BZE mlz 240/185 EME m/z 821185 
5 0.0423 0.003 0.21 
10 0.10 0.01 0.26 
20 0.16 0.05 0.54 
40 0.35 0.11 1.03 
60 0.59 0.19 l.51 
80 0.73 0.25 2.07 
100 0.92 0.35 2.71 
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Figure 2.11 Linearity of cocaine in urine 
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Figure 2.12 Linearity of Benzoylecgonine in urine 
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Figure 2.13 Linearity of ecgonine methyl ester in urine 
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Table 2.7 summarizes concentration range for the calibration curves and the limit of 
detection (LOD) and quantitation (LOQ) for each drug for both blood and urine. 
Table 2 .7 Linear calibration and concentration range of cocaine, benzoylecgonine and 
ecgonine methyl ester. 
DRUG r2 Slope LODILOQ Cone. Range 
BLOOD ng / 200~1 ng / 200~1 
Cocaine 0.987 0.0058 1 ng 1 10 ng 0- 100 
Benzoylecgonine 0.971 0.0009 1 ng I I 0 ng 0- 100 
Ecgonine methyl ester 0.964 0.0145 1 ng I lOng 0- 100 
URINE 
Cocaine 0.997 0.0092 1 ng 11 0 ng 0- 100 
Benzoylecgonine 0.991 0.0034 1 ng 1 1 0 ng 0- 100 
Ecgonine methyl ester 0.997 0.0262 1 ng 1 10 ng 0- 100 
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2.7 COMPARISON OF SFE AND SPE 
2.7.1 Experimental 
A comparison between SFE and SPE was made to investigate if the two methods 
correlate for the extraction of blood and urine for cocaine, benzoylecgonine and 
ecgonine methyl ester. Due to the lack of cocaine positive blood and urine forensic 
case specimens received into the laboratory, spiked samples were used for 
comparison between the two methods. From a stock solution of a 10 J.lg Iml, 50 J.lI of 
each drug was pipetted into three separate test tubes containing 1 ml of pretreated 
blood or urine for SPE and 200 ~d of blood or urine for SFE. Samples were extracted 
and evaporated to dryness under a stream of nitrogen and derivatised. 
2.7.2 Results and Discussion 
Results from both methods for blood and urine are listed in Table 2.8 below. 
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Table 2.8 Comparison of SPE and SFE results of cocaine, benzoylecgonine and 
ecgonine methyl ester in urine and blood. 
Cocaine Benzoy lecgo n in e Ecgonine methyl ester 
mg/L mg/L mg/L 
SPE bid 1 0.207 0.16 0.103 
SI>E bid 2 0.21 0.11 O'()84 
SPE bid 3 0.18 0.17 0.093 
SFE bid 1 0.25 0.13 0.17 
SFE bid 2 0.20 0.11 0.11 
SFE bid 3 0.26 0.12 0.12 
SPE urn I 0.19 0.10 0.08 
SPE urn 2 0.17 0.07 0.081 
SPE urn 3 0.20 0.08 0.09 
SFE urn 1 0.29 0.14 0.27 
SFE urn 2 0.23 0.13 0.26 
SFE urn 3 0.22 0.13 0.24 
The results show that a correlation existed between the two methods with small 
differences observed. The percent differences between the two methods for cocaine 
in blood were 0.04, 0.09, 0.08, for benzoy1ecgonine 0.03, 0, 0.05 and ecgonine 
methyl ester 0.07, 0.03, 0.03. For urine, the percent difference for cocaine was 0.10, 
0.06, 0.02, benzoyl ecgonine 0.04, 0.06. 0.05 and ecgonine methyl ester 0.09, 0.07, 
and 0.06. The san1ples results for blood using SFE ranged from 0.084 - 0.21 mg/l 
and SPE 0.11 - 0.26 mg/I. For SFE in urine the result range was 0.13 - 0.29mg/l and 
SPE 0.07 - 0.20mg/1. Figures 2.14 and 2.15 show graphs based on Table 2.6 for both 
methods for blood and urine, which clearly show the variation between the two 
methods. 
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Figure 2.14 Graph showing the comparison between the two methods for blood. 
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Figure 2.15 Graph showing the comparison between the two methods for urine. 
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2.8 CONCLUSION 
At present, cocaine analysis from biological matrices involves a SPE method. The 
current study demonstrates that SFE can be used as a possible alternative to 
conventional methods for the isolation of drugs of abuse such as cocaine, 
benzoylecgonine and ecgonine methyl ester from blood and urine. 
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Various temperatures. pressures, How rates and modifiers were investigated during 
method development. However, the described chosen conditions proved to give the 
best results for cocaine and its metabolites. Recoveries greater than 70% were 
reported for cocaine and greater than 85% for ecgonine methyl ester. However, 
benzoylecgonine recoveries were reported to be greater than 40%, which was lower 
than cocaine and ecgonine methyl ester. A possible explanation would be because 
the benzoylecgonine analyte is a zwitterion, a closer control of the extraction pH 
would have probably increased the yields. However since the developed procedures 
produced a reproducible extraction and was optimised to maximise the recovery of 
the major metabolite (benzoylecgonine), further development was deemed 
unnecessary. 
SPE techniques were compared to the developed SFE techniques to find if a 
correlation existed between the two. A correlation was observed between SPE and 
SFE for the extraction of cocaine and its metabolites. Small percent differences were 
observed between the two methods, however both methods were comparable. This 
developed SFE method for the recovery of cocaine and its metabolites has 
demonstrated its potential usage for the extraction from spiked whole blood and 
urIne. 
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3. OPIATES 
3.1 LITERATURE REVIEW 
3.1.1 INTRODUCTION 
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Opiates are comprised of as many as 25 different alkaloids, including 
pharmacologically active morphine, codeine and papaverine which are known abused 
drugs. In its pure form, weight for weight, heroin is several times more potent in its 
drug action as morphine.91 For many years, purely synthetic narcotic analgesics have 
been sought for the use as pain-killers. Two compounds of this nature now generally 
used are pethidine (meperidine) and methadone. Although they lack some of the 
undesirable depressant effects of morphine, these potent analgesics still produce 
addictive dependency. 
Heroin, morphine, opIUm, methadone and pethidine are all controlled under the 
Misuse of Drugs Act as Class A drugs. This makes them illegal to supply or possess 
without a prescription. Codeine and dihydrocodeine are Class B drugs, however 
prepared for injection they become Class A. Opium itself can be eaten or smoked 
and opiate powder can be dissolved in water and injected, sniffed or swallowed. 
Heroin is rarely eaten, as it is relatively ineffective this way. However it can be 
sniffed or smoked and the fumes inhaled, a term referred to as "chasing the dragon". 
The desire to experience some altered state of consciousness is an intrinsic part of the 
human condition. The indulgence in something too much can be referred to as 
addictive or a drug. The same or similar drugs may be sold under various trade 
names for medical use, but still give the same effects. Morphine is just one of these 
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drugs that is commonly misused! abused today and will be discussed further in this 
chapter. 
3.1.2 HISTORY 
The name opium is derived from the Greek name for the dried latex Guice) extracted 
from the unripe capsules of the opium poppy (Papaver somniferum).92 The 
medicinal use of opium extends from the third century BC to the next three centuries 
with the cultivation of the opium poppy spread to the Mediterranean countries, 
Persia, India and China by Arab traders. 
Clinically, opiates are used for the relief of pain with various potencies and 
pharmacological effects for the production of analgesia, sedation, diahorrea, 
respiratory depression and cough suppression.92 Heroin (di-acetyl morphine) is 
produced by acetylation of morphine and in some areas of the UK, it is a serious 
problem where prescribed substitutes are not available. It was first isolated in 1874 
at St Mary's Hospital London and then rediscovered in Germany in the 1890s. 
After the First World War, an international agreement was made by Britain 
prohibiting the non-medical use of opium and opiates. By the early 1960s, heroin 
was on the rise being prescribed by some doctors for the relief of pain, which 
resulted in the spread of addiction. As a result, in 1968 the prescribing of heroin was 
prohibited which caused the beginning of an illicit black market for heroin 
production. 
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3.1.3 PHARMACOLOGY 
Generally used as prescriptive pain-killers, opiates elicit their primary 
pharmacological effects on the central nervous, respiratory, cardiovascular and 
gastrointestinal systems. Several common central nervous system effects caused by 
opiates include euphoria, anesthesia, analgesia, increased tolerance to pain, 
stimulation of chemotrigger zone and production of miosis. The effects of opiates on 
the respiratory system include depression rate, volume and exchange of respiration 
and decreased responsiveness. Opiates also cause decreased motility and delayed 
gastric emptying in the gastrointestinal tract.93 They are mainly abused for the 
production of their euphoric and pain relief effects. 
3.1.4 PHARMACOKENETICS 
Morphine levels in the body fluids can be used as an indicator to detect therapeutic or 
harmful levels. Stead et al and Moffat reported therapeutic ranges between 0.1 to 
11lg /mI.94• 95 This indicates the tolerance range the body can develop to morphine 
over constant abuse requiring increased does for the same effect. The minimum 
lethal dose in man is approximately 200 mg, which can be exceeded by addicts due 
to tolerance. 
The approximate half-lives of heroin and 6-MAM are 3 to 30 minutes respectively, 
while morphine has a half-life of 2-3 hours depending on the dose. Due to the rapid 
hydrolysis of diamorphine to 6-MAM, it is difficult to detect it in plasma. 
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3.1.5 CHEMICAL STUCTURE 
Opiates are not naturally present in the body, but have structural similarities to a 
group of endogenous peptides called endorphins and enkephalins, discovered in 
1978, that play an important role in the bodies own control of pain relief.9b Figure 
1 shows the chemical structure of opiates. Only morphine will be discussed in this 
study, however the main related opiates have the same basic chemical structure 
differing only in the R, and R2 groups as indicated in Figure 3.1. Diamorphine (R, 
COCH3, R2 COCH)), 6-MAM (R, H, R2 COCH)) and Morphine (R, H, R2 H) 
Figure 3.1 The chemical structure of opiates76 
3.1.6 METABOLISM 
Heroin is usually self-administered intravenously, by intra-muscular injection, 
snorted or smoked. Following the administration of heroin, it is rapidly metabolized 
by deacetylation into 6-MAM, that is then hydrolyzed into morphine. Morphine is 
then metabolized by conjugation to morhine-glucuronide and by N-demethylation to 
normorphine. Normorphine is further conjugated into normorphine-glucuronide. It 
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is also possible that codeine is produced as a metabolite of morphine (3-0-
methylation).97 
Primarily, morphine and conjugated morphine are metabolites of heroin commonly 
found in urine. However, morphine presence alone is not a reliable indicator of 
heroin use and 6-MAM is commonly used as a specific marker. The most common 
analgesic for the relief of severe pain is morphine. It is readily absorbed from the 
gastrointestinal tract, with high first-pass elimination on passage through the liver. 
Figure 3.2 shows the major metabolic pathway of diacetylmorphine. 
Figure 3.2 The major metabolic pathway of diacetylmorphine. 76 
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3.1.7 CHROMATOGRAPHIC ANALYSIS 
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There are various analytical methods for the analysis of morphine from biological 
fluids. The preferred tissue of choice has been plasma where morphine is present in 
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its unconjugated form and it is likely that interference will be minimal with the 
isolation of that drug. However, in post-mortem cases plasma is seldom available 
and the tissue most commonly supplied is haemolysed, often putrefied blood. 
Therefore, a suitable method should be applied capable of detecting morphine 
concentrations down to ng/ml levels. Typically, a 1ml sample volume is used 
incorporated with a pre-treatment or clean-up step to insure adequate 
chromatographic analysis. 
Radioimmunoassay (RIA) has been used as a screening procedure before analysis, 
however for confirmation the most common analytical methods used are liquid-liquid 
extraction (LLE)98.IOI, solid-phase extraction (SPEY02-I05 and more recently 
supercritical fluid extraction (SFE).I06,)O? For chromatographic analysis gas 
chromatography - mass spectrometry (GC/MS) has been the preferred choice for 
opiates due to its sensitivity and selectivity. 
3.2 SPE AND SFE COMPARISON OF MORPHINE 
The principle of solid-phase extraction is well known and commonly used for the 
isolation of analytes from liquid matrices. Although SPE is easy and popular in 
terms of extraction techniques, supercritical fluid extraction (SFE), a relatively new 
sample preparation technique is becoming of increasing interest. Several authors 
have reported the super or sub critical analysis of opiates using various techniques. lo6 
This has lead to further research, applying SFE to biological fluids for the extraction 
of drugs of abuse. IO? A comparative study for the quantitative determination of 
morphine in whole blood using SPE and SFE has been investigated and discussed in 
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this chapter. This was to determine whether the two methods have any correlation 
when applied to authentic forensic case samples. 
3. 2.1 CURRENT METHODOLGY 
The current SPE methodology for morphine used in the routine laboratory is World 
Wide Monitoring, however, at the time of this study, the current methodology used is 
described below. The results obtained from this method were compared to the results 
obtained using SFE techniques to check that the same results were achieved for both 
methods for the extraction of blood. 
3.2.1.1 SPE of Morphine 
SPE columns were prepared by packing methanol: ethanol (1: 1 v/v) washed 
Extrelut ® into 10 ml syringes plugged with cotton glass wool. Samples were pre-
treated in vials with 1 ml of 0.1 M ammonium hydroxide solution and 50 JlI of 
internal standard (d -morphine). The contents of each vial were pi petted onto 
3 
® 
corresponding Extrelut columns, then conditioned with 5 ml of hexane and allowed 
to stand for 10 minutes. Labeled SCX columns (lcc) were placed on a VacElut and 
conditioned with 2 ml of methanol, 2 ml of de-ionized water and 1 ml of ethyl acetate 
: isopropanol (9: 1 v/v). 
® • 
The Extrelut columns were attached to the top of the SCX columns Via adapters. 
® 
The analytes of interest were transferred from the Extrelut columns to the SCX 
columns using three 4 ml aliquots of ethyl acetate: isopropanol (9: 1 v/v). The 
® 
Extrelut columns were discarded. The SCX columns were then washed with 5 ml 
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of acetonitrile: methanol (l: 1 v/v) and the analytes of interest eluted using 2 ml of 10 
% ammonia in acetonitrile: methanol (1: 1 v/v). The collected eluent was evaporated 
to dryness under nitrogen at 40°C and derivatised with 50 ).!l of BSTF A (1 % TMCS) 
at 90°C for 10 minutes. 
3.2.1.2 SFE of Morphine l08 
SFE pressure conditions were set at 3500 psi with the flow rate at set 2mllmin and 
temperature 100°C. A 10 % moditier of MeOH: Et3N 85:15 was used with 90 % 
CO for an extraction time of 30 minutes. The dried sample was derivatised using 
2 
50 J.11 of BSTF A and analyzed using GC/MS. 
The samples were prepared by loading 100 J.11 of internal standard ( d -morphine) onto 
3 
the extraction media Extrelut® that was then mixed and dried. The Rheodyne is set in 
the load position and the instrument is left to equilibrate. The sample is then loosely 
packed into a stainless steel extraction cell that was placed over the loop position of 
the Rheodyne. The extraction is started by switching the Rheodyne from the load to 
the inject position and left for 30 minutes to elute the analytes though the outlet, 
which are collected by expansion in MeOH. The sample was then evaporated under 
nitrogen at 40°C and derivatised with 50 /-ll of BSTF A at 90°C for 10 minutes. \08.109 
3.2.1.3 GC-MS Parameters 
A Fisons model GC 8000 Series (MD 800 in the EI Mode (70 ev) gas 
chromatography-mass spectrometry was used for analysis, this was equipped with a 
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HP-l (Cross linked Methyl Siloxane), capillary column, (30m x 0.531lm i.d, film 
thickness 0.88Ilm). 
The temperature was set at an initial 200°C for 1 min and a final 300°C for 5 min 
with an oven rise of 10°C Imin. The injector temperature was 250°C. Figure 3.3 
shows a GC/MS trace of morphine produced using analysis by GC/MS. The internal 
standard d -morphine mlz 432 ion, was used as a reference to calculate the 3 
concentration of morphine and ions mlz 414 and 429 for each sample. 
Figure 3.3 Chromatograph of un extracted morphine standard 
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3.2.1.4 Results and discussion 
Authentic forensic blood samples known to be morphine positives were chosen for 
this investigation. SPE is an efficient and reproducible extraction method that was 
compared to SFE to determine if the two yield corresponding results for blood. 
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Fourteen blood samples were extracted using both SPE and SFE with final analysis 
by GC-MS. For the extraction of morphine using SPE, the sample concentration of 
morphine ranged from 0.056 to 2.42 mg/ml in blood, compared to SFE results which 
ranged from 0.050 to 2.20 mg Iml in blood, shown in Table 3.1. The differences are 
also listed in Table 3.1. Small differences were shown between the two methods 
with a mean of 0.065. In addition, recoveries for SFE were found to be > 90% for 
morphine compared to that of SPE which was > 85%. 
Table 3.1 Comparison between SPE and SFE of morphine from authentic blood case 
samples 
Case # SPE mg/I SFE mg/I Difference 
T96-A 1.25 1.18 0.07 
T96-B 0.59 0.67 0.08 
T96-C 1.02 0.91 0.11 
T96-D 0.90 0.85 0.05 
T96-E 1.86 1.97 0.11 
T96-F 2.42 2.20 0.22 
T96-G 0.19 0.17 0.02 
T96-H 0.35 0.39 0.04 
T96-J 0.86 0.79 0.07 
T97-J 0.45 0.45 0 
T97-K 0.056 0.05 0.006 
T97-L 0.85 0.74 0.11 
T97-M 0.28 0.28 0 
T97-N 0.27 0.29 0.02 
Below in Figures 3.4 and 3.5 are traces showing the comparison between the same 
authentic blood samples (T98-D) run using SPE and SFE techniques. Both 
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techniques proved to be extractable for morphine III whole blood, with similar 
retention times and a percent difference of 5.9 %. 
Figure 3.4 Chromatograph of an authentic case sample extracted by SPE 
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Figure 3.5 Chromatograph of an authentic case sample extracted by SFE 
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The standard deviation and mean for comparison of both methods was 0.633 and 
0.782 with a linear relation ship of r2 = 0.986 and a gradient of m = 0.94 seen in 
Figure 3.6. This shows that good correlation for morphine extracted from whole 
blood exists between the SPE and SFE methods. In a perfect world a straight line 
would be equal to 1. 
Figure 3.6 Linear relationship between SPE and SFE for 14 authentic case samples. 
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3.2.2 CONCLUSION 
3 
Solid-phase extraction techniques have been the preferred technique for the 
extraction of drugs of abuse from various matrices. Although widely used as a 
sample preparation method, the technology is still advancing and exploiting more 
parameters to improve sample preparation, including SFE techniques. 
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SFE, a relatively new technique for sample preparation has until recently generally 
been confined to chemical processing applications. Now, it is emerging as a valuable 
analytical procedure for the forensic toxicologist. 
The investigations carried out using SPE and SFE methods, show that the two 
analytical techniques correlate well for the analysis of morphine in whole blood. 
Both techniques are fast, yield reproducible results and give good recoveries for 
morphine extracted from whole blood. 
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4. SOLID-PHASE EXTRACTION 
4.1 LITERATURE REVIEW 
4.1.1 INTRODUCTION 
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In the last few years, the use of solid-phase extraction (SPE) as a tool for the isolation 
of drugs from biological matrices has become more acceptable in both clinical and 
forensic laboratories for routine analysis.IIO'111 In analytical toxicology, the extraction 
or isolation of a compound of interest from biological specimens, is the most 
important process for the determination of a sample. A complete analytical process 
from sample collection to the final analysis of the results, has been developed for 
SPE. 
The steps necessary for SPE include, sample collection and storage, sample 
preparation, the isolation and identification of the analyte and quantification. All of 
these will be discussed later on in this chapter. The principle objectives of sample 
preparation for chromatographic analysis are dissolution of the analytes into a 
suitable solvent and removal of as many interfering compounds as possible. I 12 
With the use of a selection of commercially available sorbent columns, SPE can be 
suitably adapted to extract analytes from various samples (e.g. blood, urine, saliva, 
vitreous humor and more recently hair) with high percentage recovery and purity. 
Selective adsorption, adjustment of pH and partitioning of both the sample and the 
sorbent are very important during the extraction. The design of the extraction 
procedure is meant to selectively partition and exploit the analytes physical 
properties from interfering components in the sample. 
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As a result of the efficiency and less time consuming characteristics of SPE 
techniques, it is now the preferred technique over conventional extraction techniques 
such as liquid-liquid exaction (LLE) and has revolutionized sample preparation for 
the analysis of a wide variety of biological and non-biological samples. 
4.1.2 HISTORY 
The definition of SPE is "The separation or removal of an analyte or analytes from a 
mixture of compounds by selective partitioning of the compounds between a solid 
phase (sorbent) and a liquid phase (solvent)". This extraction technique has been 
used for the extraction of drugs in biological fluids and more recently hair samples in 
forensic laboratories. Due to its ability to provide clean, efficient extracts in a single 
step, it has recently gained popularity for many clinical and biochemical applications. 
Whitehorn, in 1923 was recognized as one of the first researches to use solid-phase 
techniques to isolate drugs from biological samples. 113 The success of the technique 
continued in the 1950s with researchers like Lund 114 and his colleagues, who used 
alumina columns to extract adrenaline and noradrenaline from blood and Bergstron 
and Hanson llS, who used amberlite IRC-50 columns, to extract adrenaline, histamine 
and catechol bases from crude extracts of glands. 
Research continued to improve extraction techniques with progress developing by 
the 1960s, with the introduction of cation exchange paper chromatography. Dole et 
aI, used this qualitative technique to detect numerous tranquilizers, narcotics, 
amphetamines and barbiturates from urine samples.
116 
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By the 1970s, the need for increased sensitivity made it necessary to develop more 
efficient techniques. The ion exchange principle was introduced to separate relevant 
drugs from biological samples using various columns. Fujimoto and Wang used 
amberlit XAD 2 resin columns to quantify narcotic analgesics at concentrations of 
0.6 mg/mrl.ll7 Adsorption techniques with average detection limits of 1 mg/mrl 
using charcoal columns were used by Meola and Yanko, to concentrate numerous 
drugs (e.g. quinine, barbiturates, morphine and cocaine and its metabolites) from 
. I 118 
unne samp es. 
With the progress of HPLC technology, came the development of silica and bonded 
silica as the stationary phase by the late 1970s. This development lead to the concept 
first developed by Water Associates and Analytical Chemistry International, of using 
sorbents packed in miniature columns. These sorbent columns were capable of 
isolating drugs or chemicals of interest from interfering impurities in samples during 
extraction. 
With the introduction of silica, bonded silica and other phases, small disposable 
cartridges termed SPE columns were commercially developed. They produced high 
recovery and purity of the analyte and reduced time, labour and solvent usage during 
extraction. 
4.1.3 LLE AND SPE TECHNIQUES 
The principles of SPE are very similar to LLE, ill that they both involve a 
partitioning of compounds between two phases. Before the use of SPE was 
developed, LLE was without a doubt, one of the most frequently employed extraction 
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techniques. In LLE, the analytes to be extracted are partitioned between two 
immiscible liquids, whereas in SPE the analytes extracted are partitioned between a 
solid and a liquid. 
Although widely employed, LLE techniques have a number of potential 
disadvantages which SPE techniques avoid or minimize.119-12o These disadvantages 
of LLE include, the formation of emulsions, serial processing of samples, the need 
for ultra-pure solvents, the use of large volumes of toxic organic solvents, time and 
labour required for extraction, and the relatively large sample volumes required for 
extraction (e.g. a minimum of 0.5-1 ml). 
With the introduction of SPE methods, came the advantages for sample preparation 
and analyte recovery which were preferred over LLE techniques. Some advantages 
of SPE include, high recovery and purity of the analytes improving analysis 
precision, reduction of extraction time and labour, especially if automated methods 
are used, small sample volumes (e.g. 50-100 Ill), small volumes of less pure solvent 
and the lack of emulsion formation that occurs in LLE. 
4.1.3.1 Recovery 
The comparison of SPE techniques with LLE techniques has been reported in 
literature showing a greater recovery range (from 80 % to 100 %) for SPE 
hn· 121-122 U' b h h' d' h . f h tec lques. smg ot tec mques, recovery stu les on t e extraction 0 t e 
compound lidocaine, cocaine, benzolecgonine and norcocaine were researched by 
123 
Sandberg. For SPE procedures, the percent recoveries were lidocaine 92 %, 
cocaine 86 %, benzoylecogonine 91 % and norcocaine 85 %. In contrast, using LLE 
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procedures for the same drugs, the percentage recovenes were lidocaine 59 %, 
cocaine 57 %, benzolecogonine 66 % and norcocaine 21 %.123 
In another comparative study, Okazaki et al reported recoveries of 39 % for 
Oflaxacin, 54.7 % for its dimethyl and < 5 % for its N-oxide metabolites using LLE 
methods respectively, as compared with 98 % recoveries using SPE Cs columns for 
all three analyte types.
124 
Numerous studies reported on the comparision of the two 
h . h CdS E h . 125·126 tec mques ave prelerre P to LLE tec mques. 
4.1.3.2 Sample Size 
Successfully quantifying smaller sample sizes depends on the sensitivity of the 
procedure and high recovery of the analyte. The usage of various SPE columns, 
increases the sensitivity and decreases the amount of sample needed for extraction. 
SPE techniques are used in many applications because of its small sample size 
requirements. 
The extraction of minute quantities of nicotine from human samples was reported by 
Sioufi et al as having achieved detection sensitivities of Ing and 20 ng/mr' in plasma 
and urine, after the treatment with transdermal patches of nicotine. 127 With the use of 
SPE CIS columns to pre-concentrate mycotoxin form river waste, Hoke et al 
increased the sensitivity of the artemia bioassay by a factor >5. 128 Using SPE C8 
columns, Huang e/ al successfully quantified etintidine using plasma samples as 
129 
small as 0.2 m!. 
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Conventional methods made it unsuitable for neonates and infant clinical studies to 
be investigated because of the large sample amounts needed. Since SPE 
developments, studies such as pharmacokenetics ofbumetamide by Wells et al using 
urine and plasma from human neonates has been reported. '30 By using SPE 
techniques in such studies, samples as small as 0.2 ml were used proving adequate. 
4.1.3.3 Time 
Employing rapid and less laborious methods is just another advantage that SPE 
techniques have over conventional LLE techniques. Extraction manifolds handling 
up to 24 samples simultaneously, which are commercially available, take less time 
for sample preparations than traditional procedures. The possibility of treating 
samples containing volatile analytes such as chlormethiazole '21 and 3-
methylindole '31 , are much more likely to be used because of these rapid procedures 
available. 
In addition to reduction of time and labor, the use of organic solvents for elution are 
reduced with only a few milliliters needed for the extraction procedure to take place. 
This reduction minimizes solvent costs, waste-disposal and sample handling, reduces 
potential fire hazards which promotes safer laboratory conditions and produces an 
environmentally friendly environment. 
Safer laboratory procedures using SPE methods have been applied and reported by 
Kupferschmidt et ai.
132 
They adapted a method to extract 3'-azido-3'-deoxythymidine 
from the blood of AIDs patients, which minimized sample handling and promoted a 
hazard free working environment. 
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4.1.4 OBJECTIVES OF SPE 
There have been several objectives quoted on SPE techniques that are important for 
the extraction process to be successful. 112 
1. The use of appropriate solvents in the washing steps to remove all interfering 
compounds. 
2. The principle objective in trace analysis starts with the pre-treatment of the 
sample for clean high recovery and purity of the analyte prior to the extraction 
process. 
3. The ability to fractionate the sample into different compounds or groups of 
compounds using different liquid phases for elution. 
4. Being able to store relatively highly volatile analytes that are unstable in liquid 
d. 112 me lUms. 
5. Derivitisation of the analyte(s) on the adsorbent surface and between relative 
groups, which can be directly eluted or retained and eluted later. 
4.1.5 SPE COLUMNS 
The principle of SPE IS well known for its applications for the removal of 
compounds from body fluids and can fall into two categories, adsorption and 
absorption. Adsorption extraction relies on the reversible binding of the compound 
of interest to a soild-phase material. Absorption extraction relies on the absorption of 
one phase (e.g. the aqueous phase) onto an absorbent support usually diatomaceous 
earth (e.g. Extrelut®) and is designed to mimic liquid-liquid extraction techniques. 
Both extraction techniques are discussed further in this chapter. 
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4.1..5.1 Silica and Bonded Silica Columns 
Silica or bonded silica gels, are the most popular SPE materials. Numerous 
functional groups with or without alkyl/chains that can be bonded to silica include 
groups such as -OH, -C6H6, NH2, -CN, -S03H and -COOH. As a result of the wide 
range of functional groups for SPE materials, the extraction can be non-polar, ion-
exchange or polar, based on the interaction mechanism. Some commercially bonded 
silica SPE columns are noted to have all the functional groups, which cause multiple 
and secondary interactions during extraction.
133 
Residual silanol groups in SPE CIS sorbent material have been reported to cause 
d . . . h I 134 secon ary Interactions In t e ana ytes. It has been reported that it is more 
advantageous in SPE applications, to make use of these groups rather than avoid or 
mask them. Utilization of residual silanol groups has been reported in the extraction 
of basic drugs from plasma. 135 
SPE columns are especially important for clean, efficient extracts, which are 
important in drug screening for the forensic toxicologist. They are generally 
disposable, polypropylene, cylindrical or conical shaped columns, with a male luer 
hub end used to fit into an extraction device (vacuum manifold). These SPE columns 
can hold up to 15 ml of sample and if necessary, can be adapted to have an 
attachment added at the top for increased volume. A solid sorbent approximately 40 
Ilm thick is sandwiched between two polyethylene discs located just above the luer 
end. \36 
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Solvation of a sorbent is necessary before the sorbet will interact reproducibly with 
isolates. Solvation is a wetting process of the sorbent bed with a solvent such as 
MeOH, creating a suitable environment for isolate retention. Once solvated, the 
excess solvent is removed by an additional solvent that prepares the sorbent to 
receive the sample. However, small amounts of the first solvent will remain 
associated with the sorbent. When the column is solvated, excess drying should be 
avoided, specifically before the sample application. Complete drying of the column 
bed requires usually at least 30 seconds of continuous airflow. Once the analytes are 
retained on the sorbent bed, drying is usually not a problem and sometimes is 
recommended between solvent steps. 
The main columns used for SPE are the non polar, polar and ion exchange columns. 
The drugs of interest interact chemically based on the polarity and ion exchange 
properties within the column. The interactions are activated by pH adjustments from 
various solvents or buffers. 
4.1.5.2 NonPolar or Reversed Phase 
The principle of the nonpolar phase used in SPE is based the exploitation of 
hydrophobic interactions to extract non-polar compounds from a polar sample 
matrix, retaining them on the column sorbent for elution. Most matrices used are 
nonpolar, therefore, using nonpolar sorbents tends to be less selective during the 
extraction and alternative optimisation is necessary to elute specific compounds. 
Adjusting the pH of the sorbent and the sample are important for hydrophobic 
interactions between the functional groups of the analyte and the sorbent to take 
place. 
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Optimal elution conditions for nonpolar compounds will result in high solvent 
solubility and low solvent polarity of the eluted compounds. This means that 
because nonpolar interactions between nonpolar sorbents and nonpolar analytes are 
facilitated by polar solvents, the polar environment are generally not capable of 
disrupting the dispersion forces of the nonpolar interactions. However, nonpolar 
interactions between the analytes and the sorbent are best disrupted by solvents 
having nonpolar characteristics (e.g. MeOH, chloroform, hexane). Even though 
MeOH is polar, it has enough nonpolar character to disrupt the nonpolar interaction 
between the analyte and the sorbent causing elution of the analyte. 
4.1..5.3 Polar or Normal Phase 
In polar phase SPE hydrogen bonding or polar and hydrogen bonding of the polar 
compounds from nonpolar matrices, allow retention on the sorbent columns. 
Hydrogen bonding is one of the more significant polar interacts, were one hydrogen 
group bonds to an electo-negative atom such as oxygen or nitrogen and so on. High 
solubility and high solvent polarity give superior extraction and elution of the 
analyte. 
Nonpolar solvents are used to condition the column prior to application of the sample 
and then used to elute interfering compounds from the sorbent bed. This is because 
strong electronic interaction between the sorbent and the analyte can not be easily 
disrupted by nonpolar solvents. Conversely, polar interactions are disrupted more by 
polar solvents because polar analytes are more soluble in polar solvents and they 
compete more effectively with the analytes for the sorbent than nonpolar sovlents. 
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At the end of the extraction, polar solvents are then used to elute the retained 
compounds of interest. 
4.1.5.4 Ion Exchange (Anion or Cation Exchange) 
The ionic character of the compound is based on its affinity for the ion exchange 
column. The ionic charge on the compound of interest should be opposite to the 
functional groups on the column for retention of the analyte. Low counter ion 
concentrations in a sample give superior extraction and elution of the analyte. The 
ion exchange columns can be cation or anion exchangers. Cation exchange columns 
attract analytes which have positive charged functional groups and anion exchange 
columns interact with the negatively charged analytes. 
For retention to occur, the solvent or matrix must be at a pH where both the analyte 
and the sorbent are charged. Therefore, the pH is below the pka of the cation by two 
units and above the pKa of the anion by two units. At this pH approximately 99 % of 
the groups will be charged. 
Ionic strength is important in ion exchange. It is a measure of the total ionic species 
concentration present in the solvent or matrix environment. Ion exchange is a 
competitive mechanism that cause the retention of analytes in the solvent or matrix 
that are capable of competing for available ionic groups on the sorbent. Low ionic 
strength promotes the retention of the analytes and high ionic strength disrupts it 
facilitating elution. 
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Table 4.1 The various phases present for SPE columns. 
Adsorption silica gel (SiOH), florisil (MgSiO) alumina (AI 0 ), KIeselguhr 
2 3 
Phase (SiO) 
Normal Phase amino (NH ), cyano (CN), diol (COHCOH), silica (SiOH) 
2 
Reverse Phase methyl (C ), ethyl (C ), hexyl (C ), octyl (C ) , octadecyl (C 8)' 
I 2 6 8 I 
cyano (CN), cyclohexyl (C
6
H
1
), phenyl (C6HS) 
Anion Exchange quaternary amine (N+), amino (NH ), diamino (NH NH) 
2 2 
Cation Exchange aromatic sulphonic (C H SO H), carboxylic acid (COOH) 
6 S 3 
4.1.5.5 Diatomaceous Earth 
Another type of substance which acts as a support for the absorption of an aqueous 
sample is called diatomaceous earth or Extrelut®. This Extrelut® is a porous material 
which is washed in solvent(s) sllch as MeOH or EtOH to clean the diatomaceous 
earth of contaminants before application of the sample. 
Diatomaceous earth material used in absorption extraction, can provide clean and 
efficient extracts of sufficient quality for analysis by GC/MS or HPLC without an 
abundance of interfering compounds which are present in some biological matrices. 
Anderson and Fuller described good results and high recovery of the analyte of 
interest in post-mortem blood.
137 
They used diatomaceous earth for the extraction of 
acid and neutral drugs prior to GC analysis. 
There is not much literature on the use of diatomaceous earth. However, some 
applications using diatomaceous earth to elute sample compounds, have reported 
good results, but the use of prepacked SPE columns still proves to be the most 
widely used extraction method for elution of sample compounds. This is because of 
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the numerous column phases that are commercially available and the ability to use 
various biological matrices on such columns. 
4.1.6 PRINCIPLE OF SPE 
The governing principle of SPE is to concentrate and isolate from a sample matrix, 
the analytes of interest. It is a physical extraction process involving a solid phase and 
.. 138 
a lIqUId phase. 
There are five principle steps and a derivatisation step required for SPE use, 
demonstrated in Figure 4.1: sample pre-treatment, column preconditioning, sample 
application, column wash and drying and elution of analytes. 
Figure 4.1 Five steps for the elution of a sample using SPE columns 
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4.1.6.1 Sample Pretreatment 
The first step in toxicological analysis is the pre-treatment of the sample prior to the 
extraction process. Depending on the type of sample used, biological or 
environmental, the sample pre-treatment will vary. The sample under goes a pre-
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treatment application normally with a buffer with adjusted pH and internal standard 
used as a marker for detection of the ions during analysis. 
The purpose of the sample pre-treatment step is to release the drugs from the matrix, 
remove interfering proteins and other endogenous irrelevant materials (e.g. salts) 
which may affect the analysis and extraction by adjusting the pH, ionic strength and 
concentration of the sample compound(s). Protein precipitation with organic 
solvents, dilution with buffers, water or sonication, may be carried out on the sample 
for extraction preparation. 
4.1.6.1.1 Adjustment of pH and Ionic Strength 
For optimal conditions, the adjustment of pH and ionic strength plays an import role 
in SPE and conventional techniques resulting in major difference in the final 
analysis. The extraction and pH of the sample depends on two factors: the physical 
and chemical properties of the relevant drug and the sorbent, and the drug 
interactions with functional groups of the sorbent. For example, for van der Waal 
forces and hydrogen bonding from non-polar sorbents (e.g. CIS octadecyl-bonded 
silica), the sample and sorbent column pH values should be adjusted so that the drugs 
to be extracted are in their uncharged forms. 
With the principle of ion exchange, because there are opposite charges of the 
functional groups on the sorbent, the sample pH values must be adjusted to make 
sure the relevant drugs on the column are in their charged form and will be retained 
by the functional groups. Changing the pH of the extraction system, either 
neutralizes the charged sorbent or the compound to be extracted. 
Chapter Four: Solid-Phase Extraction page 100 
Compounds present in neutral form should have their pH adjusted at least 2 pH units 
higher than the pKa for basic compounds and at least 2 pH units lower than the pKa 
for acidic compounds. 139 This results in a yield of approximately 99% of the 
compounds of interest being eluted in their non-ionized form. For ion exchange SPE 
it is advisable to use buffers of < 0.1 M or water as this helps to reduce ionic drug 
retention caused by highly concentrated samples which can act as counter ions. 
4.1.6.1.2 Internal Standard 
The internal standard is used in extraction procedures to correct for the recovery and 
the analytical variability during analysis. It must be added in the early process of the 
extraction procedure for accurate reflection of the recovery of the unknowns, errors 
produced from sample dilution and samples are correlated using internal standards. 
The internal standard should be chemically similar to the compound of interest, 
chemically stable, have similar detection characteristics as the unknown compound, 
elute in a blank portion of the chromatogram and should be well resolved from 
adjacent peaks. Under normal conditions, 80 % well resolved full-scale peaks should 
be noted in a diluted sample with the internal standard clearly identified for sample 
identification on the chromatogram. 
4.1.6.2 COLUMN PRE-CONDITIONING 
Prior to sample application, it is necessary to precondition the sorbent column using 
suitable solvents for conditioning to obtain high reproducible recovery of the analyte. 
Suitable organic solvents (e.g. methanol) may be used on sorbents for nonpolar and 
multiple-interaction phases to solvate bonded functional groups. These functional 
Chapter Four: Solid-Phase Extraction page 101 
groups in turn help to open hydrocarbon chains and remove interfering organic 
residues which may affect analyte interactions or interfere in the detection stage. 
Organic solvents are usually followed by the addition of water or buffers which have 
had their pH, ionic strength and polarity adjusted, to remove excess organic solvent 
and prepare the columns to receive an aqueous sample. For polar phases, the 
treatment with a nonpolar solvent (e.g. hexane) is necessary to activate the surface. 
4.1.6.3 SAMPLE APPLICATION 
Once the column has been pre-conditioned, the pretreated sample is applied onto the 
top of the pre-conditioned SPE column. Adsorption onto the sorbent bed is induced 
by applying a light vacuum or positive pressure at a flow rate of 1.5 ml Iminute. 
4.1.6.4 COLUMN WASH 
After sample application, the columns must be washed again with water, buffer or an 
appropriate solvent, to selectively remove any endogenous compounds that may 
interfere with the analysis, without substantial loss or removal of the relevant drugs. 
The flow rate of the sample passing through should be kept at 1.5 ml Iminute to 
retain the drug of interest or compound obtained from the biological sample onto the 
column. 
4.1.6.5 COLUMN DRYING 
Precautions must be taken in this step which is used to dry interfering solvents out of 
the sorbent bed before the elution step. If a water miscible organic solvent (e.g. 
methanol, buffer) is used as an eluent and the analysis is carried out on reversed-
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phase HPLC, column drying is unnecessary, as residual water does not pose a 
problem during the analysis. However, analysis carried out on GC or GC/MS using a 
water-immiscible eluent, can interfere with the analysis and elution of relevant drugs 
if the column is not completely dried prior to the elution step. 
4.1.6.6 ELUTION OF ANAL YTES 
A suitable eluent for the extraction of drugs from SPE columns should be strong 
enough to elute the relevant drugs completely using small amounts, while leaving 
behind any interfering components. Elution solvent selectivity is based on its 
polarity (PI), solvent selectivity and eluotropic strength (EO).140 Solvent strength and 
selectivity are based on the solubility of a compound in a solvent. Solvent strength is 
the polarity or preferential ability to dissolve more polar compounds, while 
dissolving particular compounds where the polarity is not very different as the 
selectivity. Snyder, has reported 71 P' values and selectivity of solvents used in SPE 
techniques. 141 
The binary mixture for A and B solvents can be calculated for desired P' values using 
h fi 11 · . 140 teo owmg equatIOn. 
<l>a I <l>b = Volume Fractions of Solvents 
A I B = in the solvent mix 
Pal Pb = P' values of pure solvents AI B 
E.g. P' of a 1: I mix of chloroform (PI= 4.4) & Acetone (PI = 5.4) is 4.9 
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The eluotropic strength depends on the elution strength that is helpful for choosing a 
suitable eluent for compounds from a particular sorbent. eO can be used to develop 
additional SPE methods and is useful in instances where the usage of an eluent 
system highly recovers not only the drug of interest, but interfering impurities as 
well. The use of another eluent with a similar eO value can overcome this problem 
without greatly affecting the extraction efficiency. 
Control of the rate of eluent flow through the column should be adequate enough for 
the mobile phase and the stationary phase to react with the relevant drug in the 
sample. The investigation of flow rates by Logan and Stafford using diatomaceous 
earth columns found that the best flow for the recovery of drugs was 2 ml Iminute.
141 
In the case of nonpolar, polar and ion exchange columns, a slower flow rate was 
found to be more suitable for ion exchange columns than polar and nonpolar 
I b f I . h . . 139 co umns, ecause 0 s ower IOn exc ange mteractlOns. 
4.1.6.7 DERIVATISATION 
Converting sample compounds into a derivative form before or after extraction is 
useful in some instances. It can be used to reduce the polarity of the analyte for the 
use of partition columns rather than adsorption or ion exchange columns or to 
increase and selectively enhance the detector response to relevant compounds in the 
sample. 
One of the derivatives used in forensic toxicology laboratories for the derivatisation 
of relevant drugs is the N,O - bis (Trimethylsilyl) trifluoroacetamide with a catalyst 
trimethylchlorosilane (BSTF A +1% TMCS). BSTF A is a colourless, clear and 
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moisture sensitive liquid that replaces labile hydrogens with a Si (CH3)3 group when 
reacted with polar compounds. 142 The addition of such groups helps to prepare 
volatile and thermally stable derivatives for GC/MS. It is an effective trimethylsilyl 
donor with donor strength similar to its unfluroinated analogue BSA (N,O - bis 
(trimethlysilyl) acetamide. 
BSTF A is preferred over many other silylating reagents because good 
chromatographic separation can be obtained. This is because its volatile by-products 
mono-(trimethylsilyl)trifluoro-acetamide and trifluoroacetamide elute with the 
solvent front. TMCS is a catalyst which is normally added to react with BSTFA 
providing stronger donor strength. With the addition of this catalyst, many amides, 
secondary amines and hindered hydroxyls will be successfully derivatised, which 
BSTF A could not have done alone. 
4.1.7 CHROMATOGRAPHIC ANALYSIS 
4.1.7.1 SPE GC/MS 
Gas chromatography- mass spectrometry (GC/MS) instruments have been widely 
used for environmental, biological and chemical sample analysis. This is mainly 
because of their sensitivity, selectivity and high resolution for the analyte from the 
compound mixture. Although good, these characteristics would not be possible if 
adequate sample preparation and extraction techniques where not carried out prior to 
analysis. 
SPE techniques using GC/MS have resulted in clean and pure extracts, which elute 
the sample compound with high recovery and resolution. Both the extraction and 
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instrumental techniques are relatively quick, less laborious, can be automated and are 
easy to use. It has become the most preferred amongst analytical procedures for drug 
. . h I bl dl43 144 I 145. h 146 • 141 extractIOns III woe 00 , serum , p asma ,vitreous umor , unne , 
1· 147. 148 d 1 h' 149 sa iva , tlssue an more recent y mr . 
4.1.7.2 SPE HPLC 
Many analytical methods employ high-performance liquid chromatography (HPLC) 
for the analysis of the sample extracts obtained from SPE techniques. The properties 
of the adsorbents in SPE columns, are very similar to HPLC adsorbents typically 
silica or bonded silica (e.g. C18, Cg, C5, C2, cyano), so the same principle applys for 
retention and desorption of the analtye. 
Efforts to automate sample preparation can lead to greater throughput of the samples 
prepared for analysis, more accurate methods, reducing time, labour and cost. 
Instrumentation and data process is far more easier to automate than sample 
preparation for SPE. This is because sample preparations are application specific and 
depend on the matrix and analyte properties, therefore manual procedures are 
preferred. 
The success of SPE automation (e.g. ASPEC automated separation preparation 
systems by Gilson), allow samples to be applied to the cartridge and can be linked 
on-line or off-line to HPLC. Over the past few years, this automated process has 
been employed in numerous applications for the analysis of aqueous and biological 
matrices. 
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4.1.7.3 On-Line-SPE HPLC 
SPE process can be performed either on-line as a trace enrichment technique or off-
line, to prepare cleaner samples prior to analysis. The on-line SPE technique is a pre-
column concentration technique that involves column-switching (e.g. automated 
valves) or coupled column process where the final eluent from the SPE column is 
injected into an HPLC system for partitioning and detection. 150 
By directly eluting SPE extracts onto the analytical HPLC system, improves the 
sensitively is enhanced and the evaporation and reconstitution steps normally used 
after the elution are eliminated thus increasing the recovery. For the confirmation of 
peak identity during analysis, a diode array detection system is employed in HPLC, 
which measures the complete UV Ivis spectrum and expands the rule of HPLC from 
its traditional uses in quantitative procedures. 
4.1.7.4 Off-Line SPE HPLC 
Off-line SPE techniques were designed to produce cleaner samples prior to analysis. 
There are automatic and semi automatic off-line SPE instruments available that can 
carry out SPE procedures exclusively in automated systems, with the transfer of the 
eluents to HPLC done manually for semi-automatic systems. Multiple extraction 
devices have been introduced for the extraction process of numerous samples, which 
are performed manually, but can be done using off-line analysis. I 12 An advantage of 
the off-line methods, is its ability to use a variety of solvents and multiple columns 
that can not be used with on-line techniques. 
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4.1. 7.5 SPE SFE/SFC 
SPE sorbents have been used in combination with SFE/SFC (supercritical fluid 
extraction and chromatography) techniques. As a result the sorbent acts as a 
chromatographic column with selective elution of the analyte of interest. Although 
SFE seems to have proven itself as a popular alternative to conventional liquid 
extraction methods, SPE will continue to be a popular sample preparation technique 
widely used in clinical and environmental laboratories. 
4.1.8 CONCLUSION 
SPE has been successfully established as the preferred sample preparation technique 
in a variety of chemical, biological and environmental applications. With numerous 
advantages over conventional methods that include; ease of automation, cost 
reduction and high sample recovery. 
There is not doubt that SPE will continue to be used as the preferred extraction 
technique over traditional methods. However, with the introduction of SFE 
techniques have come many advantages over SPE techniques, with the major 
advantage being reduced contamination. 
Using SPE techniques, impurities, antioxidants, contaminants etc., can often be 
observed causmg interference during sample analysis and reduce the lifetime of 
chromatographic columns. By cleaning cartridges with solvents and running blanks 
to minimise interferences by contaminants, reduces sample throughput and increases 
solvent consumption and processing costs. 
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In general, it has been shown that SPE techniques are the method of choice over LLE 
techniques today. LLE methods offers the option of multiple extraction steps to 
provide a clean, selective and efficient extract. However, SPE adds further 
selectivity to the extraction procedure which makes it ideal for the elution of various 
compounds. 
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5. BENZODIAZEPINES 
5.1 LITERATURE REVIEW 
5.1.1 INTRODUCTION 
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The use of psychoactive drugs dates back to prehistory. Opium has been used to 
alleviate pain in Ancient Egypt, alcohol in religious ceremonies in the Near and 
Middle East, the chewing of coca leave by the Andean Indians to lessen fatigue and 
cocaine as a local anesthetic. Over the past decade, the rapid growth of both 
legitimate medical use and illicit non-medical abuse of numerous drugs that affect 
the mind have been observed. 
A number of psychoactive drugs have been synthesized and introduced into medicine 
to treat psychological distress and psychiatric illness. Until recently, these 
tranquilizers have been thought to present little danger of abuse or dependence. 
However, long-term use can become addictive, causing dependency and withdrawals 
even under medical supervision. 
5.1.2 HISTORY 
In 1955 Dr Leo Sternbach synthesized a drug that he thought to be in the chemical 
family quinazoline N-oxide, but was later found to be a minor tranquillizer. 151 The 
drug was rediscovered later and released as chordiazepoxide, a minor sedative 
marketed as Librium® in 1961. 151 Some attributes that influenced the popularity of 
chlordiazepoxide were its calming effects, muscle relaxation and prevention of 
convulsions. 
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5.1.3 PHARMACOLOGY 
Benzodiazepines are minor tranquilizers with anxiolytic, sedative, anti-convulsive 
and muscle-relaxing effects and are widely used as anti-anxiety drugs. lSI They are 
absorbed in the body, with peak concentrations occurring within 0.S-8hrs after 
administration. They are given in a wide range of dosages from less than 0.1 mg to 
100 mg or more each day. lSI Researchers soon began to synthesis other drugs in the 
benzodiazepine family to determine the relation of its chemical structure to the drugs 
effects. Most benzodiazepines are extensively metabolized and many members of 
the group are in fact metabolites of the others. 
5.1.3.1 System Reaction 
The focus of benzodiazepines in the central nervous system has found to be located 
in specific receptors (dendrites with small areas) termed benzodiazepine receptors. 
These receptors cause the nerves to respond as if they were activated, resulting in 
release of chemical compounds called neurotransmitters. This reaction is also 
attributed to the receptors sensitivity to react to the neurotransmitter. The stronger 
the binding to a receptor, the stronger the drug will be to relieve anxiety thus, the two 
are directly related. 
Researchers have found that the neurotransmitter responsible for the reduction of 
nerve activity and increasing the receptor-binding activity of benzodiazepine is called 
GABA (gamma-aminobutyric acid).lsl It was theorise that the GABA receptor is 
structurally similar to the benzodiazepine receptors, because GABA specifically bind 
only to the benzodiazepine receptor which in turn increases GABA binding to their 
own receptors. 
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5.1.3.2 Side Effects 
Despite the success ofbenzodiazepines for the treatment of depression and anxiety, it 
does have dangerous side effects. When the problems associated with 
benzodiazepines became apparent, the initial enthusiasm and frequent uncritical 
distribution of prescription was replaced by restriction on the ease by which they 
were dispensed. They can be abused to the point where their dependability can be 
life threatening. 
Acute poisoning due to an overdose of benzodiazepines is becoming a common 
problem and is indicated by drowsiness, confusion, slurred speech, lack of co-
ordination and sometimes coma. More serious side effects that can be experienced 
are motor and memory impairment, sedation, behavior disinhibition and paradoxical 
agitation have been occasionally observed. 152 
5.1.4 PHARMACOKINETICS 
The physicochemical and pharmacokinetic properties of the benzodiazepines greatly 
affect their clinical utility.ls2 Lipophilicity is an important variable in the duration of 
action of benzodiazepines. The extent of binding correlates strongly with lipid 
solubility. The benzodiazepines are completely absorbed with the exception of 
clorazepate and some (e.g. prazepam and flurazepam) reach the systemic circulation 
in the form of active metabolites. 153 
Based on elimination half-life, benzodiazepine receptors can be divided into four 
categories: (1) ultra-short acting agents, (2) short-acting agents with tl/2 < 10 hrs, 
(3) intermediate-acting agents with t1l2 10-24 hrs and (4) long-acting agents with 
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t1l2 > 24 hrs. 154 Often, the longer the half-life of benzodiazepines can cause 
pronounced withdrawal symptoms on discontinuation of use, which may develop 
days after cessation of the drug taken. The duration of action of a certain 
benzodiazepine depends not only on the half-life of the drug itself, but on the 
possible formation of active metabolites. 
S.1.S PRESCRIPTION 
The development of clordiazepoxide has led to the synthesis of hundreds of 
benzodiazepines and at present 16 available by prescription in the United 
Kingdom. IS3·154 Diazepam, which has the trade name Valium®, is just one of the 
many synthesized benzodiazepines on the market as an effective sedative. It is much 
more potent than Librium® that results in less dosage needed to produce small but 
effective sedative effects. 
Approximately 25 benzodiazepines are available by prescription for various needs. 
The generic names for some of them are lorazepam, flurazepam, triazolam, 
chlordiazepoxide, temazepam, oxazepam, clorazepate, diazepam and alprazolam. 
They range from sleeping pills to antidepressants, with some under investigation for 
use as anesthetics. 
There are many questions that should be asked before you are prescribed 
benzodiazepines. Not all cases of anxiety should be treated using tranquilizers or 
sedatives, only in extreme cases should they be considered for use. 80th doctor and 
patient should be aware of the potential side effects, dangers and correct usage of 
benzodiazepines. 
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Table 5.1 Various prescribed benzodiazepines and their use in treatment. ISS 
Nonproprietary Trade N~lme Treatment Daily *Dosage 
Name(s) Dose, mg form 
Alprazolam Xanax® anxiolytic 0.75-1.5 0 
Clorazepate Tranxene® anxiolytic 15-60 O,SR 
Clonazepam Rivotril® anxiolytic, anti- 1.5-10 0 
seizure 
Chlordiazepoxide Librium®, others anxiolytic 15-40 0, I 
Diazepam Valium®, others anxiolytic, anti- 2-20; O,I,L, 
seizure muscle repeat in SR 
relaxant 3-4hrs 
Flunitrazepam Rohypnol® hypnotic NA O,L 
Lorazepam Ativar® anxiolytic, anti- 2-4; 30-60 0, I 
seizure 
Midazolam Hypnovel® sedative NA I 
Oxazepam Seraz®, Zazopam® anxiolytic 30-60 0 
* Dosage forms ° = Oral solid, L = Liquid, SR = Slow releasing, 1= Injection 
5.1.6 CHEMICAL STUCTURE 156 
Attempts to determine the relation of various aspects of the chemical structure of 
Librium®, have led to several other benzodiazepines being synthesized. However, 
because of the close chemical structures, most of them had very similar effects to 
Librium®, one being diazepam that is marketed as Valium®, being more potent. 
Below in Figure 5.1 is the basic structure of drugs belonging to the benzodiazepine 
class of molecules. 
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Figure 5.1 Basic Structure of I ,4-Benzodiazepine. 156 
The general structure consists of three rings denoted by the letters A, Band C in 
Figure 5.1, together with a number of locations on the drug molecule where specific 
atoms or groups of atoms are introduced at the sites labeled RI, R2, R3, R7 and 
R2' .156 By substituting different molecule groups at the R sites results in new 
molecular structures which gives different drugs with different pharmacological 
activities. 
Table 5.2 below lists the various common benzodiazepines and their structural 
groups. One example is diazepam, Valium®. By replacing RI with a methyl group 
CH3, R2 with a keto oxygen atom =0, RJ and R2' with a hydrogen atom H and R7 with 
a chlorine atom CI, the structure becomes diazepam. From diazepam, changing RI 
from CH3 to H results in nordiazepam, a second change in R3 from H to OH, the 
hydroxy group, results in oxazepam and further change at R2, from H to CI results in 
lorazepam. Going back to nordiazepam, change at the site R7 from CI to N02, the 
nitro group, gives nitrazepam and further change at R2, from H to CI gives 
clonazepam, as listed in Table 5.2. 
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Table 5.2 Structural groups of various common benzodiazepines 
BENZODIAZEPINES Rl R2 R3 R7 R2' 
Chlordiazepoxide c-) -NHCH3 -H -CI -H 
Diazepam CH3 =0 -H -CI -H 
Nordiazepam -H =0 -H -CI -H 
Nitrazepam -H =0 -H -N02 -H 
Clonazepam -H =0 -H -N02 -Ct 
Oxazepam -H =0 -OH -CI -H 
Lorazepam -H =0 -OH -CI -CI 
Temazepam 
-
CH3 =0 -OH -CI -H 
5.1.7 METABOLISM 
Benzodiazepines are extensively metabolized by several different microsomal 
enzyme systems in the liver. Active metabolites are biotransformed more slowly 
than the parent compound. Hence, the duration of action of many benzodiazepines 
has no influence to the half-time of elimination of the drug that has been 
administered. ISS 
The metabolism of benzodiazepines occur though hydroxylation (aliphatic and 
aromatic), desalkylation, reduction and acetylation reactions (phase I) followed by 
conjugation to glucuronic acid (Phase II) prior to excretion. 155 Biological activity is 
present in some Phase I metabolites which may be greater or less than that of the 
parent, whereas the conjugates possess no significant activity. Two of the most 
common metabolites of 1-4-benzodiazepine are oxazepam and nordiazepam. 
Nordiazepam has a half-life of 40-99 hours, therefore, all compounds metabolized to 
nordiazepam are considered long-acting. 155 Some parent drugs are rapidly 
metabolized into nordiazepam and are not detectable in blood or urine. 
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Figure 5.2 The Major Metabolic Route of some Benzodiazepine. l55 
Chlordiazepoxide --- Desmethylchlordiazepoxide---Demoxepam 
Diazepam 
Chlorazepate ---)~ Nordazepam -----)7 Oxazepam --)-7 G 
Halazepam Lorazepam >~ 
C 
N-Hydroxyethyl- N-Desalkylflur- 3-Hydroxy U 
Flurazepam ~ Flurazepam --)~ azepam ~ derivative --)-'} ~ 
Triazolam alpha-Hydroxy- '-
--)~ Triazolam --------------7~ 
Alprazolam --"-7 alpha-Hydroxy_-_____________ '-~ 
/ Alprazolam 7'" 
lMidazolam ~ alpba-Hydroxy:.....-____________ >...::,.. 
.. . ... . / lMidazolam 
5.1.8 CHROMATOGRAPHIC ANALYSIS 
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There are numerous publications of the analysis of benzodiazepines using methods 
such as SPE and LLE with analysis techniques using GC/MS, GCIFID and GCIECD. 
Table 5.3 lists numerous recent literature on the types of extraction and analysis 
techniques used. 
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Table 5.3 Summary of extraction and analysis techniques used for detection 
benzodiazepines in various matrices. 
Year Extraction Technique Analysis Technique 
1989157 GC/MS SPE 
1991 1)8 GC/MS/MS SPE 
1991 m GCINPD, HPLC LLE 
1991 160 FPIA, HPLC LLE 
1992161 HPLC SPE 
1994162 HPLC LLE 
1994163 I IA 
1995 164 HPLC LLE 
1995 165 GC/MS LLE 
1996166 GC/MS, HPLC LLE 
1996167 HPLC SPE 
1997168 HPLC SPE 
Recent literature published for the analysis of benzodiazepines, generally concerned 
with analysis by GC/MS. Both HPLC and GC/MS analysis can be used for 
benzodiazepine determination. However, it has been reported that HPLC has more 
advantage over GC/MS analysis for the recovery of some benzodiazepines. 
5. 2 CURRENT METHODOLOGY 
The current extraction and methodology for benzodiazepines in whole blood used in 
the routine toxicology laboratory is by SPE with analysis by HPLC with UV 
detection. The columns used for routine analysis are not sorbent columns and 
therefore, optimization was carried out using SPE columns and compared. 
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5.2.1 SPE DIATOMACEOUS EARTH 
Label and fill a plastic 10 ml syringe with a small amount of glass wool and 
approximately % full with dichloromethane washed Extrelut® (diatomaceous earth). 
Three vials blank, standard and sample were labeled. 
• Standard: 0.9ml of blank blood was added to the vial with Iml of pH 7.4 
phosphate buffer, 251.ti of 5% ammonia solution, 100).1.1 of stock mix (triazolam, 
temazepam, chlordiazepoxide, desmethyldiazepam and diazepam 1 mg Iml) and 100 
).1.1 of internal standard (prazepam 2.61 mg II 00 ml). 
• Blank: 1 ml of blank blood, 1 ml of phosphate buffer, 100 ).1.1 of prazepam and 25 ).1.1 
of 5% ammonia solution were added to a vial. 
• Sample: Iml of sample blood, Iml of phosphate buffer, 100).1.1 ofprazepam and 25 
).1.1 of 5% ammonia solution were added to a vial. 
The contents of each vial were pippetted into their corresponding columns and left to 
stand for 5 minutes. Approximately 8 ml of diethyl ether was used for elution of 
benzodiazepines under gravity, then evaporated to dryness under nitrogen. The 
dried residue was reconstituted in 180 ).1.1 of mobile phase (0.01 M Na2HP04 + MeOH 
30:70 v/v) and sonicated for 5 minutes. 
5.2.2 HPLC Parameters 
A Gilson HPLC system was used which consists of a 307 Gilson pump with a 118 
UV Ivis detector and a wavelength set at 254 nm. The mobile phase which consisted 
orO.01M Na2HP04 : MeOH (30 : 70 v/v), was pumped through a 5 micron 25 cm x 
4.6 mm i.d. Hypersil ODS Column at a flow rate of 1 ml /minute which gave a 
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pressure of approximately 2500 psi. Na2HP04 buffer was prepared by dissolving 1.78 
g of Na2HP04.2H20 in 1 liter of de-ionized water. Add 120 ml of prepared buffer to 
280 ml MeOH and de-gassed with helium for 10 minutes at room temperature. The 
injections were controlled via a 7125 Rheodyne fitted with a 20 ~I loop and the data 
collected on a 3394A Hewlett Packard integrator. 
5.3 CONCLUSION 
Method development for the extraction of benzodiazepines using solid-phase 
extraction (SPE) was carried out for forensic purposes. SPE Bond elute certify LRC 
columns were used for method development, with results compared to routine drug 
screening using diatomaceous earth columns. Benzodiazepines used in method 
development were triazolam, temazepam, desmethyldiazepam, diazepam, 
chlordiazepoxide and prazepam which was used as the internal standard. 
5.4 METHOD DEVELOPMENT 
Alternative elution, various pH buffers and extraction methods were used 
maintaining constant apparatus parameters for consistent data. An unextracted 
sample was first analyzed for the calculation of the peak area ratio (PAR) and 
retention times for each drug. The standard mix used consisted of triazolam (1.04 
mg 1100 ml), temazepam (1.21 mg 1100 ml), chlordiazepoxide (1.57 mg 1100 ml), 
desmethyldiazepam (1.58 mg 1100 ml), diazepam (1.31 mg 1100 ml) and prazepam 
(internal standard 2.61 mgl100 ml) which were prepared as 10J-lg Iml standard 
solutions. 
Chapter Five: Benzodiazepines page 120 
To find the percentage recovery for the unextracted sample, which is used as a 
reference, the PAR of the unextracted drug was divided by the PAR of the 
unextracted internal standard. The sample was then extracted and the internal 
standard added to the elution and analyzed. 
This study involved the application of SPE Bond Elute Certify® (BEC) columns of 
benzodiazepines in whole blood. To find the best sample preparation and extraction 
technique, various preparation steps were investigated to determine the most robust 
method and then optimized. Eleven methods were investigated using Bond Elute 
Certify ® column to determine which extraction method eluted all five 
benzodiazepines. The column conditioning and wash steps were varied for initial 
determination. 
5.4.1 SAMPLE PRE-PREPARATION 
All methods consisted of the same sample preparation step for relatively consistent 
results. The preparations were as followed: 
To a vial containing I ml of blank blood, I ml ofO.OIM phosphate buffer (KH2P04) 
pH 6 and 50 I ..d of 5 % ammonia prepared in de-ionized water were added. In 
addition, I 00 ~tl of benzodiazepine spike solution, that consisted of triazolam, 
temazepam, chlordiazepoxide, desmethyldiazepam and diazepam were added to the 
vial and vortexed for 30 seconds. The internal standard prazepam (lOa J..lI) was 
added to the final collected elution to establish the highest recovery from the various 
methods. 
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5.4.1.1 Experimental Method 1,2 and 7 
The column was conditioned with 2 ml of MeOH and 2ml of buffer pH 6 and then 
the sample was added. The columns were then washed with 1 ml of water and dried 
for 2 min, O.OIM acetic acid pH 3.3 and dried for I minute and 50 J.lI of MeOH and 
dried for 2 min all under full vacuum. Method 1 was eluted with 4 ml of acetone: 
chloroform (1 : 1 v/v), method 2 with 4 ml of 2 % ammoniated ethyl acetate and 
method 7 with 4 ml of diethyl ether. Samples were blown down to dryness under 
nitrogen at 40°C and reconstituted with 180 III of mobile phase. 
5.4.1.2 Experimental Method 3, 4, 5, 6 and 8 
The column was conditioned with 2 ml of MeOH, 2 ml of buffer pH 6 and then the 
sample was added. The column was washed with 2 ml of buffer and dried for 2 min, 
Iml ofO.OlM acetic acid pH 3.3 and dried for 1 minute and 1 ml of hexane and dried 
for 2 min all under full vacuum. Method 3 was eluted with 4 ml of diethyl ether, 
method 4 with 4ml of acetonitrile : MeOH (1: I v/v), method 5 with 4 ml of 100 % 
acetonitrile, method 6 with 4ml of hexane: ethyl acetate (3 : 1 v/v) and method 8 
with 4 ml of 100 % chloroform. Samples were blown down to dryness under 
nitrogen at 40° C and reconstituted with 180 III of mobile phase. 
5.4.1.3 Experimental Method 9 
The column was conditioned with 2 ml of MeOH and 2 ml of buffer pH 6 and then 
the sample was added. The column was washed with Iml of MeOH and dried for 2 
minutes, Iml ofO.DIM acetic acid pH 3.3 and dried for I minute and 1 mlofhexane 
and dried for 2 minutes all under full vacuum. Method 9 was eluted with 4 ml of 
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diethyl ether. Samples were blown down to dryness under nitrogen at 40°C and 
reconstituted with 180 fll of mobile phase. 
5.4.1.4 Experimental Method 10, 11 
The column was conditioned with 2 ml MeOH and 2ml of buffer pH 6. The sample 
was added and the column washed with 2 ml of buffer and dried for 2 minutes, 1 ml 
ofO.OIM acetic acid pH 3.3 and dried for 2 minutes and 2 ml of hexane and dried for 
2 min all under full vacuum. Method 10 was eluted with diethyl ether and method 11 
was eluted with 4 ml of 100 % chloroform. Samples were blown down to dryness 
under nitrogen at 40°C and reconstituted with 180 fll of mobile phase. 
5.4.1.5 Results and Discussion 
Comparison of the various extraction methods described, established which of the 
solvent preparations methods produced the highest recovery for all five 
benzodiazepines. The selected method was then further optimized for improved 
recovery. Table 5.4 shows the percentage recovery for benzodiazepines using pH 6 
phosphate buffer and various column conditionings, wash and elution methods. 
Table 5.4 Percent recovery ofbenzodiazepine using the various methods. 
DRUG % 1 2 3 4 5 6 7 8 9 10 11 
Triazolam 81 NR 32 85 48 63 78 37 41 39 101 
Temazepam 50 74 53 54 65 NR 51 40 50 50 68 
Chlordiazepoxide NR NR NR 22 NR NR 9 NR NR NR 18 
Desmethyldiazepam 37 24 14 34 11 NR 46 6 5 28 65 
Diazepam 51 11 36 25 30 NR 58 18 18 45 60 
*NR = the drug was not recovered 
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From the table above, it could be seen that method 11 recovered all five drugs, but 
with very low recovery. Chlordiazepoxide was very difficult to recover, as 
benzodiazepines have different pH level which they will favor. Hence, to be able to 
recover all five of the drugs with good recovery, the pH level of the phosphate buffer, 
that was pH 6, was reduced. 
5.4.2 VARYING THE BUFFER pH 
5.4.2.1 Experimental 
Five different pH levels were selected to investigate which had the most influence on 
the recovery of the benzodiazepines. Extractions using 0.01 M phosphate buffer pH 
4,4.6, 5, 5.5, and 6 were carried out for comparison using the aforementioned sample 
preparation procedure and method 11 column conditioning, wash and elution steps. 
A blank and standard sample using pH 6 were also prepared. 
5.4.2.2 Results and Discussion 
Results showed that pH 5.5 phosphate buffer had the best and the highest recoveries 
for benzodiazepines. Most of the elution solvents investigated did not elute 
chlordiazepoxide, but 100 % chloroform gave the best results during elution 
depending on the pH of the buffer used. Below in Table 5.5 are the peak area heights 
of each drug when the buffer pH is varied. Buffers pH 6, 4 and 4.6 produced low 
recoveries. However, pH 5 gave good recoveries, but not as good as buffer pH 5.5. 
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Table 5.5 Peak area heights of each of the drugs using various pH buffers. 
BUFFER Triazolam Temazepam Chlordiazepoxide DMD Diazepam 
Unextstd 114440 312970 576590 403670 395430 
pH4 129700 226230 188530 255930 270780 
pH 4.6 140040 324540 64428 153100 314170 
pHS 167620 313080 220950 317990 366110 
pHS.S 178500 333240 276810 360360 405970 
pH6 150030 312960 181660 19361 309418 
5.4.3 INVESTIGATION OF OXAZEPAM 
Oxazepam is one of the main metabolites of benzodiazepines. It was investigated 
during method development because sometimes if not properly stored or kept too 
long, benzodiazepines can be further broken-down into their metabolites. Oxazepam 
was prepared in a methanol solution of 1 mg 11 OOml and injected several times for the 
detection of its retention time. It was found that oxazepam was not a factor during 
method development. Although it has a retention time very close to 
chlordiazepoxide and temazepam, it was not present during analysis. 
5.4.4 CONSIDERATION OF EXTRACT QUALITY 
The extracts obtained from the various eluent solvents used were considered on the 
basis of cleanliness. This was assessed by visual inspection and description of the 
extract (e.g. visible residue, oily/crystalline) and then by the appearance of co-
extracted material in a chromatogram of an extract from a blank whole blood sample. 
Visual inspection of the extracts prior to reconstitution showed that most of the 
solvents chosen (e.g. hexane combinations, acetonitrile, ethyl acetate, diethyl ether) 
gave good amounts of visible material apart from an oily residue or a brown film in 
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the extracts, but chloroform gave the most clean without these characteristics. This 
subjective visual assessment of extract quality was more significant than the 
subsequent interference assessment. This was because material that does not elute 
from the chromatographic column will have a deleterious effect on the 
chromatography and on the lifetime of the column and injection liner. 
The second assessment of extract quality was based on the number of interference 
peaks in the extract from a drug-free or standard spiked blood sample. There were 
several contamination peaks within the first 4 minutes of chromatography caused by 
blood proteins. Oxazepam was investigated as a possible interference peak from 
breakdown of one of the drugs, but ruled out. Chloroform again proved to be the 
best elution solvent with the cleanest extracts and the least amount of interference 
peaks if any. 
5.5 OPTIMIZED SPE METHOD 
• Sample pre-treatment: To a vial I ml of sample blood, 50 ~l of 5 % ammonia 
solution, I ml ofO.OIM phosphate buffer pH 5.5 and 100 ~l of internal standard were 
added and vortexed for 30 seconds. 
• Column conditioning: BEC® LRC columns were conditioned with 2-3 ml of 
MeOH and 2 ml of O.OIM phosphate buffer pH 5.5 and pull through slowly not 
allowing the column to dry, then add sample (1 ml/minutes). 
• Column wash: 2 ml of buffer was added and dry for 2 min, 1 ml of 0.1 M acetic 
acid pH 3.3 was added and dry 2 minutes and 2 ml of hexane was added and dry 2 
minutes all under full vacuum (10 Hg). 
• Elution: The sample was eluted into a clean vial with 4 1111 100 % chloroform. 
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Figure 5.3 Chromatograph of benzodiazepines extracted from whole blood using 
SPE BEC ® LRC columns with the optimized method. 
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5.6 METHOD VALIDATION 
5.6.1 RECOVERY 
5.6.1.1 Experimental 
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To determine the amount of drug being recovered by the method, several spiked 
samples were extracted. The internal standard, prazepam, was added at the end of 
the extraction to the eluent to determine the percent recovery. 
5.6.1.2 Results and Discussion 
Table 5.5 demonstrates the percent recoveries for each benzodiazepine at 
concentrations of 1 O~lg/ml, ranged from 94-108% triazolam, 84-94% temazepam, 83-
95% chlordiazepoxide, 85-95% for desmethyldiazepam and 88-101 % diazepam, 
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respectively. Overall, recoveries were seen to be greater than 80% for each of the 
drugs. 
Table 5.6 Percentage recovery and run to run reproducibility of benzodiazepines 
using the optimized method. 
DRUG % I 2 3 4 5 6 7 8 9 10 11 
Triazolam 99 98 102 106 104 108 99 102 103 97 100 
Temazepam 87 88 94 87 92 94 90 89 92 87 84 
Chlordiazepoxide 95 92 95 91 91 91 87 86 85 85 85 
DMD 91 91 95 89 96 95 91 91 93 88 85 
Diazepam 94 96 97 93 100 101 94 95 96 91 88 
5.6.2 REPRODUCIBILITY 
5.6.2.1 Experimental 
Samples were extracted several times and then analyzed several times by being 
introduced into HPLC. This was to find out if the method was reproducible with 
each extraction carried out separately. 
5.6.2.2 Results and Discussion 
Samples were prepared and injected several times to find out the recovery and 
reproducibility of the optimized method developed. Table 5.6 gives the Peak area 
ratios for each drug and unextracted standard. Comparison between the twelve runs 
show that this method is reproducible and the recovery is better than 80% for each of 
the drugs. 
12 
94 
85 
83 
85 
91 
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Table 5.7 Peak area ratio of each benzodiazepine resulting from mUltiple runs for 
recovery and reproducibility. 
DRUG Unextstd 1 2 3 4 5 6 
Triazolam 0.1579 0.1566 0.1540 0.1622 0.1672 0.1651 0.1718 
Temazepam 0.3939 0.3432 0.3475 0.3729 0.3461 0.3651 0.3715 
Chlordiazepoxide 0.7133 0.6766 0.6585 0.6792 0.6542 0.6559 0.6558 
DMD 0.5987 0.5420 0.5448 0.5737 0.5372 0.5766 0.5723 
Diazepam 0.5449 0.5119 0.5228 0.5334 0.5096 0.5461 0.5506 
7 8 9 10 11 12 
Triazolam 0.1571 0.1614 0.1633 0.1540 0.1592 0.1492 
Temazepam 0.3577 0.3535 0.3639 0.3440 0.3346 0.3352 
Chlordiazepoxide 0.6208 0.6165 0.6134 0.6088 0.6101 0.5991 
DMD 0.5483 0.5493 0.5597 0.5301 0.5135 0.5102 
Diazepam 0.5176 0.5199 0.5239 0.4971 0.4839 0.4971 
The results of the unextracted standard were incorporated with the RSD for each of 
the drugs to find the overall percentage RSD. Table 5.8 gives the mean, median, 
range, RSD and recovery for each of the drugs based on table 5.7. 
Table 5.8 Method validation for benzodiazepine in whole blood. 
DRUG MEAN MEDIAN RANGE %RSD+STD %Recovery 
Triazolam 0.1604 0.1571 0.1492- 0.1718 0.6 >94 
Temazepam 0.3560 0.3475 0.3346- 0.3939 1.64 > 84 
Chlordiazepoxide 0.6432 0.6558 0.5991- 0.7133 3.32 > 83 
DMD 0.5504 0.5483 0.5102- 0.5987 2.45 > 85 
Diazepam 0.5199 0.5176 0.4839- 0.5506 1.96 > 88 
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Figures 5.4-5.8 show the variation and reproducibility between each run of each drug 
when run at least three times. It was found that by using this method developed for 
benzodiazepines good run to run reproducibility could be seen. 
Figures 5.4 Reproducibility of temazepam run in groups of three 
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Figure 5.6 Reproducibility of chlordiazepoxide runs in groups of three 
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5.6.3 INTRA AND INTER-DAY REPRODUCIBILITY 
5.6.3.1 Experimental 
The investigation of reproducibility of the method developed for benzodiazepines for 
intra and inter-day reproducibility. This was to find out if the method produced 
similar results from one day to another. A sequence of extractions were carried out 
on both days which included blank extractions to exclude any possible carryover. 
5.6.3.2 Results and Discussion 
To check the reproducibility of benzodiazepines from day to day several samples 
where prepared over the course of two days. It was found that, the intra and inter-day 
reproducibility was very good and correlated very well between both days. From 
Table 5.9 and 5.10 below the overall mean (x) and RSD for triazolam was 0.1624, 
1.56 %, temazepam was 0.3564, 3.14 %, chlordiazepoxide was 0.5876, 4.19 %, 
desmethyldiazepam was 0.5392, 4.51 % and diazepam was 0.5045,4.25 %. 
Table 5.9 Intra-day reproducibility ofbenzodiazepines 
DAY ONE UNEXTSTD RUN 1 RUN 2 RUN 3 
Triazolam 0.1929 0.l930 0.1426 0.1685 
Temazepam 0.4901 0.4186 0.3197 0.3638 
Chlordiazepoxide 0.7119 0.6247 0.5123 0.5493 
DMD 0.6486 0.6247 0.4753 0.5431 
Diazepam 0.6672 0.5833 0.4414 0.5035 
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Table 5.10 Inter-day reproducibility ofbenzodiazepine 
DAY TWO UNEXTSTD RUN 1 RUN 2 RUN 3 
Triazolam 0.1649 0.1571 0.1592 0.1579 
Temazepam 0.4115 0.3577 0.3346 0.3939 
Chlordiazepoxide 0.7772 0.6208 0.6101 0.7133 
DMD 0.5556 0.5483 0.5135 0.5987 
Diazepam 0.5620 0.5176 0.4839 0.5449 
5.6.4 LINEAR CALIBRATION 
5.6.4.1 Experimental 
The calibration curve obtained for each analyte, were constructed using linear 
regression analysis. For each of the drugs, linearity was achieved over a 
concentration range of 0.0039-1 ~lg Iml shown in Table 5.9. 
Table 5.9 Linearity concentration range from 0.007-1Jlg Iml for each of the drugs 
Cone. Jlglml Triazolam Temazepam Chlordiazepoxide DMD Diazepam 
1 0.369 0.388 0.805 0.650 0.778 
0.5 0.215 0.223 0.445 0.367 0.457 
0.25 0.111 0.116 0.234 0.191 0.239 
0.125 0.041 0.043 0.084 0.072 0.089 
0.0625 0.022 0.023 0.046 0.039 0.048 
0.0325 0.013 0.016 0.028 0.023 0.029 
0.0156 0.008 0.010 0.015 0.016 0.019 
0.0078 0 0.005 0.008 0.007 0.010 
5.6.4.2 Results and Discussion 
Figures 5.9-5.13 demonstrate the linearity for each drug obtained in the selected 
concentration range. Analysis of the data from the regression lines (n = 9). exhibited 
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correlation coefficients for triazolam r2=0.9917, temazepam r2=0.9931, 
chlordiazepoxide r2=0.9954, desmethyldiazepam r2=0.9946 and diazepam r2=0.9911 
from whole blood. 
Figure 5.9 Linearity oftriazolam in whole blood 
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Figure 5.10 Linearity oftemazepam in whole blood 
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Figure 5.11 Linearity of chlordiazepoxide in whole blood 
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Figure 5.12 Linearity of desmethyldiazepam in whole blood 
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Figure 5.13: Linearity of diazepam in whole blood 
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5.6.5 LIMIT OF DETECTION AND QUANTIFICATION 
5.6.5.1 Experimental 
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The limit of detection (LOD) and the limit of quantification (LOQ) was determined 
experimentally using blank extracted specimens with a range of 1 Ilg Iml to 7 ng Iml. 
The LOD is defined as the mean area ratio multiply three and the LOQ is defined as 
the mean area ratio multiply by ten. 
5.6.5.2 Results and Discussion 
The LOD was estimated to be 7 ng Iml and the LOQ estimated to be 60 ng Iml for 
this method. Triazolam was difficult to detect after 60ng Iml and the other 
benzodiazepines were difficult to observe and not able to quantitate very clearly 
because of the baseline noise. 
5.7 COMPARISON OF EXPERIMENTAL AND ROUTINE METHOD 
The solid-phase extraction procedure developed provides a reliable, rapid and 
reproducible technique for the isolation of benzodiazepines from whole blood. The 
Bond-Elute Certify® LRC columns selectively retains and elutes the analyte of 
interest using a mixed-mode interaction mechanism, constituting ion-exchange 
chromatography and hydrophobic and polar interactions. The high percentage 
recovery makes this method suitable for the analysis of benzodiazepines and 
detection is possible at low concentration levels. 
5.7.1 Experimental 
The developed SPE method was compared to the current routine method used in the 
laboratory. Blood case samples were analyzed using the two methods and compared. 
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Results produced between the two methods showed corresponding drug levels for 
each case sample. 
5.7.2 Results and Discussion 
The routine and experimental methods were extracted and analyzed several times to 
find the average of the peak area ratios. The experimental method produced slightly 
better recover for all five drugs than the routine method. However, both methods are 
equally robust for the extraction of benzodiazepines from whole blood. Table 5.7 
shows an average of the peak area ratios for the drugs. 
Table 5.10 Comparison of the peak area ratios average between the two methods. 
DRUG UNEXTSTD ROUTINE EXPERIMENTAL 
Triazolam 0.1929 0.1867 0.1930 
Temazepam 0.4901 0.4485 0.4186 
Chlordiazepoxide 0.7119 0.4934 0.6247 
Desmethyldiazepam 0.6486 0.6101 0.6249 
Diazepam 0.6672 0.6143 0.5833 
The percent difference was calculated for each of the drugs from the results of both 
methods. The percent difference of triazolam between the two methods was 0.006, 
temazepam was 0.03, chlordiazepoxide was 1.3, desmehtyldiazepam was 0.014 and 
diazepam was 0.031. Figure 5.14 shows a graph based on Table 5.10 of the 
comparison between the routine and experimental method. The graph demonstrates 
that in comparison to the unextracted standard, the experimental method compares 
slightly better than the routine method, however, a correlation does exists between 
the two methods. 
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Figure 5.14 Comparison between the unextracted standard, routine and experimental 
method for the extraction of benzodiazepines in whole blood. 
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Several authentic forensic case samples were analyzed using both the routine and 
experimental method and the results compared. Table 5.11 shows eleven case 
samples that were analyzed using the two methods for experimental validation. 
It can be seen that the results from the case samples extracted by the SPE 
experimental method developed for benzodiazepines, correlates well with those 
obtained from the routine SPE method currently used. Positive results for each drug 
were detected using the routine method and the experimental method with relatively 
close corresponding levels. Those that were listed as NA (not available) was because 
either the sample was negative or there was not enough sample for re-analysis. 
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Table 5.11 Comparison between the experimental SPE method and the routine SPE 
laboratory method using eleven whole blood case samples. 
Case Samples Routine Method mg/ml Experimental Method mg/ml 
T96-A oxaz 0.13, dmd 0.22, diaz 0.25 oxaz 0.23, dmd 0.56, diaz 0.71 
T96-B dmd 0.44, diaz 0.25 dmd 0.56, diaz 0.73 
T96-C tern 0.35, dmd 0.55, diaz 0.26 tern 0.56, dmd 0.4, diazO.66 
T96-D dmd 0.51, diaz 0.44 dmd 0.89, diaz 0.62 
T96-E dmd 1.1 diaz 1.58 dmd 1.35, diaz 2.45 
T96-F tern 2.79, dmd 1.29 tern 2.02 dmd 0.9, diaz 0.57 
T96-G NA diaz 0.44 
T96-H tern 0.31, dmd 0.35, diaz 0.14 tern 0.20, dmd 0.24, diaz 0.10 
T96-I tern 0.87, dmd 0.18, diaz 0.08 tern 0.35, dmd 0.13, diaz 0.10 
T96-J tern 0.38, dmd 0.55, diaz 0.64 tern 0.29, dmd 0.58, diaz 0.71 
T96-K NA tern 0.21 
*NA = not available, tern = temazepam, dmd = desmethyldlazepam, dlaz 
diazepam, oxaz = oxazepam 
Most of the samples were positive for temazepam, desmethyldiazepam and 
diazepam. An explanation for this is that temazepam and diazepam are the most 
widely abused benzodiazepines in the West of Scotland and are also mixed with 
other drugs of abuse, therefore more commonly found. Desmethyldiazepam is the 
major metabolite commonly identified where benzodiazepines have been abused, 
therefore encountered frequently. The overall average percent difference between the 
two methods for oxazepam was 0.1, temazepam was 0.34, desmethyldiazepam was 
0.22, and diazepam was 0.30. 
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5.8 CONCLUSION 
The aim of this study was to optimize and examine the applications of solid-phase 
extraction as a sample preparation technique for the screening of benzodiazepines in 
whole blood prior to HPLC analysis. 
It was found that Bond Elute Certify® LRC SPE columns, were ideal for the elution 
of benzodiazepines. The method developed consists of suitable quality solvents in 
the sample preparation, column wash and conditioning steps to suit the group of 
compounds of interest. The effect of pH on the recovery of the benzodiazepine is 
very important during extraction, because basic drugs are recovered most efficiently 
at alkaline pH conditions. Visual inspection and description of the extract showed 
that the chosen eluent was the best elution solvent, which gave clean extracts and the 
least amount of interference peaks during analysis. 
The Limit of detection and quantification was estimated to be 7 ng and 60 ng for the 
detection of benzodiazepines in whole blood. All of the benzodiazepines were 
difficult to accurately quantitative below 60ng, this was mostly because of the 
baseline noise. This method also produced good run to run reproducibility with 
overall recoveries better than 80% for each of the drugs. 
This method provides a reliable rapid and reproducible technique for the isolation of 
benzodiazepines from whole blood. Comparison between the routine method and the 
optimized method using authentic forensic samples shows good correlation between 
the two. This indicated the potential usage for the developed method for real case 
samples. Bond Elute Certify® columns selectively retains and elutes the analyte of 
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interest using a mixed-mode interaction mechanism, constituting ion-exchange 
chromatography and hydrophobic and polar interactions. The high percentage 
recovery renders this method suitable for the detection of benzodiazepine, down to 
low concentration levels. 
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6. HAIR 
6.1 LITERATURE REVIEW 
6.1.1 INTRODUCTION 
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The analysis of human hair is purported to provide evidence of the use or lack of use 
of drugs of abuse and to some extent, estimation of the time of drug exposure. It has 
been used as a marker to toxicologists for more than a hundred years. Hoppe in 1857 
published Caspers, "Practisches Handbuch der gerichtlichen Medicin", which 
reported the analysis of hair for the detection of poisons. 169 This translated means, 
Practical Guide to Legal Medicine. He investigated the presence of arsenic found in 
the hair from a body exhumed after 11 years. Nearly 100 years later, Goldblum et af 
in 1954, was the first to publish a report on the detection of barbiturates in guinea pig 
hair. 170 By 1979, Baumgartner published a report on opiates in hair analysis that has 
shaped the view of hair anaysis. 171 
Since then, over the last decade, there has been an accumulation of experimental data 
on the analysis of hair for trace elements and drugs. 172·176 This data demonstrated 
that drugs found in body fluids (e.g. blood or urine) can also be found in hair. Recent 
advances in drug testing have led to the development of new drug testing 
methodologies for the detection and measurement of drugs of abuse in hair. More 
than 400 clinical and forensic toxicology articles have been published on hair 
analysis. These methods show promise of providing drug exposure information over 
a wide window of time than is produced for traditional methods. 
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Hair analysis is a noninvasive technique, involving a relatively simple collection 
technique. It involves clipping strands of hair from the head or other regions of the 
body and extracting drugs from the hair matrix. The hair sample itself is stable 
indefinitely, alleviating many of the preservation storage and transportation problems 
associated other biological materials. l77 Due to the unique ability of hair to retain 
drugs for long periods of time, hair testing can provide a wealth of information of an 
individuals recent past. 178 A precise understanding of the mechanisms involved in 
the incorporation of drugs into hair is critical for forensic scientists to accurately 
interpret and understand the results of hair analysis in drug testing. There are basic 
structural similarities between hair of different color, ethnic origin and body region. 
The fundamentals of hair composition, anatomy and physiology a have been 
summarized in articles by Harkey l79 and Cone and Jospeh.180 
Currently, hair testing is applied to various situations as a means of monitoring drug 
usage or exposure. This has been confirmed by several independent laboratories 
around the world.181-18S The mechanisms of drug incorporation in hair are not fully 
known, with limited information on the physiochemical characteristics of how drugs 
bind to hair. 181 It has been suggested that drug incorporation into hair may depend on 
ethnic hair type, color and treatments. However, further research is necessary to 
clarify these issues which may cause any potential bias in hair testing. 
6.1.2 ANATOMY OF HAIR 
Hair is a complex fiber or tissue whose structure and biology are only partially 
understood. It is an epidermal outgrowth composed of cylindrical structures or shafts 
made up of matrix cells that grow from small sac-like organs called follicles. It can 
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also be described as an annex of skin originated from the hair follicle where the 
germination center is formed by matrix cells. Hence, these cells form different layers 
of the hair shaft for example the cuticle and medulla. The cells actively proliferate in 
the root, while residual metabolism is negligible in the hair shaft. 
Hair consists of the definite morphological components; cuticle. cortex, medulla, 
melanin granules and cell membrane complex, each distinct in morphology and 
chemical composition. Sulfur rich proteins known as keratin form long fibrils in the 
shaft and are also a main component contained in hair. Keratin is tightly bound 
through the replacement of S-H bonds with S-S bridges that produce a tough, highly 
stable structure. 179. 180 
6.1.3 PHYSIOLOGY OF HAIR 
During the growth of hair, moving In an upward direction, morphological and 
structural changes of the matrix cells occur to form different layers of the hair shaft. 
They may also acquire pigment in hair cells as they differentiate to form individual 
layers of hair that determine the color of the hair shaft. Differences in the type and 
quantity of proteins and pigments can be distinguished in individual layers of hair. 
These differences determine which structural components and layers of hair are 
responsible for binding drugs. 
6.1.4 HAIR FOLLICLE 
There are approximately 80,000-100,000 hair follicles on the human head with a 
decrease in the number with age. 186 The hair follicle is a highly complex skin 
appendage embedded 3-4mm below the epidermal epithelium of skin. They are 
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closely related to the apocrine and sebaceous glands that empty into the follicle and 
consist of epithelial (matrix and outer root sheath) and dermal (dermal papilla and 
connective tissue sheath) tissues. 187 
6.1.5 STUCTURE OF THE HAIR SHAFT 
Regardless of hair color and ethnicity, there are basic structural similarities among all 
hair types. The diameter of individual hair shafts may range from 15-120 J!m 
depending upon the type of hair a region of body the follicle is 10cated.179 The cuticle 
is the outermost layer of hair where the alpha (A) layer is located beneath the cell 
membrane and the exocuticle between the A-layer and the endocuticle. The cortex is 
located between the cuticle and innermost region, the medulla. 179. 186 The cortex 
forms the bulk of the hair shaft and is located immediately beneath the cuticle. 181 
The medulla is small in relation to the cortex and consists of scattered cells and 
hollow spaces that may be continuous, discontinuous or absent in adult hair. 180. 184 
Melanin is among the most frequently occurring pigment in nature. 188. 189 It is 
synthesized in melanosomes that are discrete organelles located within 
melanocytes. 187 Melanin granules are the cell components of melanocytes situated in 
the upper portion of the hair bulb. 189 Melanosomes are transferred by the melanocytes 
to different cortical and medullary cells during growth as these cells move upward 
from the hair bulb to form the hair shaft. 190 Hair cells that form the hair shaft do not 
produce melanin. 189 Hair color depends on the number of melanin granules present, 
their size, arrangement and distribution in the hair shaft and their melanin 
composition. 
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Figure 6.1 Illustrates the anatomy of hair follicle and hair shaft. 191 
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The hair shaft consists of three main functional zones, the innermost zone, the 
keratinogenous zone and the region of permanent hair. The innermost zone is the site 
of biological synthesis of hair cells in and around the bulb. Hardening and solidation 
of the hair and keratinization of the matrix cells occurs in the keratinogenous zone 
directly above the bulb. Fibrils fused by intercellular binding are composed of 
dehydrated cornified cells in the hair shaft, becoming the region of permanent hair. 
6.1.6 CHEMICAL COMPOSTION 
Hair is composed of approximately 1-9 % lipids, small quantities of trace elements, 
polysaccharides and water and 60-95 % protein, with the majority of sulfur-rich 
protein referred to as keratin. 179. 183 Although different in each layer, keratin is 
comprised in the cortex, cuticle and medulla in large amounts to form long fibers in 
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the hair shaft. High concentrations of cystine are contained in the keratin to form 
disulfide bonds that link the A-layer to the exocuticle. This makes the cuticle tightly 
bound together and protects the cortex from damage. This results in a very tough, 
highly stable structure. 
In the cortex, keratin is comprised of 85 % or more of the mass of the hair shaft and 
two types of structural protein, matrix and fibrous proteins. 192-195 Matrix proteins are 
nonhelical structures with a high sulfur content and polypeptides, whereas fibrous 
proteins are helical structures that incorporate into matrix proteins with a low sulfur 
content. The structure, arrangement and ratio of matrix and fibrous proteins 
contribute to the physiochemical properties of keratinous tissues. 196•197 Fibrous 
proteins aid in the production of the cortex and the medulla in the keratogenous zone. 
6.1.7 GROWTH CYCLE OF HAIR 
Hair grows in cycles, alternating between periods of growth and quiescence. It has 
been stated that hair grows at a rate of lcm per month or 0.5 inches per month. 
However, precise values for human hair growth rates are difficult to obtain. This is 
because the anatomical location and age of hair and growth does not occur all at 
once. Anatomical location and hair type are the most important factors determining 
growth rate, which is somewhat dependent on race, sex and age. 
Literature reports scalp hair grows faster than pubic hair or axillary hair that grows 
faster than beard hair. Reported hair growth rates for scalp hair are between 0.2 
mmldayand 1.12 mm per day.179 There are three phases of hair growth, anagen 
(growing stage), catagen (transition stage) and telogen (resting stage). 
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6.1.7.1 Anagen Stage 
The onset of the anagen stage starts the hair growth by increasing the metabolic 
activity of the matrix cells. The longer the stage, determines the length and type of 
hair. 187 The follicle becomes embedded into the dermis caused by continuous cell 
division that stimulates new hair growth as the cells elongate to form a thin filament. 
This activity causes the hair cells to form the cortex, cuticle and medulla region of 
the hair. At this time the keratinization process begins and this is where drugs and 
trace elements are incorporated into hair. 198 
6.1.7.2 Catagen Stage 
During this transitional phase, the cell division taken place in the anagen stage is 
finished resulting in the base of the shaft becoming keratinized. A dry white node is 
formed followed by the degeneration of the bulb and the follicle shortens. 187 
6.1. 7.3 Telogen Stage 
This is known as the resting phase where the growth of the hair shaft stops making it 
easier for it to be pulled out or plucked retaining the white node. Depending on the 
area of the body, the percentage of hair that is growing varies compared to the 
percent resting. 
The possible length of the hair and the density of a scalp depend on the duration of 
these stages and rate of growth. The duration of these stages varies from person to 
person, even in the scalp of one person. Each hair follicle has its own growth cycle, 
the longer the hair the longer the growing phase. Approximately 15% of scalp hair is 
at rest and the remaining 85% growing. 180, 199 
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The duration of this process can be affected by a number of factors such as 
pregnancy, disease or nutritional deficiencies. Hair in the vertex region of the scalp 
is usually chosen as the best specimen, as it has the largest amount of hair in the 
telogen phase and the fastest growth rate. 179 
6.1.8 COMPARISON OF HAIR TYPES I79 
There are three main types of hair specimens that can be collected for analysis they 
are scalp, beard and pubic hair. Scalp hair has the highest growth rate of all the hair 
types. There are considerable variation in various regions and the growth rates in 
scalp hair. These variations make the choice area of sampling very important. Scalp 
hair is also exposed to external contamination, sweat and cosmetic treatments that 
can cause changes to its composition. 
Beard hair has the slowest growth rate and can be exposed to external contamination 
and sweat like scalp hair. It is less likely to be contaminated through the sebaceous 
gland ducts because the hair shaft is in a separate channel of exit, where the hair shaft 
of scalp hair is directly exposed to the sebaceous ducts. 
Pubic hair grows slower than scalp as well and has a longer resting period. It is less 
likely to be exposed to external contamination or chemical treatments, however it can 
be contaminated through sweat and urine. Segmental analysis can be very difficult 
with pubic hair as opposed to scalp hair because it is curled rather than straight. 
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6.1.9 MECHANISM OF DRUG INCORPORATION IN HAIR 
The mechanism of drug entry into hair and the specific sites of drug sequestration is 
complicated and likely to involve a number of propertied processes. Several modes 
of entry suggested are: 200 
- Passive diffusion from blood 
- Drug excretion in sweat with subsequent transfer to hair 
- Drug excretion in sebum with subsequent transfer to hair (the oily secretion from 
sebaceous gland) 
- Entry into hair from external environment 
Figure 6.2 Drug entry into hair via the bloodstream 191 
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By the ability of hair to directly absorb the drug, contamination by direct 
environmental exposure should be reasonably excluded if hair results are to be used. 
For example, nicotine is found in the hair of non-smokers and cocaine is found in the 
hair of children of cocaine users. 191 . 201 
Baumgartner et ai, have postulated that drugs enter the hair via the blood stream in 
direct proportion to their concentration.202 However, recent studies have indicated 
that drug entry is likely to occur by passive diffusion from the blood stream into the 
growing hair cells at the base of the follicle. They then become bound in the interior 
of the hair shaft during subsequent keratogenesis (protein synthesis of the follicle as 
matrix cells move up the shaft). 
The drug incorporation into hair is dependent on the drug concentration in blood that 
is dependent on the dose of drug ingested. Good correlation can sometimes be seen 
between the concentration of the ingested drug and the concentration of drugs in hair, 
while others correlate badly.203.204 This may be due to external contamination or inter-
subject variability. 
6.1.9.1 Sweat Transfer 
There have been various studies to determine the contribution of drugs in sweat to 
drugs in hair. Drugs of abuse in concentrations often higher than in blood, have been 
found in sweat.200 However, there are many factors that can influence the amount of 
drugs found in hair due to sweat contributions. Inter-individual differences of drug 
levels in subjects consuming known amounts of a drug may be an explanation. In 
addition, the fact that drugs are dispersed over a large area of the hair shaft can 
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conclude the excretion of sweat. For some individuals, sweat may be an important 
vehicle for the transfer of drugs into hair. 
6.1.9.2 Skin Transfer 
Another possible transfer of drugs into hair is through the skin. The skin can act as a 
reservoir for certain drugs, especially lipophilic drugs because of its two layers, 
epidermis and subcutaneous layer.20o Studies have revealed that when drugs 
penetrate from the external environment across the skin, they are retained by the lipid 
layers of the outer layer of the epidermis and are released very slowly into the 
bloodstream. From the bloodstream, the drugs are retained primarily by adipose 
tissue of the subcutaneous layer and the outer layer of the epidermis where they 
surround the hair follicle and its associated glands. 
6.1.9.3 Environmental Exposure 
There are a variety of ways hair is exposed to environmental contaminates. Cosmetic 
treatments (e.g. bleaching), smoke (e.g. cigarette or drug exposure), or air (e.g. 
pollutants) are all possible contaminates which make it difficult to establish a 
concentration baseline for trace elements in hair.2oo External contamination could be 
a possible route of entry into hair for drugs that are smoked, therefore, various 
surface decontamination methods have been developed to eliminate such 
contamination before analysis. 
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Figure 6.3 Diagram of drug incorporation into hair showing drug transfer from 
potential pathways.20S 
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6.1.10 FACTORS AFFECTING RETENTION OF DRUGS IN HAIR 
There are a number of factors that affect retention of drugs into hair. From a 
chemical point of view, some factors for drug incorporation into hair are melanin 
affinity, lipophilicity, basicity206 and pH191. 
6.1.10.1 Melanin 
Scientific data show that melanin plays an important role from drug incorporation 
into hair.2os, 206 Studies have confirmed that in human hair, drug concentration in 
pigmented hair was higher than in nonpigmented hair?07-210 Hair color is just one 
factor which affects binding of drugs. Studies have concluded that black hair from 
African and Asian people, tend to retain higher levels of drug than weakly pigmented 
Caucasian hair. 191,210 
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Melanin may also be considered to behave like weak cationic exchange polymers 
that form simple ionic bonds with metals and chemicals. 180 This may possibly 
explain why drugs with cationic properties such as cocaine, amphetamine and opiates 
appear to be bound and retained by hair to a greater degree in comparison to anionic 
compounds such as aspirin and tetrahydrocannabinol (THC). 180 
6.1.10.2 Lipophilicity 
Lipophilicity of drugs is another key factor for drug incorporation into hair. An 
example is cocaine and 6-acetylmorphine being incorporated better than 
benzoylecgonine and morphine.2II . 212 
6.1.10.3 Basicity 
Another factor that affects the uptake and! or retention of drugs in hair is the basicity 
of the drug. As the pH of hair is slightly acidic, it is more likely for acidic drugs to 
have lower concentrations in hair than basic drugs. 19l , 199 Nakahara 1995, found that 
the pKa of amphetamine analogues plays a significant role in its drug retention in 
hair.20b 
6.1.10.4 Cosmetic Treatment 
The everyday treatment of hair has a significant affect on the retention of drugs in 
hair. Controlled experiments have shown that with frequent use of shampoo, 
hydrogen peroxide and conditioners contributes to losses of some drugs in hair.2I302lS 
Bleaching hair also reduces the concentration of drugs such as heroin and cocaine 
metabolites in hair. 215 
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6.1.10.5 Effects of pH in Hairl91 
Hair contains three major functions whose characteristics can vary as a function of 
pH (i.e. side chains of aspartic acid, glutamic acid and sulfate groups produced by 
oxygen degradation of the amino acid cystine). Chemically treated or damaged hair 
contains sulfate groups that have a lower isoelectric point than pH4. At pH 4 
(acidic), drugs bind through weak hydrophobic interaction provided they have similar 
hydrophobicities and charge as hair. The pH of hair can produce a change in the 
charge of the hair, drug and hydrophobicity of both the drug and hair, which 
determine the relative uptake of drugs into hair. 
Positively charged drugs at a low pH (pH 4) bind less well than neutral or negatively 
charged drugs. If the hair has a pH higher than its isoelectric point (pH 7), aspartic 
and glutamic acid side chains become deprotonated and hair becomes negatively 
charged and some drugs (i.e. benzoylecgonine) become zwitterionic, some bind and 
some repel via ionic interaction. Hence the more positively charged the drug, the 
more the binding. Increasing the pH further (pH 9), more side chain carboxyl groups 
are deprotonated and hair becomes more negatively charged. Hence, some drugs 
become negatively charged and are bound or repelled via ionic interaction. 
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Figure 6.4 A model of the drug incorruption into the hair based on pH. 191 
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6.1.11 DRUG CORRELATION STUDIES 
page 156 
There are numerous studies on the correlation between drug intake and the 
concentrations found in hair. Positive correlations have been reported by 
Baumgartner and co-workers using self reported drug use history and concentrations 
of either heroin214, marijuana216, cocaine217 or PCp21S in their hair. However, these 
studies compared immunoassay data with self-reported drug intake. Other methods 
(e.g. GC-MS) have more recently been used to show positive correlation between 
dose and the amount of drug in hair. 
In a five subject study, Nakahara el al found good correlation between the dose of 
methozyamphetamine and the concentration of drug in the hair.219 Similarly Cone et 
al using two subjects, found positive correlation between the dose of opiates and the 
concentrations in beard hair.22o In contrast, Puschel el al analyzed hair from 
carcinoma patients receiving morphine doses and found poor correlation between the 
d d . . h· 22 1 dose an rug concentratIOn In aIr. 
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Other studies for cocaine have suggested that increased cocaine dose leads to 
increase in the concentration found in hair. However, inter-subject variability is so 
great that to estimate the drug amount administered based on the hair drug 
concentration is very difficult. Further, this variability could not be explained by 
plasma pharmacokinetic difference because of relatively small differences in 
pharmacokinetic parameters not sufficient enough to explain the large differences in 
the hair drug concentrations. 
6.1.12 PARENT DRUG-METABOLITE RATIOS 
Drugs of abuse are metabolized by the liver to form polar metabolites readily 
eliminated from the body via urine. The chemically nonpolar parent drug is rapidly 
metabolized compared to urinary excretions. However, urinary excretion of the 
chemically polar metabolites is more rapid and extensive than the parent drugs. 
Generally, finding drug metabolites in body fluids are used to prove the ingestion or 
injection of a drug into the body, since the bodys metabolism is responsible for the 
formation of the metabolite. The plasma drug metabolite concentration (or ratio 
between parent drug and metabolite) is also used to differentiate between acute and 
chronic drug administration. However, these drug distribution generalities do not 
always hold when hair is the matrix. 
Current studies clearly show high parent drug to metabolite ratios found in hair. 
Goldberger et a/ have reported high metabolically labile drugs in hair like heroin and 
its metabolite 6-monoacetylmorphine.222 Cocaine with its relatively short half-life 
has also been studied as the primary analyte in hair. It showed approximately 6-fold 
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and 10 fold greater concentrations In hair than its pnmary metabolites 
benzoyl ecgonine and ecgonine methyl ester.m-225 
6.1.13 DECONTAMINATION OF HAIR 
There are a number of published surface decontamination methods for hair. It is not 
clear which technique offers any real advantage over any other, but all are considered 
suitable for reducing surface contaminants. Several methods include the use of 
sodium dodecyl sulfate (SDS)I72, acetone2l3 , water and acetone226 , methanol174 , 
ethanol 175, and dichloromethane 176 • Wash procedures are used to remove external 
contamination and are based on the following properties of hair with respect to 
exogenous incorporated drugs. These properties have been established by earlier 
studies. 
• Cocaine, opiates, amphetamines, manJuana and phencyclidine and their 
metabolites do not bind strongly to keratin proteins and can be removed by 
washing. 
• Through contact with hair, metabolites can not be formed from the original drugs. 
• Endogenous and exogenous deposition of drugs in hair involve three domains, 
surface, accessible interior and inaccessible interior domain.227 
1. Surface Domain: Located at the surface of the hair, this domain is readily 
accessible to drug incorporated by external contamination. However, because 
they are loosely bound to the hair, they can be easily removed by washing 
solvents. 
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ii. Accessible Interior Domain: Located in the interior structure of the hair, this 
domain resists the penetration of exogenous drugs through hair swelling solvents 
such as water or possible perspiration. However, as a result the drugs can also be 
removed by swelling the hair using water. Since the accessible interior domain is 
smaller in comparison to the inaccessible interior domain and contains majority of 
the exogenous drugs, the loss of endogenous drugs from the accessible domain 
through washing is not very significant to the overall detection of drug in hair. 
iii. Inaccessible Interior Domain: Located in the interior of the hair, this domain 
can not be contaminated by exogenous drugs or washed out using wash 
procedures. It is a relatively large domain and appears to depend on the type and 
condition of hair (e.g. thick or thin, porous or nonporous). Endogenous drugs are 
only released though digestion and extraction of the hair. 
6.1.13.1 Wash Procedures 
There are two main wash procedures used in the pre-treatment of hair, they are 
extended and truncated wash procedures. Continual washes carried out until a 
plateau drug concentration is reached is termed extended washes. 184 Fixed wash 
procedure over a fixed length of time is known as truncated wash procedures. This 
wash procedure can be used for mass sample production, where extended procedures 
are used for individual forensic samples. 
General wash procedures consist of first a cleansing wash with a detergent (e.g. 
SDS), then a solvent wash with an alcohol (e.g. MeOH, EtOH), followed by an 
aqueous and final solvent wash. Washing with an alcohol ensures that all of the oils 
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incorporated in hair do not interfere analysis and to remove loosely adhering drugs 
from the surface. The aqueous wash causes the hair to swell and in turn allows 
penetration into the interior. A final solvent rinse step is advisable to help the hair 
dry. These steps can be repeated before the final rinse step to ensure full surface 
decontamination. 
6.1.14 ANALYTICAL METHODS 
The isolation of drugs in hair has become of increasing interest to the analytical 
chemist, with numerous extraction techniques being published. A typical analysis is 
usually in four stages, washing the hair of any exogenous contaminates, the pre-
treatment (e.g. solvents, hydrolysis), extraction of the sample (e.g. SPE, LLE, SFE) 
and analysis (e.g. GC/MS, HPLC). 
Treatment of the hair without solubilisation (e.g. methanol or enzymes) can lead to 
reduced extraction yield. A ball mill is commonly used to pulverize hair followed by 
extraction into methanol or dilute buffer that helps to minimize drug loss. Despite 
intentions, variability in drug hair concentrations are affected by the washing and 
extraction method chosen. Therefore, the method of choice should always be taken 
into consideration when evaluating hair drug concentration data. 
An alternative extraction procedure to conventional techniques is the use of SFE for 
the extraction of drugs of abuse in hair. With the use of SFE, the aforementioned 
preparative wash, pre-treatment and extraction steps can be carried out using the 
same apparatus, minimizing potential problems associated with other techniques.228 
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6.1.15 HAIR ANALYSIS USING SFE 
During SFE, the rate of extraction is due to the solubility of the analyte in the 
supercritical fluid and the transfer of the mass of the solute outside of the matrix. 
Diffusion of the analyte depends on the particle size, therefore in hair analysis. the 
pulverization of hair will increase the recovery of the drug in interest. With the 
addition of a more polar modifier subsequently increases the recovery even more. 
The extraction of drugs of abuse in hair using SFE was first reported by Sachs and 
Uhl in 1992. ~2'1 Sachs was also the first to quantitatively determine opiates in hair 
using SFE techniques and GC/MS analysis.23U Further studies by Edder et al 231 and 
Morrison et aim also investigated the possible use of SFE for the selective recovery 
of drugs of abuse from hair. More recent investigations by Cirimele et al in 1995 
reported a methodology for the extraction of opiates from hair with investigations on 
the effective parametl'rs that influence recovery.2JJ Staub and co-workers in 1996 
modified the ml'thod by Edder for the extraction of opiates and methadone.228 
6.1.16 CONCLUSION 
Hair testing for drugs of abuse can provide useful information for questionable drug 
usage. It is a noninvasive technique that provides an extended analysis time window 
for drug detection and can not be adulterated, unlike urine or blood. Several 
publications have proposed various wash criterias to distinguish active from passive 
exposure. However. there is no set criteria as yet. 
The extraction of drugs from the hair is another important variable besides 
decontamination. Not all extraction solutions can remove all the drugs from hair. 
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therefore. dissolution or pulverization is necessary to ensure removal for analytical 
purposes. Already hair analysis has proved useful in a variety of applications. 
However. further research in this field is necessary to establish definitive data 
regarding some of the unanswered issues for hair analysis. 
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7. AMPHETAMINES IN HAIR 
7.1 LITERATURE REVIEW 
7.1.1 INTRODUCTION 
page 163 
Most of the literature written dealing with the detection of amphetamine in hair has 
come from Japanese researchers. In the past, target drugs have been amphetamine 
(AP) and methamphetamine (MA), however, more recently methylene-
dioxyamphetamine (MDA) derivatives like methylenedioxymethamphetamine 
(MDMA) are of particular interest. 
Nakahara published a detailed review in 1995 on the detection of amphetamines in 
hair. 234 Techniques published before 1990 used acid or alkaline hydrolysis or a 
combination of hydrochloric acid and methanol followed by SPE or LLE and 
derivatised. Recently Rohrich and Kauert developed a screening procedure for the 
simultaneous detection of AP, MA, MDA, MDMA and MDEA based on methanol 
sonication with methaqualone used as the internal standard.235 Kintz and Cirimele 
compared four different procedures for AP, MDA and MDMA (methanol sonication 
and acid, alkaline and enzymatic hydrolysis) where alkaline hydrolysis was 
determined to give greatest recoveries.236 
The detection of amphetamine and ecstasy in hair is becoming of growing interest in 
the forensic laboratory. Since Moeller et al first identified MDMA in human hair, it 
has become one of the most frequently identified, especially in Europe.237 Therefore, 
it is included in all screening procedures. 
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7.1.2 HISTORY 
The Substance MDMA has been said to have first been synthesized as early as 
1898238, although, it was patented by the German pharmaceutical company E. Merck 
in 1914. It was allegedly for the use as an appetite suppressant for the German army, 
however, because of the side effects, its use was discontinued. Merck also 
synthesized MDA (3,4-methylenedioxyamphetamine) which is closely chemically 
related to MDMA. MDMA reappeared in 1977 in the pharmacopoeia when a 
Californian chemist, Alexander Shulgin synthesized MDMA in his laboratory. 
Shulgin is known as the father of ecstasy, but refers to himself as the stepfather as he 
only rediscovered MDMA. He has also synthesized and tested 179 different 
phenethylamines and may other psychoactive drugs.239 
The substance known as "ecstasy", has become a prevalent hallucinogenic drug 
associated with the "rave scene" or described as the pre-eminent youth movement of 
the decade. However, ecstasy is not a new drug, it is also know as MDMA (3,4-
methylenedioxymethamphetamine ). MDMA belongs to a large family of 
hallucinogenic substances known as phenethylamines.239 
Ecstasy has been incorrectly described as a "designer drug" because MDMA is a 
synthetic combination of hallucinogens and amphetamines.24o-242 Smith and Seymour 
contend that, MDMA is not a designer drug, quoting Donald R. Wesson's definition 
of a designer drug as "where the defined p.'Jychoactive properties of a scheduled drug 
have been retained, but the molecular structure has been altered in order to avoid 
prosecution under the Controlled Substance Act". 243 
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Today drugs purported to be ecstasy, may not necessarily contain only MDMA, but 
adulterants or MDMA related drugs in combination to produce similar effects.244•246 A 
wide variety of combined drugs known as cocktails of MDMA and other 
psychoactive substances exist, that produced similar effects.243 
7.1.3 PHARMACOLOGY 
As a group, amphetamines are relatively strong bases with pKa values ranging from 
9.5 to 10. High pKa values account probably for the significant urinary elimination 
as unchanged drugs.w They are lipid soluble as free bases, but water soluble as the 
hydrochloride or sulfate salts, which are the common dosage forms. Following 
ingestion the compounds are transferred to the brain rapidly and appear to localize in 
this tissue relative to plasma. The short term and side effects of MDMA have been 
documented well, with consistent clinical, laboratory and self-reported findings.24802s3 
The initial effects common to MDMA include an increased pulse rate and blood 
pressure, peaking one half to three hours following ingestion.248 These effects are 
greatest with the highest levels of dose to body weight. Blood pressure is eventually 
reduced to below pre-ingestion levels after approximately six hours. 
MDMA is a monoaminergic drug which are a group of neurotransmitters, like 
serotonin (5-HT2 (5-hydroxytryptamine)), dopamine and noradrenaline.2S4 The main 
function of serotonin is to control mood. Serotonin is pumped out of the neuron by 
transporter proteins into the synapse, then taken back into the same neuron by the 
transporter protein. This process helps to continuously replenish the neuron with 
serotonin, keeping the signal brief. 254 MDMA works by binding to these transporter 
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proteins and preventing the reuptake of serotonin. A full review of the neurotoxic 
effects ofMDMA is given by McKenna and Peroutka.255 
Peroutka, et al conducted a study usmg five recreational MDMA users for any 
abnormalities in serotonegic, dopaminergic and adrenergic activity.256 Extraction and 
analysis of the lumbar cerebrospinal fluid taken from the subjects found no evidence 
suggesting long term neurotoxic effects in humans. However, it is possible the 
MDMA may cause neurotoxic effects to some extent similar to other amphetamine 
derivatives and drugs. If such damage occurs, it may be acute and reversible, with 
the possibility of long term damage. 
The after effects of MDMA are very similar to those associated with amphetamines. 
Users have reported complaints of insomnia, muscle aches and jaw.248 With more 
sever reactions, paranoia, weight loss, exhaustion, flash backs, jaundice, irritability 
and depression have been included.257 Several other side effects of ecstasy use 
include loss of appetite and alertness, dry mouth, pupil dilation, tachycardia, 
nystagmus (eye wiggle), bruxism (teeth grinding) and trismus Gaw clench). 
7.1.4 CHEMICAL STUCTURE 
The basic chemical structure contained in speed and ecstasy tablets or powders are 
shown in Figure 7.1. The R in each structure represents where a substitute group 
should be place when synthesized. AP, R = H, MP, R = CH3, MDA, R, = CH3, R2 = 
H, MDMA R, = R2 = CH3, MDEA, R, = CH3, R2 = C2H5 
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Figure 7.1 Structure of the drugs contained in "speed" and "ecstasy" tablets. 
7.1.5 METABOLISM 
The methylenedioxy derivatives of amphetamine have received a great deal of 
attention because of the popularity of MDMA as an illicit recreational agent.257 MDA 
and MDEA are both analogs of MDMA. MDMA is demethylated into MDA and 
then is demethylated into the catechol dihydromethylamphetamine (DHMA) by 
cytochrome P450.247 MDMA being the most recognized metabolite of ecstasy, at 
single dose levels of 75-1 OOmg is moderately effective, with effects experienced after 
20-60 minutes after ingestion and lasting for several hours.247 
Chapter Seven: Amphetamine in Hair page 168 
Figure 7.2 The products of drugs formed during synthesis or when metabolized. 
MA AP 
CH3 
MDMA MDA 
MDEA 
7.1.6 PHARMACOKINETICS 
There are several reports on the pharmacokinetics available.258•26o The half-life of 
amphetamine ranges from 7 +/- 1.2 to 11 +/- 2.1 hours. Approximately 30% of an 
amphetamine dose is excreted unchanged. Excretion in sensitive to urinary pH and 
by acidifying it (pH-5), the urinary excretion half-life becomes -4.6.258 
The half-life of methamphetamine in urine at pH 5 was determined to be -4.9 hours. 
Under these conditions, 70 % of the dose is eliminated as methamphetamine 
therefore the condition of the urine determines the concentration of drug excreted. 
Studies involving the pharmacokinetics of MDMA enantiomers in rats, was 
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investigated by Cho et al. 261 The half-life of (+) isomers was found to be 74 minutes 
and that of the (-) isomer was 100 minutes. 
7.1.7 ROUTES OF ADMINISTRATION 
Amphetamines can be taken via various routes either orally, intranasal or 
intravenous. If the amphetamine is in its powdered form, then it can be sniffed, 
smoked or injected. If in capsule or tablet form, which most of the time MDMA is 
presented, then it can be taken by mouth. Illicitly manufactured amphetamine 
powders can be found on the illicit market and some capsules or tablets are produced 
for medical use. After cannabis, amphetamines are the most widely misused 
controlled drugs. 
7.1.8 EFFECTS OF ECSTASY 
7.1.8.1 Psychological Effects 
Often feelings of euphoria and increased physical and emotional energy, empathy 
and personal insight have been reported by users.246 MDMA does not produce 
hallucinogenic or disillusioned states, hence, if these symptoms are reported then it is 
likely that MDMA was not the only drug present.238 Unlike most drugs, MDMA does 
not appear to produce psychological dependence. It has been reported that the more 
often MDMA is used, the less enthusiastic the user becomes about the drug.262-263 
7.1.8.2 Social Effects 
Experimental studies on the social effects that MDMA has on the users life, indicated 
varied response either positive or negative.249 Some claimed that the drug improved 
their lives, enhancing personal communication skills even with strangers?64 Ecstasy 
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has also been known to be an aphrodisiac, partly because of its association with 
MDA (the love drug) and its name "ecstasy". Buffum 1986 conducted a study of 76 
users, which concluded that, the use of MDMA increased emotional closeness, but 
not sexual desire. 265 
7.1.9 CHROMATOGRAPHIC ANALYSIS 
7.1.9.1 AMPHETAMINE HAIR ANALYSIS 
Until recently, literature on the detection of amphetamines in hair has been 
published. 173. 18~. 20S. 234. 235 A large number of the literature published has been by 
Japanese researchers marking the prominence of amphetamine consumption in the 
Far East. In 1983 Ishiyama used GC/MS to identify methamphetamine, nicotine, 
amitriptyline and imipramine.206 By 1984 Suzuki, published a method to detect 
amphetamine in a single hair.267 In Genoa in 1993 standard screening procedures for 
the identification of amphetamine-like designer drugs were easily identified.268 More 
recently Nakahara published an informative survey detailing the interpretation of 
amphetamine in hair.269 
7.1.10 CONCLUSION 
In the UK, ecstasy tablets have been found to contain a range of stimulants (e.g. 
amphetamine, caffeine) without containing the psychoactive ingredients or variants 
of the MDMA compound (e.g. MDEA). Some tablets have been found to contain the 
anesthetic ketamine and some variable amounts of the active ingredient. Therefore, 
it is unlikely that consumers will be aware what substance they are consuming. 
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In addition to this, consumers usually takes a combination of recreation drugs as 
adjuncts to the ecstasy tablets and therefore, it is not possible to attribute their 
behavior unequivocally to MDMA. Although studies have attempted to measure the 
extent of ecstasy-related harm and the prevalent use; there is still a need for more 
research on MDMA or ecstasy and its effects. 
7.2 CURRENT METHODOLOGY 
There are numerous methods for amphetamines and at present the method of 
extraction employed in the routine laboratory is solid-phase extraction for biological 
samples. There are several methods that have investigated the extraction of 
amphetamines in hair. However, not many include the investigation of a correlation 
between the self-reported use of speed and ecstasy consumed and levels found in 
hair. 173 
The worldwide monitoring method is used for the extraction of amphetamines from 
blood and urine in the routine Laboratory. 
• Blood sample pre-treatment: To a vial 1 ml of blood or urine, 100J..lI of internal 
standard, (dJ-amphetamine) and 2 ml of 100mM phosphate buffer pH 6 were added. 
• Column conditioning: The column was conditioned with 3 ml of MeOH, 3 ml of 
de-ionized water and I ml butTer. The sample was then added to the column 
• Column wash: The column was washed with 3 ml de-ionized water, 2 ml 1.0 M 
acetic acid and 3 ml MeOH and dried for 5 min at ~ 10inches Hg). 
• Elution: The analytes were eluted with 3 ml of dichloromethane: isopropyl 
alcohol: ammonium hydroxide (78:20:2 v/v), which was prepare daily. 
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The eluent containing the drugs was evaporated to dryness without heat at room 
temperature or under nitrogen. The vial was sealed and derivatised with 50 JlI of 
PFPA for 20 min at 70°C. It was evaporated to dryness at 40° C and reconstituted 
with 1 00 ~ll of Etoac. The sample was removed from the heat source, cooled and 1 JlI 
was injected into the GC/MS for analysis. 
7.2.1 GCIMS Parameters 
A Fisons model GC 8000 M0800 series was fitted with a HP-l capillary column. 
The initial temperature was 55°C held for 2 minutes and final temperature was 280°C 
held for 5 minutes. The oven rise was at a rate 0[20 °C I min. 
Figure 7.3 Chromatograph of an unextracted sample of the five amphetamines 
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7.3 AMPHETAMINES IN HAIR 
The aim of this study was firstly to investigate and confirm the accuracy of self-
reported use of speed and ecstasy using hair analysis procedures. Second, to 
optimize a method which would extract and identify amphetamine (AP), 
metamphetamine (MA), methylenedioxyamphetamine (MDA), methylenedioxy-
methamphetamine (MDMA) and methylenedioxyethylamphetamine (MDEA) in hair. 
Third to determine the existence of a correlation between the self-reported amounts 
of drug consumed and drug levels found in hair. 
7.3.1 Experimental Overview 
This study took place in Glasgow Scotland jointly by the Faculty of Law at the 
University of Sheffield; the Scottish Centre for Criminology and the Department of 
Forensic Medicine and Science at the University of Glasgow. 
Ecstasy was investigated because of its expanded use among adolescents, especially 
in the rave scenes or discotheques. Subjects were recruited through chain referral 
(e.g. subjects referring others) from several rave scenes and asked to honestly answer 
a detailed questionnaire on their drug used over the last 12 months. They were then 
asked to donate a hair sample for completion of this study, which was collected after 
completion of the questionnaire. 
The most important information gained from the questionnaire was the subjects self-
reported account of their past drug usage in the last 12 months. The amount of 
ecstasy used was recorded by the number of tabs consumed per month and speed was 
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recorded as ever consumed and how often (previous week, month or year) over the 
past 12 months. 
7.4 SUBJECTS DRUG HISTORY 
From the interview conducted, a report on drug use histories was recorded for over 
the past 12 months. Out of 100 subjects, 90 admitted consuming ecstasy, with the 
number of tabs consumed ranging from 1-144 (mean 19, median 10). Most reported 
consuming ecstasy regularly and 28 subjects reported sporadic or irregular 
consumption of the drug, where 6 - 72 tablets were consumed in a month, one case 
reported consuming 400 tabs. 
Subjects were also asked to record to their best knowledge, their use of other drugs 
beside for amphetamine and ecstasy over the past year. Table 7.1 summarizes the 
various drugs consumed. Majority of the subjects consumed alcohol (96%), cannabis 
(95%). Speed (84%) and tobacco (84%). 
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Table 7.1 Drugs consumed by the 100 subjects over the past 12 months 
DRUG YES NO NO RESPONSE 
ALCOHOL 96 4 -
CANNABIS 95 5 -
SPEED 84 16 -
TOBACCO 84 16 -
LSD 67 33 -
COCAINE 53 42 5 
NITRILES 46 50 4 
MUSHROOMS 30 67 3 
TEMAZEPAM 29 68 3 
OTHER BENZOS 19 75 6 
OTHER OPIATES 13 82 5 
GLUE 7 88 5 
HEROIN 6 86 8 
TEMGESIC 6 84 10 
KETAMINE 5 86 9 
7.5 HAIR SAMPLING TECHNIQUES 
Collection procedures have not been standardized, but hair was often collected from 
the area at the back of the head (vertex posterior), cut as close as possible to the scalp 
and stored in dry tubes. In this case they were wrapping in foil and put in labeled 
plastic ziplock bags. This area is said to have less variability in hair growth rate, the 
number of hairs in the growing phase is more constant and the hair is less subject to 
age and sex-related influence.270 
Hair samples were collected and separated into categories of male and female and the 
age, length and color was recorded. 100 subjects were interviewed, 51 were male 
and 49 female with the age range from 15 to 44 years (mean = 24yrs). The hair 
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samples taken had lengths that ranged from 1. 5 to 12 em for 100 samples. Although 
hair growth may vary from 0.6 to 3.36 em, the rate of growth is approximately leml 
month, therefore 12 months is equivalent to 12em worth of hair growth. 
The hair samples were separated for segmental analysis by measuring 6 cm from the 
root (proximal) along the hair shaft and 6em from that cut off point from the tip 
(distal). This gave a total of 12 cm or 12 months hair growth data. Some of the 
samples were either too small for analysis or had less than 6 months (6 cm) worth of 
hair growth, therefore they were analyzed as full samples. In total 139 hair segments 
were analyzed, with 46 of them analyzed in full for self-reported speed and ecstasy 
use. Table 7.2 shows details the data used for hair analysis. 
Table 7.2 Data of the hair region, length and number of hair segments analyzed. 
Hair Region Length data (em) Number analyzed 
Roots <3 em 4 
3 em<6 em 10 
6em 40 
Tips 6cm 29 
6 em < 12 em 10 
Full 12 em 46 
Total Analyzed 139 
7.6 SAMPLE PREPARATION 
Stock standard solutions of AP, d3-AP, MA, MDA, MDMA and MDEA (O.lmg/ ml) 
were prepared in methanol. From these, solutions of 1 and 10 J.l.g/ ml were prepared 
as working standards. 
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7.6.1 Experimental 
A detailed description of the wash procedures is described in the hair chapter. The 
sample preparation used for ecstasy hair samples is as follows: 
• Hair samples were stored in glass vials and washed once with 0.1 % SDS (sodium 
dodecyl sulfate), three times with de-ionized water and sonicated for 15 minutes. 
The hair was rinsed with MeOH and dried overnight in a dessicator. 
• The washed hair was weighted, measured and cut into root and tip segments for 
analysis. Using liquid nitrogen and a pestle and mortar, the hair was cut and 
ground into a fine powder and weighed for further analysis. 
• The powdered sample was pretreated using an enzymatic hydrolysis (2ml O.lM 
phosphate buffer pH 7.4 and 50 III of O.lmg Iml p-glucuronidasel arylsulphatase 
in prepared in buffer) with the addition of 1 OO~tl d3-AP (IS) heated at 40°C for 2 
hrs. 
• The sample was vortexed then centrifuged and the supernatant pipetted off into a 
clean vial. The addition of 2ml of buffer was repeated and centrifuged and the 
supernatant added to the first fraction. 
7.6.2 Solid-Phase Extraction Methodology271 
• Column conditioning: 2ml of MeOH was added to the column and dried under 
vacuum, then 2ml of phosphate buffer pH 7.4 was added to Isolute™ Confirm 
HCX-3 mixed mode column. 
• Sample application: The pretreated sample containing the combined fractions 
was added to the conditioned column under slow vacuum. 
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• Column wash: The column was washed with 2ml of de-ionized water and the pH 
was adjusted using Iml O.OIM acetic acid pH 3.3 and dried under full vacuum for 
4 minutes. 2ml MeOH was added and dried under full vacuum for 1 minute. 
• Elution: The acidic and neutral drugs (fraction A) were eluted first using 2mI 
acetone : chloroform (1: 1) and discarded. The basic drugs (fraction B) were 
eluted using 2ml of 2% ammoniated ethyl acetate and blown down to dryness 
under nitrogen with no heat or left to evaporate at room temperature. 
• Derivatisation: Fraction B was reconstituted with 50~Ll PFPA : Etac (2: 1) and 
sonicated for 5minutes. Then derivatised for 15 minutes at 50° C, evaporated to 
dryness and reconstituted in 50 J..lI ethyl acetate. I J..lI was injected for analysis by 
GC/MS. 
Various ions were chosen to identify the drug during chromatographic analysis. AP 
(rnlz 118, 190*), MA (rnlz 118, 160, 204*), MDA (m/z 135, 162, 190, 325*), 
MDMA (rnlz 185,162,204,339*) and MDEA (rnlz 135, 162, 190,218,353*). The 
astrex (*) indicates the ions which were used for quantitation of each drug. 
7.6.3 Results and Discussion 
Blank hair was spiked (10 mg) were known amounts of standard mix were 
incorporated into the hair at levels of at 5, 10 and 20 ng/mg for method validation. 
Each drug had very good recoveries, which were all over 70 %. AP 71 %, MA 79 %, 
MDA 82 %, MDMA 87 % and MDEA 85 % relatively. The method proved linear 
over a concentration range of 0 to 100 ng/ mg. The LOD for AP and MA was 0.5 ng 
Img and O.Ing Img MDA, MDMA and MDEA. These results are summarized in 
Table 7.3. 
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Table 7.3 Method validation for the confirmation of amphetamines from hair. 
DRUG %RECOVERY %RSD LOD ng/mg LINEARITY r 
AP 70.6 7.92 0.5 0.990 
MA 79.4 8.68 0.5 0.993 
MDA 82.2 6.26 0.1 0.993 
MDMA 87.1 4.62 0.1 0.995 
MDEA 85.4 2.12 0.1 0.996 
7.7 DRUG CONCENTRATIONS IN HAIR 
The amount of drug found in hair can vary depending on the amount consumed. The 
use of segmental analysis to determine drug usage patterns is based on the 
assumption that hair grows at a constant rate and drug diffusion is absent along the 
hair shaft. 
7.7.1 Experimental 
Table 7.4 lists the type of drug investigated the number of positives for each drug, 
the range of drug levels and the median and mean of the concentrations detected in 
hair. 
Table 7.4 Drug concentrations detected in hair. 
Drug Sample Range Median Mean 
Positives ng/mg ng/mg ng/mg 
AP 11 0.7 - 97.7 2.5 12.5 
MA 27 0.6 - 32.3 2.6 5.2 
MDA 20 0.1-8.4 1.0 1.9 
MDMA 56 0.1 - 82.9 0.7 4.6 
MDEA 23 0.1-15.0 0.5 2.8 
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7.7.2 Results and Discussion 
The amount of drug concentration in hair was determined for all five drugs for 139 
samples. In total, 73 (52.5 %) tested positive for at least one of the amphetamines 
and the remaining 66 tested negative for all five drugs. Each drug had a relatively 
large range from very low levels to very high levels, which are consistent with other 
studies. 173, m, 266. 267, 272 It is important to note that these hair samples were analyzed 
once due to the sample size and the reliability of this single analysis should be taken 
into account when interpreting the results summarized in Table 9.4. 
7.8 DRUG - METABOLITE RATIOS 
Goldberger et al had found that highly metabolically labile drugs like heroin and its 
short-lived metabolite 6-MAM are present in hair. Cocaine, with its short plasma 
half-life, has similarly been identified as the primary analyte in the hair of individuals 
that have ingested cocaine. Cocaine is present in high concentrations in hair even 
though it has a short-lived plasma half-life, 6-fold and lO-fold greater than its 
metabolites benzoylecgonine and ecgonine methyl ester respectively.22S· 273·276 The 
Society of Hair testing has set ratios for cocaine and heroin and their metabolites, but 
not as yet for amphetamines.277 
7.S.1 Experimental 
To determine whether a positive result is due to contamination or from ingestion of a 
drug, the metabolite to parent drug ratio is determined. The concentration of the 
parent drug is normally higher than that of the metabolite, but expected to be lower 
than 1.0 due to parent drug to metabolite incorporation. However, levels reported to 
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be greater than 1.0 are determined to be caused from contamination·277• 278 The 
metabolite to parent ratios are summarized in Table 9.5. 
Table 7.5 Metabolite to parent drug ratio 
Metabolite and Number and Median Mean 
Parent (Range) 
MAandAP 9 (0.15 -44.40) 0.85 7.26 
MDAandMDMA 12 (0.01 - 6.28) 0.40 0.54 
MDAandMDEA 11 (0.1 0 - 6.50) 0.67 1.59 
MDA(MDMA+ 14 (0.03 - 6.50) 0.33 0.95 
MDEA) 
7.S.2 Results and Discussion 
All of the ratios except for those of MDA and MDMA had greater ranges than in 
other studies. This can be explained by the various materials incorporated in some of 
the tabs where the contents are unknown. For example, although methamphetamine 
is a metabolite of amphetamine, speed can contain the parent drug and the 
metabolite, which can affect the metabolite to parent drug ratio. 
Where a range of 0.03 to 6.5 was reported for MDA: (MDMA+MDEA) ratios, Rothe 
and co-workers reported a range of 0.03 to 0.2 (n = 67) with some cases having ratios 
> 1 like in this study.173 Similarly, this can be explained as in the case of AP and 
MA, if unknown to the user, MDA was consumed as well as the parent drugs 
MDMA and MDEA. 
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7.9 ECSTASY PREPARATIONS 
7.9.1 Experimental 
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At the time of the hair analysis study, 15 illicit ecstasy tablets were analyzed in the 
laboratory. A Home Office licence was obtained to be able to collect substances that 
were sold as ecstasy. This was investigated to find the percentage composition of the 
ecstasy tablets or powders that were in circulation at the time of sampling, which 
would identify the predominant parent drug(s). Table 4 details the percentage, actual 
amounts found and the type of drug found in various brands of ecstasy tablets or 
powders analyzed during the study. 
7.9.2 GC-FID and GC-MS Parameters 
Samples were analyzed using a HP 5890 gas chromatography fitted with flame 
ionization detection (GC-FID) and a CP-Sil 5 0.5id x 10 m column. The initial 
temperature was set at 80°C, with a final temperature of 200°C at a rate of 10°C per 
minute held for 5 minutes. The injector and detector temperatures were set at 290 
°C. Confirmation was carried out by GC-MS using a Fisons GC 8000 MD 800. The 
initial temperature was 60°C and final temperature was 300°C at 10°C/ minute held 
for 10 minutes. 
7.9.3 Results and Discussion 
Table 7.6 shows a list of the 15 substances thought to contain ecstasy, which were 
analyzed during this study. Overall, MDMA was the parent drug identified in the 
majority of the tablets ranging from trace levels t070 % (trace - 239 mg median 90 
mg). Trace levels of MDMA were a result of AP and caffeine, which comprised of 
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87% of the tablet. MDEA was detected in several samples, but only from trace levels 
to 3.5 mg. 
Although MDA was not detected in any of the substances analyzed, these are not 
representative samples and it does not eliminate the possibility that ecstasy was 
consumed by individuals in this study contained MDA. It has been reported that 
substances known to contain ecstasy seized in Britain have been identified as having 
MDA as one of its main constituents.279• 28o 
Table 7.6 List of 15 ecstasy samples analyzed at the time of hair study 
ECSTASY NAME FORM MDMA% OTHER DRUG 
Emerald E Capsule MDMA trace AP(46%)CAF(41 %) 
Tornado Powder Powder MDMA 13 -
Rhubarb+Custard Capsule MDMA 17 -
Lemon and Lime Capsule MDMA 19 MDEA (1%) 
Clog Tablet MDMA20 
-
Pink Snowball Tablet MDMA20 
-
Madman Tablet MDMA21 
-
Turbo Tablet MDMA21 
-
Disco Biscuit Tablet MDMA31 MDEA (trace) 
Un-named Tablet MDMA43 -
Blaster Tablet MDMA46 
-
White/Love Dove Tablet MDMA 58 
-
Madwoman I Powder MDMA65 
-
Super dove/robin Powder MDMA68 MDEA (trace) 
Madwoman II Tablet MDMA 70 
-
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7.10 SELF-REPORTED AND LABORATORY FINDING 
7.10.1 Experimental 
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A direct comparison was made to find if a correlation exists between self-report data 
and the levels detected in hair for the 139 segments. Out of 73, 71 of the segments 
tested positive for at least of one of the amphetamines and agreed with the self-report 
data, where 2 were positive but disagreed. The remaining 66 tested negative for any 
amphetamine, however 6 out of the 66 agreed with having taken any amphetamine. 
There was an overall concordance of over 50% with a low number of false positives, 
which is consistent with other studies. 
Figure 7.4 Summary of the overall concordance between self-report and hair analysis 
SELF-REPORT 
YES NO 
YES 71 2 
(51.1 %) (1.4%) 
LAB 
6 60 
NO (4.3%) (43.2%) 
7.10.2 Results and Discussion 
The relatively large number of false negatives reported can be caused by a number of 
possible problems. With the amount of any amphetamine present in tablets (e.g. very 
low contents, if any), the method may not be sensitive enough to recover low levels. 
The over-reporting of drug use and the influence of cosmetic treatments on the hair 
could also be an explanation.281-283 However true this may be, information was not 
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available to assess this hypothesis. In addition, many of the hair samples collected 
were very small which could also influence the number of false negatives reported. 
7.11 COMPARISON BETWEEN ROOTS, TIPS AND FULL 
7.11.1 Experimental 
By comparing root samples with tips, root samples are expected to be more accurate 
than tips because they are not greatly exposed to environmental or cosmetic 
influence, which can affect drug stability in hair. Figure 7.5 A, Band C compare the 
segments as well as show the concordance between self-report and laboratory 
recorded data. 
Figure 7.5A Summary of self-report and hair analysis data for roots (n=54) 
SELF -REPORT 
YES NO 
YES 29 0 
(53.7%) (0%) 
LAB 
22 3 
NO (40.7%) (5.6%) 
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Figure 7.5B Summary of self-report and hair analysis data for tips (n=29) 
SELF-REPORT 
YES NO 
YES 13 0 
(44.8%) (0%) 
LAB 
14 2 
NO (48.3%) (6.9%) 
Figure 7.5C Summary of self-report and hair analysis data for full (n=56) 
SELF-REPORT 
YES NO 
YES 29 2 
(51.8%) (3.6%) 
LAB 
24 1 
NO (42.9%) (1.8%) 
7.11.2 Results and Discussion 
Root samples have a higher concordance (53.7%) than tips (44.8%) and full (51.8%), 
In addition, roots having a higher correlation is possibly due to the more accurate 
self-reporting over the last 3 months of the 12 month due to better recollection. 
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7.12 COMPARING SPEED AND ECSTASY SELF-REPORT 
7.12.1 Experimental 
When individually comparing speed or ecstasy self-report data to hair data, a low 
concordance for speed (28.3 %) is seen. This can be explained by the cut-off levels 
being higher compared to ecstasy, the speed data not being recorded for each month 
over 12 months and subjects were not aware of what they had consumed. A 
combination of these can affect the number of expected positives. The figures shown 
in figures 7.6A and B summarize the concordance for both speed and ecstasy only. 
Figure 7.6A Speed data for self-report and hair analysis data. 
SPEEDONLY* 
SELF-REPORT 
YES NO 
YES 23 6 
(16.7%) (4.3%) 
LAB 
93 16 
NO (67.4%) (11.6%) 
(*) Indicates that one subject did not answer question on speed use. 
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Figure 7.6B Ecstasy data for self-report and hair analysis data. 
ECSTASY ONLY 
SELF-REPORT 
YES NO 
YES 58 7 
(41.7%) (5%) 
LAB 
52 22 
NO (37.4%) (15.8%) 
7.12.2 Results and Discussion 
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Looking at the speed and ecstasy data in Figure 7.6 A and 7.6 B, 6 subjects denied 
the use of speed, but their hair tested positive (false positive) and 5 were positive for 
ecstasy and admitted consuming ecstasy. In the ecstasy data, 6 out of the 7 false 
positives admitted consuming speed but denied ecstasy use with only one case 
positive for speed. 
7.12 TOTAL ECSTASYv. DETECTED LEVELS 
7.12.1 Experimental 
The amount of ecstasy recorded being consumed was compared to the levels detected 
in hair analysis to find if a correlation existed. Figure 7.7 shows the correlation 
between the number of ecstasy consumed over the prior 12 months compared to the 
levels found in hair 
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Figure 7.7 Comparison between the amount of ecstasy consumed and the levels 
detected in hair for 139 samples. 
ECSTASY CONSUMED v. NG LEVELS IN HAIR 
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7.12.2 Results and Discussion 
The amount of ecstasy found in hair was based on a combination of MDMA and 
MDEA levels compared to the total amount of ecstasy tabs consumed by the subject 
over twelve months. A large degree of scattering of data was observed with the 
majority gathered along the axis. A linear dose response relationship was not 
observed (r2 = 0.0484). If ecstasy was used sporadically, then this result would prove 
true with the results varying greatly. However if ecstasy had been consumed on a 
regular basis consistently over twelve months, then a higher correlation would 
possibly exist between ecstasy consumed and the amount detected in hair. 
This correlation was expected because of assumed irregular consumption and the 
possibility that what was thought to be consumed as ecstasy was probably not or 
contained very low amounts. In addition, comparing the amount of ecstasy 
consumed month to month to corresponding hair data, it was found that a relationship 
Chapter Seven: Amphetamine in Hair page 190 
existed between the data. Similar results were produced comparing the amount of 
ecstasy consumed and MDMA or MDA+MDMA+MDEA data. 
7.13 ECSTASY CONSUMED PER MONTH 
7.13.1 Experimental 
Hair segment data was separated into groups of five based on the frequency of 
ecstasy consumed each month. Each group consisted of approximately 20 % of the 
segments analyzed. Table 7.7 summarizes the number of ecstasy tabs consumed 
each month, the average consumption of each month and the mean, median and range 
of the levels detected in hair. 
Table 7.7 Correlation between ecstasy consumed per month and ng levels detected 
for MDMA +MDEA 
Ecstasy tablets Frequency ng 1 mg Levels in Hair 
consumed per month mean/median Range 
None 29 0.086/0.00 0- 1.00 
< 0.5 29 1.493/0.10 0-20.3 
0.5 - 1.25 28 4.425/0.00 0-93.4 
1.25 - 3.5 27 1.615/0.00 0-23.9 
>3.5 + 26 4.285/0.55 0-55.8 
TOTAL 139 1.942/2.00 0-93.4 
7.13.2 Results and Discussion 
A correlation between the number of ecstasy tablets consumed each month and 
MDMA + MDEA levels found in hair was investigated. The mean and median 
values increased from low to high, with the exception of ecstasy tabs consumed each 
month in the range of 0.5 - 1.25. The mean value is higher due to one case what has 
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a total concentration of 93.4 ng I mg, which can be considered to be an outlier, being 
the only high level found. In addition, the number of high false negatives recorded, 
were due to subjects claiming ecstasy use, which influenced the data. 
7.14 INTERLABORATORY COMPARISON 
The purpose of this study was to determine whether a concordance could be 
established between two laboratories using similar techniques for the recovery of 
amphetamines and its derivatives in hair samples. Work was carried out in Lab one; 
the Tricho-Tech Laboratory Ltd., located at the Cardiff Medicentre in Cardiff 
England and Lab two; the Department of Forensic Medicine and Science in Glasgow 
Scotland. 
Hair samples were analyzed without prior knowledge of the data and procedures by 
either lab. Both laboratories used different extraction procedures with GC/MS for 
confirmation of AP, MA MDMA and MDA. In addition, MDEA was only screened 
for by Lab two and Lab one screened also for opiates using RIA techniques. 
7.14.1 METHODOLOGY 
Lab one analyzed 49 case hair samples (n = 93 segments analyzed total) which were 
divided into two segments of 3 cm for root and tip analysis. Lab two analyzed 100 
case hair samples (n = 139 segments were analyzed total) which were also divided 
into two segments. However the segments where in 6 cm lengths for root and 6 cm 
for tip. 
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If the sample was deemed too small to be analyzed in separate segments, the whole 
sample was analyzed. Table 7.8 shows a summary of the number of hair sample 
lengths and the total amounts analyzed by both labs. 
Table 7.8 Summary of the number of hair sample lengths analyzed by both labs. 
Sample Lab one Lab two Total 
ROOT 49 54 103 
<3em 4 4 8 
3em Root 45 0 45 
3.1em -5.gem 0 10 10 
6cm Root 0 40 40 
TIP 44 29 73 
(leml2em)Tips 3 0 3 
3cm Tip 41 0 41 
6em Tip 0 29 29 
FULL 0 56 56 
6.1 em - 11.gem 0 10 10 
12 em 0 46 46 
TOTAL 93 139 232 
Limited information was available regarding the precise extraction and wash criteria 
used by Lab one due to commercial interests. The analysis of the hair samples was a 
four-phase process. 
7.4.1.1 Experimental 
7.14.1.1.1 Lab One: Pre-treatment and Analysis 
The Hair sample was accurately measured and weighed. The sample was then fully 
digested to release all of the bound drugs from the hair and extracted with organic 
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solvents to remove potentially interfering material and concentrated extracted drugs. 
The analysis used was GC/MS for AP, MA, MDA and MDMA. The limit of 
detection was recorded as being 0.5 ng/mg for 10 mg of hair. 
7.14.1.1.2 Lab Two: The pre treatment, extraction method and analysis carried out 
for Lab two has been listed throughout this chapter. 
7.14.1.2 Results and Discussion 
Despite several differences between the two laboratory techniques, analysis and the 
amounts of hair sample (e.g. 3 cm v. 6 cm) used for analysis, both labs produced 
similar results for the selected case samples. Table 7.9 below lists the drug, range, 
median and mean of the number of positives recorded from both labs. 
Table 7.9 Drug concentrations detected in hair samples by both labs. 
Drug! Lab One No. (Range)ng/mg Median Mean 
AP 22 (0.3 - 48.4) 3.2 6.7 
MA 2 (0.3 - 0.6) 0.5 0.5 
MDA 17 (0.20 - 8.8) 0.4 1.1 
MDMA 46 (0.30 - 44.6) 1.9 5.3 
Drug !Lab Two 
AP 11 (0.7-97.7) 2.5 12.5 
MA 27 (0.6 - 32.3) 2.6 5.2 
MDA 20 (0.1 0 - 8.4) 1.0 1.9 
MDMA 56 (0.1 0 - 82.9) 0.7 4.6 
MDEA 23 (0.10 - 15.0) 0.5 2.8 
Concordance between self-report and laboratory findings for the total amounts of 
amphetamines was compared for both lab one and lab two. Lab one had a 
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concordance of 61.1 % (n = 93) which was a slightly better concordance than Lab 
two which had a concordance of 56.8 % (n= 139). The false positives were low for 
both labs where lab one had one false positive and lab two had two. 
For concordance between root and tip for both labs, Lab one which analyzed 3 em of 
root hair, had a concordance of 71.5 % (n = 49) and Lab two which analyzed 6 cm of 
root hair had a concordance of 61.1 % (n = 54) both recorded no false positives. For 
concordance of tip hair samples, Lab one (3 cm) had a concordance of 50 % with 1 
false positive (n = 44) and Lab two had a concordance of 55.2 % (n = 29) with no 
false positives. As expected, it can be seen that samples containing the 3 cm root 
samples were found to yield more accurate results than the 6 em root samples. 
However, the 6 cm tip samples were slightly more accurate than the 3 cm tip 
samples. 
7.15 CONCLUSION 
Hair analysis is a very new technique in the field of the analytical chemist. Hair is an 
attractive matrix for the detection of drug exposure because of the accessibility of 
hair and its presumed ability to retain drugs longer than either plasma or urine. The 
method developed has proven successful for the extraction of five amphetamines 
(AP, MA, MDA, MDMA and MDEA) using enzymatic extraction followed by SPE 
with confirmation carried out using GC/MS. Authentic hair samples were used in 
this study taken from participants in the Glasgow dance scene to confirm speed and 
ecstasy use. 
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All five amphetamines could be detected in hair using this method with over 50% 
concordance between self-reported and lab findings. However a high number of 
false negatives (43.2 %) were recorded, which may highlight the methods possible 
lack of sensitivity in confirming low use of speed and or ecstasy. It is also possible 
that by asking participants to tick a check list of the possible drugs they may have 
consumed over the past year might be difficult to remember. The self-reported use 
can only be taken as an estimation of what that person felt they consumed. Another 
methodological consideration would be that the ecstasy or speed the subject thought 
they might be taking, may not in fact be pure MDMA, rather contain other active or 
non-psychoactive materials or stimulants. 
No correlation was observed between the amount of ecstasy consumed and the levels 
detected in hair. However, there is evidence of a relationship existing between the 
level of use (measured in average ecstasy tabs consumed each month) and the levels 
detected in hair from low to high use. A combination of low concordance between 
self-report data and hair analysis results and the high number of false negatives raises 
questions regarding the sensitivity of the method and reliability of the self-report 
data. 
The collection of hair samples is also an important factor in this study. Where 
possible, a sample should be analyzed in triplicate to decrease experimental errors 
and increase the validity of the analytical result. Some of the samples were too small 
to be analyzed more than once as mentioned earlier in this study. This led to the 
possibility of false negative results, as the sample size was too small to give a 
significant level by the method used with subsequent GC/MS analysis. However, 
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obtaining larger samples on a voluntary basis can prove to be problematic due to the 
area being sampled (vertex region). 
It was very difficult to accurately correlate the amount of ecstasy tabs consumed with 
the levels detected in hair because of a lack of dose-response relationship for the 
segments analyzed. Large discrepancies observed in some cases could explain this 
correlation. One example of this was where one subject reported over a sixth month 
period, consuming 52 ecstasy tablets, however the hair analysis was negative for all 
amphetamines. Conversely, another subject denied ecstasy use, but 0.6 ng / mg was 
found in the corresponding 2 em of hair segment. 
Determining the smallest dose detectable in hair, in combination with dose- response 
studies, would explain the variation of levels consumed and levels detected. In one 
case, a subject consumed 5 ecstasy tabs and a level of l.Ing / mg of MDMA was 
detected. However, when another subject consumed 50 tabs, 0.5 ng / mg of MDMA 
was detected. As mentioned earlier in the ecstasy preparation study, this can be due 
to the constituents in the tabs taken. Some may contain ecstasy in small quantities 
and the major constituent could be caffeine or speed. 
There are many influences that can effect the levels detected in hair. Chemical 
treatments, an individuals metabolism, hair characteristics (i.e. damaged hair), sweat 
and other parameters must be taken into consideration during hair analysis. There 
are no set wash procedures or followed criteria for hair analysis yet, however there 
are quite a few methods investigating the extraction of amphetamines from hair. 
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In order to obtain more precise results for the comparison of self-report data and any 
amphetamine consumption, a controlled study must be carried out. This would 
include controlled dosages given to set amounts of subjects (with same hair colour) 
in a controlled environment what included controlled daily hair treatment procedures. 
Although possible, in the real world, this is not; therefore, the accuracy of the self-
report data compared to the levels detected in hair will only prove useful as an 
indicator for drug usage. 
From the results of both labs, it can be seen that even though different size samples 
and techniques were used, both laboratories reported similar results for the detection 
of amphetamines in hair. The data also reported that in general, root samples give 
more accurate concordance than tip and full samples. Tip samples were slightly 
more accurate than full but they did not differ significantly. In addition, by using 
smaller hair samples (3 cm or the first three months growth) yields a higher and 
possibly more accurate result, depending on the purported recent drug use. 
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8. SFE OF AMPHETAMINES IN HAIR 
8.1 LITERA TRUE REVIEW 
8.1.1 INTRODUCTION 
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Amphetamine and methamphetamine are the two most abused drugs in the far East 
and were amongst the first drugs investigated in hair.284 The recent spread of illicit 
drugs in the West has made these drugs and their analogues the third most prevalent 
in hair analysis. The determination of methamphetamine has also been detected in 
nails, sweat and saliva by Suzuki el at .285 
Nakarhara286, Kintz el aP36 and other researchers have published literature on the 
detection of amphetamine and their analogues in hair. It has been proven that these 
drugs can be extracted from hair following the addition of various extraction 
solutions, followed by GC/MS analysis to confirm their presence in hair. Table 8.1 
lists several studies on the extraction of amphetamine and its analogs from hair. 
Table 8.1 Amphetamines in Hair 
Drug Hair Cone. ng fmg Reference 
Amphetamine 0.1 - 4.8 Rothe et al 1997 1 {" 
0.02 - 6.5 Rohrich & Kauert 199i35 
Methamphetamine 0.05 - 0.89 Rothe et al 1997 1 (-' 
1 - 39 Nakahara et al 1990287 
MDMA 0.1-8.3 Rothe et al 1997 1 {" 
0.05 - 2.9 Rohrich & Kauert 1997235 
MDA 0.05 - 0.89 Rothe et al 1997 (-' 
0.04 - 1.2 Rohrich & Kauert 1997235 
MDEA 0.8 - 3.07 Rohrich & Kauert 1991"-'-' 
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8.1.2 SFE HAIR ANALYSIS 
Although, the analysis of amphetamine and its analogues (e.g. MDMA, MDEA and 
MDA) have been detected in hair using several extraction techniques, there is no 
present literature on the extraction of hair for amphetamines by SFE. However, there 
has been literature published on the applications of SFE for the extraction various 
other drugs from hair. 229,230,232,233 
The purpose of this study was to investigate the use of SFE for the detection of 
MDA, MDMA and MDEA in human hair. Second, to optimize a method that would 
extract and identify the selected amphetamines. Also, to determine if this method 
can be used for the extraction of authentic case samples. 
8.2 HAIR PREP ARA TION 
8.2.1 Wash Procedure 
It is necessary to wash the hair to remove any exogenous contaminates, prior 
cosmetic treatments and grease that can interfere with analysis or create false 
positives. The samples are first washed with a detergent sodium dodecyl sulfate 
followed by a wash with distilled water and then dichloromethane with a final wash 
with methanol. Each stage was repeated twice followed a 15 minute sonication at 
room temperature and dried at room temperature overnight. 
8.2.2 Pulverization Procedure 
Hair samples were ground to provide a large surface area to particle size ratio for 
better drug recovery. 
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8.2.3 Spiking Procedure 
A measure of Igm of blank hair sample was spiked with 1 ml (10 J..lg Iml) of each 
drug standard (MDA, MDMA, MDEA) in a glass vial. To ensure the hair was 
coated sufficiently, 3 ml of MeOH was added to the vial, sealed and sonicated for 15 
minutes. The sample was then left dry at room temperature. The internal standard 
for all drugs was added to the hair during hair spiking preparation or before packing 
the hair into the extraction cell. 
It is possible that this method of spiking is not the most ideal, as most drugs coat the 
surface of the hair and do not incorporate into the hair structure. However, it is 
accurate enough for estimation of exact concentration levels and is the only way to 
spike hair samples with known concentrations. 
8.3 METHOD DEVELOPMENT 
Hair samples were collected from persons known not to have taken any drugs for the 
use as blank hair samples. The hair samples were washed, ground and spiked with 
the appropriate prepared standards (l O~lg/ gm) as described above and in the hair 
chapter. All samples extracted were spiked samples based on 500ngl 50mg 
(10ng/mg) of hair for each extraction. 
The optimization of amphetamines by SFE can be achieved in three ways: 
1. Increase or decrease in temperature 
2. Increase or decrease in pressure 
3. Increase or decrease in the % of modifier and CO2 
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These three parameters will be investigated further to find the optimum conditions 
for the extraction of amphetamines from human hair. 
8.3.1 EFFECTS OF TEMPERATURE 
8.3.1.1 Experimental 
The temperature is known to effect the extraction of a sample under supercritical 
condition. It is one of the parameters that determine whether a drug can be eluted 
under such conditions. By varying the temperature and pressure can increase or 
decrease the polarity and or mass transfer of the SF and density. To determine the 
optimum temperature for the extraction of amphetamines (MDA, MDMA and 
MDEA), temperatures at a range of 60° C to 100° C with a rise of 10° C increments 
were studied. Several samples were extracted for each temperature. 
8.3.1.2 Results and Discussion 
The optimum temperature was found to be 70°C with the pressure set at 3500 psi 
and flow rate at 2 mIl min. Various modifiers were also used to determine optimum 
conditions. The extraction was carried out in dynamic mode (continuous) for 30 
minutes with the analytes collected in a vial containing chloroform. The solvent 
strength of the SF was dependent on the pressure and temperature used for the 
extraction. Constant temperatures at high pressures allowed the extraction to be 
optimized for a particular compound class. Table 8.2 lists the various temperatures 
investigated. 
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Table 8.2 Varying the temperatures of the extractions with chloroform: isopropyl 
alcohol (90: 1 0 v/v) 
DRUG UNEXTSTD 60° C 70° C 80° C 90° C 100° C 
MDA 1.662 1.1208 1.6955 1.6756 0.4895 0.4873 
MDMA 0.890 0.4846 0.7593 0.7660 0.272 0.4538 
MDEA 0.4878 0.2770 0.3582 0.3986 0.1719 0.1456 
Table 8.2 showed that 70 and 80°C were the best temperatures, however, it was 
shown that the higher the temperatures, the worse the recovery and chromatography 
for each drug. Figure 8.1 shows the percent recovery of each drug extracted at 
different temperatures. 
Figure 8.1 Percent recovery of MDA, MDMA and MDEA extracted at different 
temperatures 
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Recoveries at 70°C were 110 % for MDA, 85 % for MDMA and 74 % for MDEA. 
Recoveries at 800 C were equally as high for each of the drugs as 700 C, however, 
70 a C was chosen as the best temperatures as amphetamines are relatively stable at 
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lower temperatures. Figure 8.1 compares the PAR of the temperatures from Table 
8.2. 
Figure 8.2 Comparison of the PAR of the temperatures used for the extraction of 
amphetamines from hair 
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With comparison to the PAR of the unextracted standard, 70° C and 80° C proved to 
be the best extraction temperatures for MDA, MDMA and MDEA. 
8.3.2 EFFECTS OF PRESSURE 
8.3.2.1 Experimental 
As described in chapter one of supercritical fluids, pressure has a great effect on the 
SF and its solvent strength. An increase in pressure causes the solvent power or fluid 
density to increases at a given temperature. The pressure dependency of the SF 
solvating power is very important in SFE and is exhibited by all solids and many 
liquid solutes. 
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The pressure during SFE was investigated to determine the optimal pressure for the 
extraction of amphetamines. The temperature was set at the optimum 70 0 C, the 
flow at 2 mIl min and the modifier at 10 % chloroform: isopropyl alcohol (90: 10 
v/v) and 90 % C02 
8.3.2.2 Results and Discussion 
There was fluctuation during each extraction that made it a little difficult to observe 
an accurate pressure. However, from the pressure study, it was determined that 
pressures between 3500 - 4000 psi produced the best extractions for amphetamines. 
Pressure ranges of 45- 5000 psi had just as good peak area ratios, but there seemed to 
be more fluctuation. Table 8.3 lists the various pressure ranges investigated for the 
extraction of MDA, MDMA and MDEA from hair. 
Table 8.3 Pressure ranges of the peak area ratios 
PRESSURE RANGE PSI 
DRUG UNEXTSTD 28 -3000 32-3300 35-4000 45-5000 55-6000 
MDA 1.4299 0.1598 0.1548 1.212 1.2484 0.4318 
MDMA 0.9485 0.2118 0.1205 0.4974 0.5470 0.1645 
MDEA 0.4813 -- 0.395 0.2727 0.2705 0.0918 
Figure 8.3 shows a comparison of the pressure ranges during each extraction from 
MDA, MDMA and MDEA based on Table 8.3. 
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Figure 8.3 Comparison of the range of pressures used in the SFE of amphetamines. 
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Figure 8.2 shows that temperatures ranging from 3500 - 5000 psi produced greater 
peak area ratios compared to the unextracted standard. Temperature was selected at 
3800 psi for extraction. Recoveries within that pressure range, ranged from 85-87 % 
for MDA, 52-58 % for MDMA and 56-57 % from MDEA. 
8.3.3 EFFECTS OF MODIFIER 
8.3.3.1 Experimental 
The use of modifiers during extraction increases the polarity of the CO2 during 
extraction to increase the recovery of the analytes. Various modifiers were used to 
investigate which gave the best recoveries for the selected amphetamines. At the 
selected temperature of 70° C and the selected set parameters, four different 
combinations of modifiers were used. Table 8.4 lists the extraction modifiers used 
for the extraction of amphetamines in hair. 
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Table 8.4 Extraction modifiers selected. 
EXTRACTION MODIFIERS 
1 Chloroform: isopropyl alcohol (90 :10 v/v), 
2 100 % chloroform 
3 chloroform: isopropyl alcohol: isoamyl alcohol (90:9.5:0.5 v/v) 
4 chloroform: n-heptane: isopropyl alcohol (50: 17:33v/v) 
8.3.3.2 Results and Discussion 
In combination with C02, modifiers listed in Table 8.4 were introduced through the 
column at 10 %. The best recoveries were found with chloroform: isopropyl alcohol 
(90: 10 v/v) at the set parameters. Table 8.5 shows the concentration ratios for each 
drugs extracted and modifiers used in the extraction. 
Table 8.5 The average concentration ratio for each drug produced by each modifier. 
EXTRACTION MODIFIERS 
DRUG UNEXTSTD 1 2 3 4 
MDA 1.384 1.6345 0.3819 1.5684 1.3353 
MDMA 1.180 1.2941 0.4530 1.2661 1.3611 
MDEA 0.967 0.593 0.2397 0.4677 0.045 
The percent recovery was calculated for each of the extraction modifiers. 
Chloroform: isopropyl alcohol (90: 10 v/v) was found to produce the best recovery 
for each of the drugs. Modifier 4 produced good recoveries for MDA and MDMA, 
but recoveries were low for MDEA. 
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Table 8.6 The average percent recovery for each of the modifiers. 
DRUG % RECOVERY FOR EXTRACTION MODIFIERS 
1 2 3 
MDA 118 28 113 
MDMA 109 38 107 
MDEA 61 25 48 
8.3.4 EFFECTS OF PERCENTAGE CO2 AND MODIFIER 
8.3.4.1 Experimental 
4 
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By varying the percent modifier can establish the optimum conditions for the 
extraction. The modifier was varied from 5 % to 30 % at increments of 5 (e.g. 5, 10, 
15, 20, 25, 30) and the CO2 was varied in accordance to the percentage of modifier 
introduced into the system (e.g. 95,90,85,80, 75, 70). 
8.3.4.2 Results and Discussion 
The percent modifier was introduced into the system from 5 - 30 %. An increase in 
the percentage of the modifier decreases the amount of CO2 being pumped thought 
the system under supercritical conditions. This decrease in CO2 leads to the decrease 
in the supercritical state the extraction is under. Therefore, it is recommended that if 
a modifier is used, it must be 15 % or less. Although Cleland et al reported the use 
of 20% methanol-modified CO2 to recover arsenic from dogfish muscle.288 Studies 
showed that using a 10 % gave good recoveries for MDA, MDMA and MDEA. Less 
than 10 % modifier recovered less drug and greater than 10 % recovered just as much 
as 10 %. 
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8.3.5 EFFECTS OF DERIVATISATION 
8.3.5.1 Experimental 
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Derivatisation is an important step for the analysis of some samples using GC/MS. 
Amphetamines are known to be labile, therefore, the effects of derivatisation on 
MDA, MDEA and MDMA were investigated to find out how long amphetamines are 
to be derivatised 
8.3.5.2 Results and Discussion 
Samples containing 500 ng ofMDA, MDMA and MDEA were left to derivatise over 
a period from 15 to 45 minutes. Table 5 lists the peak area ratios of each drug over 
the selected derivatisation times. 
Table 8.7 Derivatisation of Amphetamines 
DRUG 
TIME MDA MDEA MDMA 
15 MIN 4.77cUUO 2.64cUUO 5.92cuu, 
30 MIN 4.601:.UU6 2.86cUUO 5.89cuu, 
45 MIN 5.09L:UU6 2.911:.uulS 5.66cuu , 
*E = 10 to the power 
It was found that derivatising MDA, MDMA and MDEA for 15 minutes gave similar 
peak areas as 30 and 45 minutes. Therefore it can be concluded that the length of 
derivatisation up to 45 minutes does not effect the recovery of MDA, MDEA and 
MDMA. 
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8.4 DEVELOPED SFE CONDITIONS 
Pressure: 3800 psi 
Temperature: 70° C 
Flow rate: 2 mIl min 
Modifier: chloroform: isopropyl alcohol (90: 10 v/v) @ 10 % 
CO2 : 90 % 
Collection solvent: 4 ml of 100 % chloroform 
Dynamic extraction for 30 minutes 
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Extractions were carried out under the above conditions for the extraction of MDA, 
MDMA and MDEA in 10 ng /mg of hair. Figure 8.4 shows a chromatography of the 
drugs identified using SFE at the above set parameters. 
8.4.1 GC/MS Parameters 
A Hewlett-Packard gas chromatography model 5890 fitted with a VO Analytical 
VG70- 250S mass spectrometry was used for analysis. The MS is a magnetic sector 
instrument that was operated in EI and SIM mode. The GC was fitted with a HP-5 
x- link 5 % PH Me silicone capillary column, 30 m x 0.25 J-lm, 0.88 J-lm film 
thickness. 
The selected ions were monitored in the electron ionization mode at 70 e V and the 
trap current was set at 200 ~lA. The initial temperature was 55° C held for 2 minutes 
and final temperature was 280° C held for 5 minutes. The oven rise was at a rate of 
20° C Imin. The ions monitored were mlz 218 mephentermine, mlz 325 MDA, mlz 
339 MDMA and mlz 353 MDEA. 
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Figure 8.4 Chromatography of MDA, MDMA, MDEA and internal standard 
mephentermine from a 10ngl mg spiked hair sample. 
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8.5 METHOD VALIDATION 
8.5.1 RECOVERY 
8.5.1.1 Experimental 
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Hair samples at levels of 10 ngl mg were extracted under the aforementioned SFE 
parameters to investigate the percent recovery of MDA, MDMA and MDEA. The 
internal standard (mephentermine) was made up to 10 ).1g Iml solution and 50 ).11 of 
that standard was added to each extracted eluent. 
8.5.1.2 Results and Discussion 
Under the developed SFE parameters from amphetamines, several hair samples were 
extracted and analyzed using GCI MS. At lOng Img hair samples produced 
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recoveries at an average of 84 % for MDA, 71 % for MDMA and 77 % for MDEA. 
Table 8.8 shows the average recoveries and peak area ratio range of each drug. 
Table 8.8 Peak area ratios and average recovery for MDA, MDMA and MDEA from 
hair. 
DRUG %AVG 
RECOVERY 
MDA 84.2 
MDMA 71.2 
MDEA 77 
8.5.2 REPRODUCIBILITY 
8.5.2.1 Experimental 
UNEXTRACTED PAR RANGE 
STDPAR 
1.6722 1.0976 - 1.5090 
0.7352 0.4071 - 0.7345 
0.3785 0.2294 - 0.3690 
Hair sample individually extracted at a concentration of 20 ng/ mg five times were 
investigated for reproducibility from sample to sample. 
8.5.2.2 Results and Discussion 
Summarised in Table 8.9 below shows five different extractions of hair containing 
the same concentration of hair taken from the same spiked hair batch. 
Table 8.9 Run to run reproducibility ofMDA, MDMA and MDEA in hair 
DRUG 1 2 3 4 5 
MDA 12.309 9.263 9.058 9.169 11.214 
MDMA 9.072 6.782 6.733 6.962 8.292 
MDEA 6.900 5.593 5.208 5.558 6.214 
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The mean, range, StdDev and percent RSD was calculated for the reproducibility of 
each drug for n = 5 runs. The results are summarized in Table 8.10 below. 
Table 8.10. Reproducibility of amphetamines in hair. 
DRUG MEAN RANGE StdDev %RSD 
MDA 10.202 9.058 - 12.309 1.47 14 
MDMA 7.556 6.733 - 9.072 1.065 14 
MDEA 5.899 5.208 - 6.900 0.665 11 
8.5.3 INTRA-DAY AND INTER-DAY REPRODUCIBILITY 
8.5.3.1 Experimental 
Over a period of two days, a sequence of hair samples were extract at the same 
concentration under the developed SFE conditions. The investigation of intra and 
inter-day reproducibility was to show that the method can be reproduced on a day to 
day bases. 
8.5.3.2 Results and Discussion 
Five hair samples at 10ng/ mg were extracted. Table 8.11 and 8.12 list the peak 
areas ofMDA, MDMA and MDEA extracted over period of two days. 
Table 8.11 Day one reproducibility of each drug 
DRUG UNEXTSTD 1 2 3 4 5 
MDA 2.119 1.913 1.1897 2.7397 2.2025 2.4690 
MDMA 2.0746 2.068 1.788 1.939 1.6371 1.5929 
MDEA 2.0549 0.456 0.677 0.855 0.7037 0.7699 
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Table 8.12 Day two reproducibility of each drug 
DRUG UNEXTSTD 1 2 3 4 5 
MDA 3.3182 2.1934 2.1173 2.6670 3.3232 2.2103 
MDMA 2.5970 1.7711 1.8597 1.9111 3.133 1.9840 
MDEA 2.0833 1.1376 1.2789 1.1837 1.6681 1.2103 
For MDA, MDMA and MDEA for day one, the standard deviation was 0.595, 0.200 
and 0.148, the mean 2.102,1.804 and 0.692 and the RSD 28 %, 11 % and 21 %. For 
MDA, MDMA and MDEA for day two, the standard deviation was 0.507, 0.565 and 
0.214, the mean 2.5022, 2.1318, 1.2960 and RSD 20 %, 26 % and 16 %. 
There was some variation between the two days but comparable. MDEA for day one 
is much lower than for day two. A possible explanation for this could be because of 
the spiking of the blank hair. Spiking blank hair with a drug does not incorporate into 
the hair as fortified hair samples, therefore not all the time will there be precise 
consistency from batch to batch. However, it is accurate enough for estimation of 
exact concentration levels and is the only way to spike hair samples with known 
concentrations. Also the sensitivity of the GC/MS from day to day can be a possible 
contributory factor. 
8.5.4 LINEAR CALIBRATION 
8.5.4.1 Experimental 
Linearity of the developed method over a concentration range from 20ng fmg to 
0.02ng fmg was investigated. Five individual samples (n = 5) at each of the six 
concentration levels were extracted for validity purposes. 
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8.5.4.2 Results and Discussions 
Over the selected range of 20ng/mg to 0.02ng /mg of hair, the linearity of each drug 
was extracted five times and the average taken. Table 8.13 below shows the 
concentration range investigated detailing the average peak area ratios for each drug. 
Table 8.13 Linear range of MDA, MDMA and MDEA over a range from 20 ng/mg 
to O.lng/mg 
CON CENTRA TION OF HAIR ng/ mg 
DRUG 20 10 2 1 0.1 
MDA 10.2024 2.9308 1.2761 0.4507 0.3934 
MDMA 7.5682 2.4232 1.1079 0.3827 0.1683 
MDEA 5.899 2.3561 0.6522 0.2006 0.1038 
Figures 8.5-8.7 show the linear calibration range of the three drugs based on the 
average peak area ratios listed in Table 8.13. 
Figure 8.5 Linearity of MDA in hair 
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Figure 8.6 Linearity of MDMA in hair 
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Figure 8.7 Linearity of MDEA in Hair 
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The correlation coefficient, range, LOD, intercept and slope were calculated for each 
of the drugs. The method proved linear over a concentration range of 0 to 20 ng/ mg. 
The LOD for MDA was 0.02 ng/mg and MDMA and MDEA was O.lng /mg. These 
results are summarized in Table 8.14. 
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Table 8.14 Method validation for the detection ofMDA, MDMA and MDEA in hair 
DRUG Correlation Conc range LOD Intercept SLOPE 
coefficient (r2) ng/mg ng/mg A B 
MDA 0.9703 0.02 - 20 0.02 0.4736 0.085 
MDEA 0.9775 0.02 - 20 0.1 0.3535 0.0106 
MDMA 0.9938 0.02 - 20 0.1 0.2870 0.0581 
8.6 AUTHENTIC CASE SAMPLES 
8.6.1 Experimental 
Hair samples taken from subjects participating in the self-report study for 
amphetamine use which was discussed in Chapter 7 were analyzed under SFE 
conditions. The samples were too small (too short or had only a few hairs) to be 
separated into segments of root or tip so they were analyzed in bulk or Full. 
Before analysis, the hair samples were washed and dried under the aforementioned 
wash conditions and the colour, weight and length were applicable of each hair 
sample were recorded. Table 8.15 below lists twenty cases analyzed for MDA, 
MDMA and MDEA. 
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Table 8.15 Case samples analyzed for MDA, MDMA and MDEA 
CASE # MDAng/mg MDMAng/mg MDEA nglmg Length cm Weight mg 
A99-A 0.255 0.638 0.396 11 60 
A99-B 0.125 0.288 0.067 4 30 
A99-C 0.252 0.153 0.171 11 40 
A99-D ND 0.117 ND 11 70 
A99-E ND 0.659 0.286 11 19 
A99-F ND ND ND 12 78 
A99-G ND ND ND 11 60 
A99-H 0.274 0.53 0.11 5 35 
A99-J 0.061 0.336 0.082 4 20 
A99-J ND ND ND 11 53 
A99-K ND 3.88 ND 11 60 
A99-L ND ND ND 11 21 
A99-M 0.059 1.15 ND 12 10 
A99-N ND ND ND 11 40 
A99-0 ND ND ND 2 66.5 
A99-P ND ND ND 2 7 
A99-Q 2.14 6.44 ND 8.5 10 
A99-R ND 0.71 ND 11 9 
A99-S ND 1.62 ND 11 10 
A99-T ND ND ND 11 52.5 
ND = Not detected 
8.6.2 Results and Discussion 
Authentic hair samples analyzed in Table 8.15 were taken from subjects claiming 
amphetamine use over the past 12 months. Out of the 20 samples analyzed, 5 were 
positive for MDA, MDMA and MDEA, 5 were positive for MDMA only, 2 were 
positive for MDA and MDMA only, 1 was positive for MDMA and MDEA only and 
7 were not detected. Samples that were not detected may not have been negative but 
the levels were possibly to small to detect. Below in Figure 8.8 are the result 
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summarized for the case samples positive overall for all three drug. Samples that 
were listed as not detected are not included. There were 7 overall MDA positives, II 
MDMA positives and 6 MDEA positives. 
Figure 8.8 Chart of overall positive cases 
7 
The self-report data was compared to the SFE findings from the hair samples to find 
if a correlation existed. It was found that some of the subjects that reported no use or 
little use (e.g. half an ecstasy tablet monthly) over the past 12 months were found to 
be negative and others found positive with low levels detected. Figure 8.9 below 
summarizes the results of the self-report data to the hair findings. 
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Figure 8.9 Self-report data compared to hair analysis for MDA, MDMA and MDEA 
SELF-REPORT 
YES NO 
YES 11 3 
(55%) (15%) 
LAB 
6 0 
NO (30%) (0%) 
Out of the 20 hair samples analyzed, 11 (55 %) were positive for all or either MDA, 
MDMA or MDEA and said yes to consuming ecstasy. 3 (15 %) also tested positive 
but disagreed with having taken any ecstasy and 6 (30 %) were negative for MDA, 
MDMA or MDEA, but agreed with having consumed ecstasy in the past 12 months. 
There was no one that claimed to be negative and was found to be negative. 
8.7 CONCLUSION 
Supercritical fluid extraction is a good technique that can be used as an alternative 
extraction method to conventional techniques. Among its many advantages, SFE is 
fast, inexpensive and produces less solvent waste. The use of SFE for the extraction 
of hair has been reported in various studies. Despite the controversial aspects of hair 
testing, the use of hair analysis is rapidly expanding. 
The aim of this study was to determine if amphetamines, MDA, MDMA and MDEA, 
could be extracted from hair samples using SFE, optimize a method for extraction 
and its application to authentic hair samples. The results in this chapter demonstrate 
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that MDA, MDMA and MDEA can be extracted from hair under the developed SFE 
conditions. Recoveries better than 84 %, 71 % and 77% were produced for MDA, 
MDMA and MDEA. Based on spiked hair samples, the method was found to be 
linear of a concentration range of 0.02 to 20 ng/mg of hair. The correlation 
coefficient (r2) for MDA, MDMA and MDEA was 0.9703, 0.9775 and 0.9938 
showing the linearity of the method. The method was also found to be reproducible 
from sample to sample and on a day to day basis. 
It has also been demonstrated that by the application of a polar modifier directly 
through the system providing better extraction conditions for the drugs of interest. 
By varying the temperature and pressure for optimal conditions increased the 
extraction potential. Temperature and pressure are the two main parameters that 
effect SFs. An increase in pressure at a constant temperature, increasing the density 
and mass transfer of the SF to allow more polar and higher molecular weight 
analytes of interest to be eluted. 
Authentic hair samples taken from subjects participating in a self-report study were 
analyzed using developed SFE techniques. Out of the 20 samples analyzed, 7 overall 
were positive for MDA, II for MDMA and 6 for MDEA. Samples were positive for 
either MDA or MDMA or a combination of MDA, MDMA and MDEA. Samples 
that were not detected may not have been negative, but had levels too low to detect 
using this method. The results from the hair analysis were compared to the self-
report data collected to find if a correlation existed between vhe two. It was found 
that with some of the subjects, a corrleation did exist between what they had reported 
to have consumed from month to month and hair findings and others it did not. The 
accuracy of the self-report data was questionable because of the possibility of under 
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or over reporting of consumption and whether or not what was taken contained 
MDA, MDMA or MDEA. 
It can be concluded that, SFE is an appropriate method for the extraction of 
amphetamines in hair. It is fast (30 minutes), reproducible and can be applied to 
authentic hair samples with results comparable to those generally observed in hair 
analysis. 
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9. SFE OF COCAINE IN HAIR 
9.1 LITERATURE REVIEW 
9.1 .1 INTRODUCTION 
page 222 
Although during metabolism, cocaine rapidly degrades and benzoylecgonine is the 
predominant drug found in biological tissue, cocaine is the primary analyte found in 
hair. This is also observed to be true when hair is soaked in aqueous solutions 
containing equal amounts of cocaine and benzoylecgonine.73 This can be attributed to 
the greater affinity of cocaine to bind to the binding sites than benzoylecgonine. Once 
cocaine is incorporated into the hair, it is very stable compared to biological fluids. 
Other metabolites found in hair include, ecgonine methyl ester, ecgonine, 
cocaethylene, norcocaine, anhydroecgonine methyl ester and norcocaethylene. 
Hair texture differences, ones diseased state and damaged hair can all lead to varying 
amounts of cocaine incorporated into hair and subsequently detected. Harkey et al 
observed little correlation between self-reported and cocaine concentrations in hair of 
light users compared to heavy users.275 The incorporation of cocaine in hair is still 
very unclear. Investigators have consistently reported higher cocaine concentrations 
in hair than any of its metabolites.225, 211, 274, 289 This is surprising since 
benzoylecgonine and ecgonine methyl ester have longer plasma half-lives than 
cocaine and are present at higher concentrations in biological fluids. 
Nakahara and kikura investigated the incorporation of cocaine and its metabolites in 
rat hair using trideuterated standards.2l1 From this it was suggested that most of the 
benzoylecgonine detected during hair analysis arises from the hydrolysis of cocaine 
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incorporated into hair and the benzoyl ecgonine and ecgonme methyl ester 
incorporation rates are relatively low. 
9.1.2 COCAINE IN HAIR 
Early studies employing immunoassay indicated that hair analysis was effective for 
detecting cocaine and its metbolites?90-292 As interest grew a variety of analytical 
methods and assays evolved for the analysis of hair samples for cocaine and 
benzolyecgonine. Studies of hair obtained from cocaine users have revealed that 
cocaine is the primary chemical species found in hair. 225 
Early publication concerning cocaine in hair have been investigated by Valente in 
1980.290 By 1987, Balabanova and Homoki293 identified cocaine by GC/MS, 
followed by Kidwell in 1988224 using pyrolysis and CIIMSIMS. By 1991, cocaine 
and selective metabolites were quantified from hair by Cone.225 
9.2 METHOD DEVELOPMENT 
Blank hair samples were collected for method development from persons known not 
to have used drugs. The hair samples were prepared by washing, grinding and then 
spiking with the appropriate prepared standards. For the method development of 
cocaine and its metabolites from hair, several conditions have to be investigated for 
optimum extraction. They are the effects of temperature, pressure and the amount of 
modifier introduced during the extraction. These three parameters will be described 
throughout this chapter. 
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9.2.1 EFFECTS OF TEMPERATURE AND MODIFIER 
9.2.1.1 Experimental 
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The effects of temperature were investigated to determine the best temperature for 
the recovery of cocaine and its metabolites from hair. Temperatures from a range of 
60 to 100° C at 10 °e increments were investigated. A combination of varying 
temperature and modifier were used to first find out if cocaine, benzoylecgonine and 
ecgonine methyl ester could be extracted from hair before a method could be 
developed. 
Samples containing 50 ng (1 Ong/ mg) of spiked hair were packed individually in an 
extraction column that was set at varying test temperatures to find the best 
temperature for extraction. The flow rate was set at 2 ml /min, pressure 3500 psi and 
90 % of CO2 with a 10 % selected modifiers was applied to the system to assist with 
analyte elution during extraction. Some modifiers were introduced directly thought 
the system and others directly into the extraction column before extraction. 
9.2.1.2 Results and Discussion 
Two hair samples were extracted at each temperature range of 60, 70, 80, 90 and 
1000 e. Modifiers made up of 16 various solvent combinations were either added to 
extraction column or through the system to the extraction column. Hair samples were 
prepared and extracted for each modifier used. Table 9.1 lists the various modifiers 
used. 
Cocaine was not elute out using most of the modifiers listed in the table however, 
modifiers 5, 6, 7 and 9 did eluted cocaine. Benzoylecgonine and ecgonine methyl 
ester were only eluted out with modifiers 6 and 7, but in very low concentrations. 
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Modifier 6 (H20: NH3 85: 15 v/v) gave better results than 7 and 9 gave the best 
results for cocaine only. However, during extraction modifier 6 caused a precipitant 
to develop that caused blockage in the Rheodyne value and tubing so its use was 
discontinued. The other modifier combinations (e.g. 1 - 4 and 8. 10 and 11) did not 
elute cocaine or its metabolites. 
Table 9.1 Modifiers used during SFE extraction of spiked hair samples 
No. SFE MODIFIERS 
1 OCM: IPA: TEA (78:20:2 v/v) 
2 OCM: H20: TEA (80: 17:3 v/v) 
3 MeOH: IPA: TEA (80:17:3 v/v) 
4 Chloroform :IPA: TEA (80:17:3 v/v) 
5 H20: TEA (85:15 v/v) 
6 OCM: IPA: NH3 (78:20:2 v/v) 
7 H20: NH3 (85: 15 v/v) 
8 IPA:TEA (85:15 v/v) 
9 H20: TEA (85:15 v/v) 
10 MeOH: TEA (85:15 v/v) 
11 MeOH:NH3 (85:15 v/v) 
12 100% Chloroform 
13 Chloroform: IPA (90: 10v/v) 
14 Chloroform: n-Heptane: IPA (55:33: 17 v/v) 
15 Chloroform: IPA: Isoamyl alcohol (90:9.5:0.5 v/v) 
16 Toluene: IPA: Isoamyl alcohol (70:20:10v/v) 
Several other modifiers listed in Table 9.1 (12-16) were used to investigate if all 
three drugs would be eluted. These modifiers were pumped directly thought the 
system at 10 % with CO2 at 90 % using the aforementioned temperature range. 
Studies showed that by using various combinations of all five modifiers. eluted 
cocaine and ecgonine methyl ester only at all temperature. However, only with 
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100% chloroform was benzoylecgonine eluted, but in small amounts along with 
cocaine and ecognine methyl ester at higher concentrations. Table 9.2 shows the 
peak area ratios of each drug extracted using various modifiers and temperature 
conditions. 
Table 9.2 Effects of temperature and modifier under SFE conditions for cocaine and 
ecgonine methyl ester in hair 
DRUG TEMPERATURE °C 
Chloroform (Chlor) 60 70 80 90 100 
Cocaine 0.6388 0.9607 0.8534 0.5638 0.2570 
Benzoylecgonine 0.1566 0.2199 0.1255 0.0276 0.0921 
Ecgonine methyl ester 0.2142 0.4453 0.3218 0.1577 0.0628 
Chlor: IPA 
Cocaine 0.8342 0.620 1.5323 0.1496 0.8630 
Benzoy lecgonine -- -- -- -- 0.1520 
Ecgonine methyl ester 0.3542 -- 0.4670 0.5020 0.4360 
Chlor: IPA:n-Heptane 
Cocaine 1.6319 1.5280 1.6677 1.5320 --
Benzoy lecgonine -- -- -- -- --
Ecgonine methyl ester 0.5730 0.6002 -- 0.4686 --
Chlor: IPA:Isoamyl 
Cocaine 0.1460 1.5815 1.6670 1.5313 0.6268 
Benzoylecgonine -- -- -- -- 0.0268 
Ecgonine methyl ester 0.3125 0.5113 -- 0.4886 0.1448 
Tolulene:IPA:Isoamyl 
Cocaine 1.4899 1.5008 1.4732 1.4563 1.4466 
Benzoylecgonine -- -- -- -- --
Ecgonine methy 1 ester 0.4563 0.5452 0.4732 0.5908 0.5775 
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Toluene: IPA and isoamyl alcohol (70:20: 1 0 v/v) at 70° C was chosen as the 
modifier because it produced good recovery and reproducibility overall for both 
cocaine and ecgonine methyl ester. 
9.2.2 EFFECTS OF PRESSURE 
9.2.2.1 Experimental 
The pressure of the extraction was varied from 3500 psi to 5500psi, which was the 
limit that the pressure could reach in intervals of 500 psi (e.g. 3500, 4000, 4500, 
5000, 5500). Parameters were set at temperatures of 70° C and flow rate of 2mll min 
with only the pressure varied. By increasing the pressure and keeping temperature 
constant should increase the solvating strength of the supercritical fluid (C02) for 
more polar and high molecular weight analytes to be eluted out better (e.g. 
benzoylecgonine ). 
9.2.2.2 Results and Discussion 
For the set temperature (70°C) it seem that between 3600 to 3800 psi was the best 
pressure to elute cocaine and ecgonine methyl ester from hair samples. However, 
benzoylecgonine was not eluted out at any of the pressures. 
9.2.3 EFFECTS OF CO2 AND MODIFIER 
9.2.3.1 Experimental 
Using modifiers during extraction, aid to enhance the extraction of polar analytes 
from the sample matrix to increase the recovery of the drug during extraction. 
Several extractions were carried out using spiked powdered hair samples containing 
50 mg (20ng /mg) and various combinations of C02 and modifier (toluene: IPA: 
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isoamyl (70:20: 1 0 v/v)). Combinations ranged in intervals of 5 %, where CO2 was 
measured from 95%-80% and toluene: IPA: isoamyl from 5 %- 20 %. 
9.2.3.2 Results and Discussion 
Out of the combinations of CO2 and modifier used, 90% CO2 and 10 % toluene: IPA: 
isoamyl (70:20: 10v/v) was preferred. This combination seemed to produce the best 
results for the extraction of cocaine and ecgonine methyl ester. Using the other 
combinations did not produce any of the drugs. 
9.3 DEVELOPED SFE CONDITIONS 
Pressure: 3800 psi 
Temperature: 70° C 
Flow rate: 2 mIl min 
Modifier: Toluene: IPA: Isoamyl alcohol (70:20: 1 0 v/v) 
C02: 90% 
Collection solvent: 2 ml of MeOH 
Dynamic extraction for 30 minutes 
Extractions were carried out under the above conditions for the extraction of cocaine 
and ecgonine methyl ester in lOng Img of hair. Figure 9.1 shows a chromatography 
of the drugs identified using SFE at the above set parameters. 
9.3.1 GC/MS Parameters 
A Hewlett-Packard gas chromatography model 5890 fitted with a VO Analytical 
V070- 250S mass spectrometry was used for analysis. The MS was a magnetic 
sector instrument operated in electron ionization and single ion monitoring (SIM) 
Chapter Nine: SFE of Cocaine in Hair page 229 
mode. The GC was fitted with a HP-5 X- link 5 % PH Me silicone capillary column, 
30 m x 0.25 ).tm, 0.25 ~lm film thickness. 
The selected ions were monitored in the electron ionization mode at 70 e V and the 
trap current was set at 200 )lAo The initial temperature was 100° C held for and 
final temperature was 2800 C held for 2 minutes. The oven rise was at a rate of 10° 
C Imin. The ions monitored were mlz 271 ecgonine methyl ester, rn/z 303 cocaine, 
m1z 362 benzoylecgonine and m1z 306 d3 cocaine. 
Figure 9.1 Chromatography of the extraction of cocaine and ecgonine methyl ester 
from 10 ng/mg of hair 
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9.4 METHOD VALIDATION 
9.4.1 RECOVERY 
9.4.1.1 Experimental 
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Using lOng Img spiked hair samples, developed SFE conditions were applied to find 
the percent recovery for cocaine and ecgonine methyl ester. 
9.4.1.2 Results and Discussion 
From the 1 Dng/mg spiked hair samples, Six (n = 6) samples were extracted under the 
developed SFE conditions. Recovery for cocaine was 70 % and 100 % for ecgonine 
methyl ester. 
9.4.2 REPRODUCIBILITY 
9.4.2.1 Experimental 
Samples were extracted five times (n = 5) using spiked hair samples containing 
1 Dng/mg of cocaine, benzoylecgonine and ecgonine methyl ester. 
9.4.2.2 Results and Discussion 
Below in Table 9.2 are the results from the reproducibility of cocaine and ecgonine 
methyl ester from lOng Img of hair. The extraction of cocaine and ecgonine methyl 
ester under the developed SFE conditions has shown good reproducibility from 
sample to sample. 
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Table 9.3 Run to run reproducibility of cocaine and ecgonine methyl ester in hair 
DRUG Unextstd 1 2 3 4 5 
Cocaine 2.351 1.6448 1.5995 1.669 1.5907 1.682 
Ecgonine 0.594 0.3406 0.4613 0.4370 0.4939 0.4427 
methyl ester 
The overall mean, StdDev and % RSD for cocaine and ecgonine methyl ester were 
calculated and the results summarized in Table 9.4. 
Table 9.4 The reproducibility of cocaine and ecgonine methyl ester in hair 
DRUG MEAN RANGE StdDev %RSD 
Cocaine 1.6372 1.5905 - 1.682 0.0408 2.4 
Ecgonine 0.4351 0.3406 - 0.4613 0.0573 13.1 
methyl ester 
9.4.3 INTRA AND INTER-DAY 
9.4.3.1 Experimental 
Over a period of two days, the intra and inter-day reproducibility of cocaine and 
ecgonine methyl ester were investigated. Samples of 10ng/mg of hair were extracted 
five (n = 5) times under the same conditions each day. 
9.4.3.2 Results and Discussion 
Cocaine and ecgonine methyl ester were reproducible on a day to day basis and from 
sample to sample. Tables 9.5 and 9.6 summarize the reproducibility results from day 
to day. 
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Table 9.5 Day one intra-day reproducibility 
DRUG Unextstd 1 2 3 4 5 
Cocaine 2.953 2.459 2.368 2.244 2.290 2.356 
Ecgonine 1.152 1.023 0.8057 0.871 0.8606 1.026 
methyl ester 
For day one, the mean for cocaine was 2.343, StdDev 0.0819 and % RSD 3.4%. For 
ecgonine methyl ester, the mean was 0.8900, StdDev 0.0931 and % RSD 10.4 %. 
Table 9.6 Day two inter-day reproducibility 
DRUG Unextstd 1 2 3 4 5 
Cocaine 3.045 1.973 2.538 2.547 2.133 2.329 
Ecgonine 1.061 0.8404 0.9716 0.8833 0.8003 0.8870 
methyl ester 
For day two, the mean for cocaine was 2.304, StdDev 0.251 and % RSD 10.9 %. 
The mean for ecgonine methyl ester was 0.876, StdDev 0.0638 and % RSD 7.2 %. 
9.4.4 LINEAR CALIBRATION 
9.4.4.1 Experimental 
Linear calibration of the developed method was investigated from a concentration 
range on lOng Img to 0.05 ng Img. Five samples (n = 5) were extracted at each 
concentration level. 
9.4.4.2 Results and Discussion 
Over the selected concentration range, the average PAR of each sample was 
calculated for each concentration level. Table 9.7 shows average PARs for the linear 
range for cocaine and ecgonine methyl ester. 
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Table 9.7 Linearity of cocaine and ecgonine methyl ester in hair 
CONCENTRATION OF HAIR ng / mg 
DRUG 10 5 1 0.5 0.1 0.05 
Cocaine 1.6372 0.9354 0.2589 0.1815 0.1032 0.0755 
Ecgonine 0.4351 0.2573 0.1351 0.102 0.0737 0.0582 
methyl ester 
Figures 9.3 and 9.4 show the linear calibration for cocaine and ecgonine methyl ester 
over a concentration range of 0.05 to lOng Img of hair. 
Figure 9.5 Linearity of cocaine in hair 
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Figure 9.6 Linearity of ecgonine methyl ester in hair 
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The results for the method validation for the developed SFE method are summarized 
in Table 9.8. 
Table 9.8 Method validation for cocaine and ecgonine methyl ester in hair 
DRUG Correlation LOn ng/mg Intercept Slope 
Coefficient r2 A B 
Cocaine 0.9987 0.05 0.0976 0.0911 
Ecgonine 0.9951 0.05 0.0767 0.0360 
methyl ester 
9.5 CONCLUSION 
In recent years, a large number of drug abuse studies based on the analysis of human 
hair have been described and reported. With the epidemic spread of cocaine and 
crack use, attempts have been made to take advantage of this ostensibly longer 
detection time of hair analysis compared to urine testing for identifying cocaine 
users. SFE is just one of the techniques being explored as an alternative to 
conventional methods for the extraction of drugs of abuse from human hair. 
The aim of this study was to develop a method which SFE could be applied for the 
extraction of cocaine and its metabolites from hair. Based on spiked hair samples, 
successful methods were developed for cocaine and ecgonine methyl ester with 
recoveries of 70 % and 100 %. 
By altering the temperature and pressure during extraction aided to enhance the 
extraction potential for the recovery of both cocaine and ecgonine methyl ester. The 
method was found to work best at a temperature of 70° C with at a pressure of 
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3800psi. The introduction of the polar modifier, toluene:IPA:isoamyl (70:20: I 0 v/v) 
enhanced the solvating power of the supercritical fluid to extract cocaine and 
ecgonine methyl ester, however benzoylecgonine was not eluted, even with the use 
of various modifiers. 
The method was found to be linear over a concentration range of 0.05 to 10 ng/mg of 
hair, with detection limits down to 0.05 ng/mg for cocaine and O.OIng/mg for 
ecgonine methyl ester. It was also found to be reproducible on a day to day basis 
and from sample to sample. 
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CONCLUSIONS 
The objective of this study was to develop new sample extraction methodology using 
solid-phase extraction and supercritical fluid extraction techniques for the 
determination of drugs of abuse from biological matrices. Benzodiazepines, 
morphine, amphetamines and cocaine and its metabolites were all investigated using 
either of these techniques and applied to authentic case samples. 
The use of SPE was applied for the extraction of benzodiazepines from whole blood. 
At present, a routine method does exist, however, optimization was necessary to find 
a more robust method for routine analysis. Successful methodology was established 
for benzodiazepines in spiked whole blood and authentic forensic case samples. 
SPE and developed SFE techniques were carried out for the extraction of morphine 
from whole blood on authentic forensic samples and compared to determine if a 
correlation existed between the two methods. A correlation was found between the 
two methods with comparable results for morphine from authentic whole blood 
samples. 
For the extraction of cocaine and its metabolites from blood and urine, SFE 
techniques were developed. It was found that cocaine and its metabolites could be 
extracted under SFE conditions with relatively good recoveries with the exception of 
benzoylecgonine, which had low recoveries. Using a modifier combination of 
dichloromethane, isopropyl alcohol and ammonia at a temperature of 40°C and 
pressure of 3500 psi, successfully extracted cocaine, benzoylecgonine and ecgonine 
methyl ester from blood and urine samples. 
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Human hair was another matrix investigated for drugs of abuse. The interest of hair 
for drug testing has grown as an alternative biological sample in the field of 
forensics. Its use has been investigated in a number of extraction techniques because 
of its wide window of drug analysis time and noninvasiveness compared to that of 
blood and urine. 
SPE methods were successfully developed to extract amphetamines (AP, MA, MDA, 
MDMA and MDEA) from spiked and authentic human hair samples. This study 
determined and confirmed the accuracy of the self-reported use of amphetamines 
using hair analysis. It was found that a correlation did not exist between the self-
reported consumed amounts of drug and the drug levels found in hair. 
SFE techniques were also developed and applied to specific amphetamines (MDA, 
MDMA and MDEA) for the investigation in human hair. With the aid of chloroform 
as the polar modifier, recoveries better than 71 % were found overall for 
amphetamine use with reproducible results. The application of this method to 
fortified human hair samples proved successful for the recovery of MDA, MDMA 
and MDEA in hair. These findings render SFE as an appropriate method for the 
extraction of amphetamines in hair. 
For the extraction of cocaine and its metabolites (benzoylecgonine and ecgonine 
methyl ester) from spiked hair samples, developed SFE techniques were applied. 
Results showed that cocaine and one of its metabolites, ecgonine methyl ester, were 
extracted under the developed SFE conditions. Reproducible results were produced 
with recoveries for cocaine and ecgonine methyl ester of 70 and 100 %. 
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It has been demonstrated that SFE is an appropriate method for the extraction of 
drugs of abuse from various biological matrices. It has proven to be rapid, 
reproducible and efficient for solid matrices such as human hair with excellent 
results for authentic hair samples. Comparing SFE to conventional techniques such 
as SPE has proven to give comparable results with good correlation from sample to 
sample. 
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Comparison of Solid-Phase Extraction and Supercritical 
Fluid Extraction for the Analysis of Morphine in Whole 
Blood 
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Department of Forensic Medicine and Science, University of Glasgow, Glasgow, G 12 8QQ, Scotland 
I i\bstract I 
A comparative study of the quantitative determination of morphine 
in whole blood using solid·phase extraction (SPE) and supercritical 
fluid extraction (SF E) is described. Comparative studies were made 
of the two techniques for the extraction ai morphine from authentic 
forensic blood specimens. Quantitative mults indicate that 
morphine levels measured using sPE comspond w!II to morphine 
levels produced using sFE. The two techniques are therefore 
comparable, although sFE is faster and cleaner and extracts may be 
produced with higher analyte recoveries than with SPE. This paper 
presents a comparison of the two techniques and the morphine 
concentrations determined in blood. 
Introduction 
Solid-phase extraction (SPE) techniques are widely used for the 
isolation of anaiytes from liquid mabices. Although SPE is easy 
and popular in tenns of extraction techniques. supercritical fluid 
extraction (SFE). a relatively new sample preparation technique, 
is becoming of increasing interest. 
SFE is based on the use of carbon dioxide above its critical tem-
perature and pressure. The development of SFE as an alternative 
extraction method to SPE methods has aroused interest because 
of the limitations of conventional methods. Supercritical fluids 
are gases and liquids at temperatures and pressures above their 
critical points; in this state. they have the solvation powers of a 
liquid while retaining properties such as high diffusivity and low 
viscosity of a gas (1). The high diffusivity of the supercritical 
carbon dioxide allows for rapid and effective extractions of mainly 
nonpolar solutes without costly organic solvent use (2). 
An ideal extraction method should be rapid, yield quantitative 
recovery of the target anaiyte without loss or degradation. be rei· 
atively simple and inexpensive. permit minimal sample handling, 
and generate no additional laboratory wastes (3). 
The use of SFE as a sample preparation technique is rapidly 
increasing as an alternative for the analysis of compounds from a 
wide variety of matrices. Studies have been carried out using con-
ventional SPE methods, and they have been compared with SFE 
methods to investigate the correlation bet.veen the two methods 
for the extraction of morphine from authentic forensic blood 
specimens. 
Experimental 
Apparatus 
AFisons model GC 8000 series (MD 800 in the EI Mode [70ev]) 
gas chromatograph-mass spectrometer (GC-MS) was used for 
analysis, and it was equipped with an HP-l (cross-linked methyl 
siloxane) capillary column (30 m x 0.53-mm i.d, 0.88-~m film 
thickness). 
Temperature was initially set at 200°C and held for 1 min; oven 
temperature increased IO°Clmin to a final temperature of 300°C 
and was held for 5 min. The injector temperature was 250°C. 
Materials 
Tri-ethylamine (Merck G-P-RTM grade) and isopropanol 
(AnalaR grade) were supplied by Merck (Poole, U.K.). 
Chromatographic (HPLC)-grade ethyl acetate, methanol, and 
acetonitrile were obtained from Analytical Sciences Lab-Scan 
(Dublin, Ireland). CO2 was from Air Products (Walton-on-
Thames, U.K.); IO-mL plastic syringes were from Becton 
Dickinson (Oxford, U.K.); silanized·glass wool was from Jones 
Chromatography (Mid Glamorgan, U.K.); and Extrelut® columns 
were from Merck. Six-milliliter HypoviaJTM SFE vials were 
obtained from Pierce (Oud-Beyerland, The Netherlands); butyl 
rubber septa were from Pierce and Warner (Chester, U.K.). 
Columns for SFE (3.4 em x 4.6-mm i.d. stainless steel tubing) and 
SPE (I-mL SCX columns) were from Varian. 
Stock solutions 
Drug and internal standard stock solutions were prepared in 
methanol (1 mg/IOO mL). 
SPE sample preparation 
SPE columns were prepared by packing Extrelut washed with 
methanoVethanol (1:1, v/v) into 10-mL syringes plugged with 
cotton glass wool. One-milliliter whole-blood samples were pre-
treated in vials with 1 mL of O.1M phosphate buffer (pH 6), 50 III 
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of ammonium hydroxide solution, and 50 ~L of internal stan-
dard (morphine-d3). 
The contents of each sample vial were pi petted onto corre-
sponding Extrelut columns, then conditioned with 5 mL of 
hexane and allowed to stand for 10 min. Labeled SCX columns 
(I mL) were placed on a VacElut and conditioned with 2 mL of 
methanol, 2 mL of deionized water, and 1 mL of ethyl acetate/ 
isopropanol (9:1, vlv). 
The Extrelut columns were attached to the top of the sex 
columns via adapters. The analytes of interest were transferred 
from the Extrelut columns to the SCX columns using three 4-
mL aliquots of ethyl acetate/isopropanol (9:1, vlv). The Extrelut-
columns were discarded. The SCX columns were then washed 
With 5 mL of acetonitrile/methanol (1:1, vlv), and the analytes of 
interest were eluted using 2 mL of 10% ammonia in acetoni-
trile/methanol (1:1, vlv). The collected eluent was evaporated to 
dryness under nitrogen at 40°C and derivatized with 50 III of 
N,O-bis(trimethylsilyl)trifluoroacetimide catalyzed with 1% 
trimethylchlorosilane (BSTFA + I%TMCS) at 90°C for 10 min. 
SFE set-up, sample conditions, and preparation 
The pump pressure at the end of the system (i.e., before the 
extraction cell) was measured by a Gilson 805S manometric 
module and monitored using Gilson 715 software. The software 
Controller allowed programming of up to four pumps. A Gilson 
8UB dynamic mixer was used to premix the CO2 and modifier 
being pumped through the system. An HPLC 7125 rheodyne 
valve fitted with a 100-11L injection loop was used to apply the 
samples to the extraction vessel. This was placed in line between 
the dynamic mixer and the extraction cell that was housed in a 
CCoven. 
SFE pressure conditions were set at 3500 psi with a 2-mUmin 
flow rate and 100°C temperature. Three-hundred microliters of 
MeOHlEt3N (85:15, vlv) was used as a modifier, and 90% C~ was 
used as the supercritical fluid. 
The samples were prepared by loading 1 00 ~L of internal stan-
dard (morphine-d3) onto the extraction media Extrelut that 
Contained 100-300 llL of mixed and dried blood. The rheodyne 
was set in the load position, and the instrument was left to equi-
librate. The sample was then loosely packed into a stainless steel 
Table I. Comparison of SPE and SFE Results for Morphine 
Case. SPE (mg/L) SFE (mg/L) %I>ifferenm 
T9frA 1.25 1.18 0.07 
T96·8 0.59 0.67 0.08 
T96.( 1.02 0.91 0.11 
T96·D 0.90 0.85 0.05 
T96·E 1.86 1.97 0.11 
T96·F 2.42 2.20 0.22 
T96·C 0.19 0.17 0.02 
T9frH 0.35 0.39 0.04 
T96·1 0.86 0.79 0.07 
T96.j 0.45 0.45 0 
T96·K 0.056 0.05 0.006 
T96·L 0.85 0.74 0.11 
T96·M 0.28 0.28 0 
T96·N 0.27 0.29 0.02 
...... 
extraction column, and 300 ~L of modifier was added. The 
column was sealed and placed over the loop position of the rheo-
dyne into an oven set at 100°C. The extraction was started by 
switching the rheodyne from the load (equilibrate) to the inject 
(extract) position. The instrument was left for 30 min to elute 
the analytes through the outlet; the anaiytes were collected by 
expansion in methanol. The sample was then evaporated under 
nitrogen at 40°C and derivatized with 50 llL of BSTFA at 90°C 
for 10 min (4). 
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Results and Discussion 
Authen~ic forensic blood samples known to be morphine posi-
tive were chosen for this investigation. SFE is an efficient and 
reproducible extraction method that was compared with SPE to 
determine if the two yield corresponding results. 
Fourteen blood samples were extracted using both SPE and 
SFE with final analysis by GC-MS. The internal standard mor-
phine-d3 mlz 432 ion was used as a reference to calculate the con-
centration of morphine using ions m/z 414 and 429 for each 
sample, as shown in Figure 1. For the extraction of morphine 
using SPE, the sample concentration of morphine ranged from 
0.056 to 2.42 mgtmL in blood compared with SFE results that 
ranged from 0.050 to 2.20 mgtmL in blood. Recoveries for SFE 
were found to be > 90% for morphine. 
The standard deviation and mean for comparison of both 
methods were 0.633 and 0.782 with a linear relationship of il = 
0.990 and a gradient of m = 0.94, seen in Figure 2. Table I lists 
very small percent differences between the two methods (mean 
0.0647). This indicates that good correlation for morphine 
extracted from whole blood exists between the SPE and SFE 
methods used. 
Conclusions 
SPE techniques have been the preferred technique for the 
extraction of drugs of abuse from various matrices. Although 
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widely used as a sample-preparation method, the technology is 
still advancing and exploring more parameters to improve sample 
preparation, including SFE techniques. 
SFE, a relatively new technique for sample preparation, has 
until recently generally been confined to chemical-processing 
applications. Now, it is emerging as a valuable analytical proce-
dure for the forensic toxicologist. 
The investigations carried out using SPE and SFE methods, 
show that the two analytical techniques correlate well for the 
analysis of morphine in whole blood. Both techniques are fast. 
yield reproducible results, and give good recoveries for morphine 
extracted from whole blood. 
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Abstract 
Supercritical fluid extraction (SFE) is emerging as a valuable analytical technique for 
the use as an alternative to conventional solid-phase and liquid-liquid extraction 
(SPEI LLE) techniques. It is a relatively new technique based on the use of 
supercritical fluids (SF) for the isolation of analytes from various matrices. It is 
attracting great interest because of the increasing need for a simple, rapid, 
environmentally friendly, automated and selective extraction method. 
A new method was developed using SFE procedures for the extraction of cocaine 
(COC) and its major metabolites, benzoylecgonine (BZE) and ecgonine methyl ester 
(EME) from whole blood and urine. This study has shown that cocaine and its 
metabolites can be successfully extracted from blood and urine using SFE 
techniques. 
Levels measured USll1g SFE have shown analyte recovery better than 70 % for 
cocaine, better than 40 % for benzoylecgonine and better than 85 % for ecognine 
methyl ester from whole blood and urine. Good run to run reproducibility was 
observed between each extraction with limits of detection and quantitation of 1 ng 
and lOng based on 200 III of blood and urine. A comparison between solid-phase 
extraction (SPE) and developed SFE techniques was investigated to observe if a 
correlation existed between the two methods. Studies proved that a correlation did 
exist between the two methods for spiked blood and urine samples with comparative 
results. This paper details a procedure for the extraction of cocaine and its 
metabolites from blood and urine. 
Introduction 
A Supercritical fluid (SF) is a substance that is above its critical temperature and 
pressure. I They have unique physical properties, which make them suitable as 
alternative extraction solvents. An important feature of SFs as solvents is that the 
solvating strength of the f1uid is directly related to density. The density can be varied 
easily as a function of pressure and temperature. However, in general, SFs have 
solvating properties similar to a liquid, while having viscosities closer to a gas. 
The SF of choice is CO2 because of its low critical pressure and temperature (73.8 
bar and 31.1 0 C). It is a non-polar gas that exhibits great solvent strength towards 
polar molecules2. CO2 is non-toxic, non-flammable, inexpensive, a good solvent for 
organics and can be used with small amounts of entrainers (e.g. MeOH). These 
entrainers or modi tiers can vary the extraction power of the f1uid to produce greater 
analyte recovery. In addition, for quantitative analysis, the selection of suitable 
conditions to extract analytes from complex matrices is relatively straightforward. 
SFE is simple to carry out and can be analysed using any technique that is 
appropriate for the extracted analytes (e.g. GC/MS). Supplied by a pump, a known 
pressure of the extraction t1uid (C02) is applied to the extraction column at ambient 
conditions. The extraction cell containing the sample is placed in an oven at a set 
temperature above the critical temperature of the supercritical fluid. During the 
extraction, soluble analytes are partitioned from the sample matrix into the 
supercritical fluid. The analytes are then swept through a restrictor at ambient 
pressures and depressurised into a collection vial containing a solvent (e.g. MeOH). 
The extraction fluids are vented from the collection vial while the analytes are 
retained for analysis. 
There are numerous studies for the extraction of drugs of abuse from vanous 
biological matrices, such as serum3 or plasma4, urine5, hair6 and vitreous humor' 
using solid-phase or liquid-liquid extraction, immunoassay and other extraction 
techniques. However, most literature published on SFE relates to organic chemical 
substances, including organic chemical separation from water, caffeine from coffee 
beans, pesticide residue, polynuclear aromatic hydrocarbons and polychlorinated 
biphenyls8 and oils from natural products.9 More recently, SFE has been used for the 
extraction of drugs of abuse from various matrices IO- 14 . Several authors have reported 
the super or subcritical analysis of drugs using various techniques. Janicot et al lO 
used CO2 for the successful separation of opium alkaloids from poppy straw followed 
by Edder et al" who reported the lise of SF-C02 for the extraction of opiates from 
biological matrices and Lawrence et al who used SFE to extract benodiazepines from 
their solid dosage forms.15 More recently, other authors such as Sach and Uhl 16 and 
Sach and Rafr 7 demonstrated for the first time the use of supercritical fluids in the 
extraction of drugs in hair. 
There are various analytical methods for the analysis of cocaine and its metabolites 
from both blood and urine. However, in forensic analysis of post-mortem case 
samples, plasma is seldom available and the tissue most commonly supplied is 
haemolysed, often putrefied blood. Therefore, a suitable method should be applied 
capable of detecting concentration levels of cocaine and its metabolites down to 
nanogram levels. This study reports the development of an application of SFE to the 
recovery of cocaine and its metabolites (benzoylecgonine and ecgonine methyl ester) 
from both whole blood and urine. 
Experimental 
Materials 
AnaiaR grade isopropyl alcohol was supplied by Merck (Poole, UK) and HPLC 
grade methanol, dichloromethane and ammonia were supplied by Analytical 
Sciences Lab-Scan in Dublin, Ireland. CO
2 
-Air Products were provided by Walton-
on-Thames in the UK and the diatomaceous earth (Extrelut®) was supplied by 
Merck. SFE 6mL HypoviaFM vials were purchased from Pierce in Oud-Beyerland, 
The Netherlands and the Butyl rubber septas from Pierce and Warner, Chester, UK. 
The columns for SFE were 3.4 cm x 4.6 mm i-d. stainless steel tubing. 
Cocaine, d3-cocaine, benzoylecgonine and ecgonine methyl ester stock standards 
were purchased in ampules of 1 mg/ml and 1 00 ~lg/ ml , which were supplied by 
Sigma Chemicals, St. Louis MO. The derivatisation agent N,O - bis (Trimethylsilyl) 
trifluoroacetamide (BSTF A) was supplied by Pierce Chemical Co., USA. The SFE 
instrument used was manufactured by Gilson Instruments and supplied by Anachem 
Instruments in Luton UK. 
Stock solutions 
Drug and internal standard stock solutions were prepared in methanol (1 Jlg/ ml and 
10 Jlgi ml). 
Supercriticai Fluid Extraction 
The pressure, CO2 amount, modifier and flow rate were all measured using a Gilson 
308 "master" pump, that controlled a Gilson 306 "slave" pump. The slave pump 
delivers organic modifier solvent to a Gilson 811 B dynamic mixer that mixes the 
solvent with the CO2, The Gilson 821-pressure regulator was controlled by the 308 
pump that controlled the operation of the pressure regulation valve indicated by P2 
and P I on the program. P2 was used to maintain the required pressure levels at the 
outlet. PI was used to implement the flow rate accuracy corrections and ensures that 
the system pressure was not above or below the limits entered in the program. 
An HPLC 7125 Rheodyne valve, was placed in-line between the 811B mixer and the 
extraction cell, that was housed inside a Gilson 831 temperature regulator (oven), for 
the application of the gas and modifier to the cell. A second valve located below the 
7125 valve was used to switch the extraction from static to dynamic (continuous) 
mode. SFE pressure conditions were set at 3500 psi with a flow rate of 2 mIl min 
and temperature 40° C. 100-200~ll DCM:IPA:NH3 (78:20:2 v/v) was used as a 
modifier and added to the extraction cell with 100% CO2 as the supercritical fluid. 
Samples were prepared in weighing boats containing approximately O.13g of the 
extraction media Extrelut®. I 00 ~Ll of internal standard (100 ng d3-cocaine) and 100 
JlI from each stock standard (100 ng COC, BZE, and EME) were added to 200 JlI of 
blood or urine, which was then pipetted onto the media. The contents of the boat 
were mixed and allowed to dry overnight in a drying chamber at room temperature or 
until a friable consistency was achieved. 
The Rheodyne valve was set to the load position and the instrument left to equilibrate 
until ready for extraction. The sample was loosely packed into a stainless steel 
extraction cell and 100 - 200 ).11 of modifier was added directly to the sample cell. 
The extraction cell was sealed and placed inside the temperature regulator that was 
set at 40° C. 
The extraction was started by switching the Rheodyne valve from the load 
(equilibrate) to the inject (extract) position and left for 10 minutes in static mode, 
then switched to dynamic mode for 20 minutes. The analytes were eluted though the 
outlet and were collected by expansion into a Hypovial containing 3 ml of MeOH. 
Figure 1 shows the depressurisation of the analytes into the Hypovial containing 
solvent. The sample was evaporated under nitrogen at 40° C and derivatised with 50 
).11 of BSTF A at 70° C for 20 minutes and 1 ~tl was injected into the GC/MS. 
Figure I: Depressurisation of analytes from the SFE system into a collection vial 
containing MeOH 
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Gas Chromatography-Mass Spectrometry Analysis 
A Fisons model OC 8000 Series (MD 800 in the EI Mode (70ev) gas 
chromatography-mass spectrometry operated in single ion monitoring mode (SIM) 
was used for analysis. This was equipped with an HP-l (Cross-linked Methyl 
Siloxane), capillary column, (30 m, 0.53 mm i.d ., film thickness 0.88 llm). The 
carrier gas was Helium with gas flow rates of I ml I min. The temperature was set at 
an initial 1000 C and a final temperate of 3000 C for 2 min with an oven rise of 100 C 
per min. The injector temperature was set at 2500 C. 
Comparison between SFE ~lDd SPE 
A comparison between SFE and SPE was made to investigate if the two methods 
correlate for the extraction of blood and urine for cocaine, benzoyl ecgonine and 
ecgonine methyl ester. Due to the lack of cocaine positive blood and urine forensic 
case specimens received into the laboratory, spiked samples were used for 
comparison between the two methods. From a stock solution of a 10 Ilg Iml, 50 III of 
each drug was pi petted into three separate test tubes containing 1 ml of pre-treated 
blood or urine for SPE and 200 ~tl of blood or urine for SFE. Samples were extracted 
and evaporated to dryness under a stream of nitrogen and derivatised. Then 1 III of 
sample was injected into the GC/MS for analysis. 
Results and Discussions 
SFE can be used as an alternative sample extraction technique for the extraction of 
cocaine, benzoylecgonine and ecgonine methyl ester from blood or urine. The 
favourable mass transport and variable solvating powers of supercritical fluids have 
encouraged researchers to investigate SFE as an alternative to conventional 
procedures for drug testing. However, there is very limited literature on the SFE of 
drugs of abuse from biological matrices, with the exception of matrix bound drugs 
from hair. 
Several spiked blood and urine samples were prepared and extracted under the 
aforementioned conditions. Quantition by SFE method was achieved by the addition 
of d3-CaC m/z = 185 that was used as a reference ion to calculate the concentration 
ratios of cac mlz = 182, 303, BZE mlz = 361, 240 and EME m/z = 82 for both 
blood and urine. Figure 2 shows a chromatograph of a typical GC/MS trace for 
cac, EME and BZE. 
Figure 2: Chromatograph ofa COC, BZE and EME trace analysed by GC/MS. 
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Good run to run reproducibility was observed between each extraction (n = 5) 
indicating the accuracy of the method from run to run. Table 1 and 2 show 
comparison of the variability of each drug for each SFE run for blood and urine 
(n=5). 
Table 1: Method repeatability of cocaine, benzoylecgonine and ecgonine methyl ester 
for blood. 
Blood COC m/z 182/185 BZE m/z 240/185 EME m/z 82/185 
1 0.746 0.22 1.28 
2 0.849 0.278 1.30 
3 0.949 0.27 1.55 
4 0.876 0.251 1.43 
5 0.769 0.267 1.51 
Table 2: Method repeatability of cocaine, benzoylecgonine and ecgonine methyl ester 
for urine. 
Urine COC m/z 182/185 BZE m/z 240/185 EME m/z 821185 
1 0.758 0.298 1.09 
2 0.675 0.316 1.31 
3 0.75 0.30 1.31 
4 0.81 0.28 1.32 
5 0.791 0.27 1.22 
Recoveries for cocaine in blood were better than 70 %, benzoylecgonine 40 % and 
ecgonine methyl ester 85 %. Recoveries for cocaine in urine were better than 75 %, 
benzoylecgonine 49 % and ecgonine methyl ester 90 %. Because of the low 
recoveries of benzoylecgonine, each drug was individually spiked onto blood and 
urine Extrelut® samples and extracted under SFE conditions. This was to investigate 
possibility of hydrolysis of cocaine to benzoylecgonine or ecgonine methyl ester, 
which were not observed. 
Overall, reproducibility from run to run for cocaine, benzoylecgonine and ecgonine 
methyl ester in blood and urine produced good standard deviations and relative 
standard deviations (% CV). Table 3 summarises the method validation of cocaine 
and its metabolites from both blood and urine. Methods producing RSDs of less than 
10 % are reported to be acceptable for method validation of biological specimens. IS 
Table 3: Method Validation of cocaine, benzoylecgonine and ecgonine methyl ester 
in blood and urine 
DRUG StdDev %RSD Menn %Recovery 
BLOOD 
Cocaine 0.0823 9.8 0.837 70 
Benzoylecgonine 0.0229 8.9 0.257 40 
Ecgonine methyl ester 0.1213 8.5 1.41 85 
URINE 
Cocaine 0.0518 6.8 0.756 75 
Benzoylecgonine 0.0180 6.1 0.292 49 
Ecgonine methyl ester 0.098 7.8 1.25 90 
Three calibration curves shown in Figures 3 and 4 were produced for each drug from 
200 J.lI of blood and urine over a range of 5 - 100ng. The results are summarised in 
Tables 4 and 5. 
Table 4: Linearity of cocaine, benzoylecgonine and ecgonine methyl ester in blood 
Cone" ng/J.lI COC mlz 182/185 BZE mlz 240/185 EME mlz 821185 
5 0.008 0.001 0.76 
10 0.032 0.006 0.97 
20 0.07 0.02 1.21 
40 0.19 0.03 1.52 
60 0.27 0.44 1.83 
80 0.42 0.068 1.97 
100 0.58 0.10 2.21 
Figure 3: Linearity of cocaine, benzoylecgonine and ecgonine methyl ester in blood 
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Table 5: Linearity of cocaine, benzoyJecgonine and ecgonine methyl ester in urine 
CODen Dghd COC m/z 182/185 BZE mlz 240/185 EME m/z 821185 
5 0.0423 0.003 0.21 
10 0.10 0.01 0.26 
20 0.16 0.05 0.54 
40 0.35 0.11 1.03 
60 0.59 0.19 1.51 
80 0.73 0.25 2.07 
100 0.92 0.35 2.71 
Figure 4: Linearity of cocaine, benzoylecgonine and ecgonine methyl ester in urine 
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Table 6 summarises concentration range for the calibration curves and the limit of 
detection (LOD) and quantitation (LOQ) for each drug. The limit of detection 
(LOD) for cocaine, benzoylecgonine and ecgonine methyl ester was determined by 
using 200 ).11 of blank blood spiked from a 1 ~lg/ ml solution. For the three drugs, the 
LOD was 1 ng with a limit of quantification (LOQ) of lOng in blood and urine. 
Table 6: Linear calibration and concentration range of cocaine, benzoyl ecgonine and 
ecgonine methyl ester. 
DRUG r2 Slope LOD/LOQ Cone Range 
BLOOD ng I 200).11 ng I 2OOl-li 
Cocaine 0.987 0.0058 1 ng / lOng 0-100 
Benzoylecgonine 0.971 0.0009 1 ng / lOng 0-100 
Ecgonine methyl ester 0.964 0.0145 1 ng / 10 ng 0-100 
URINE 
Cocaine 0.997 0.0092 1 ng 110 ng 0-100 
Benzoylecgonine 0.991 0.0034 1 ng 110 ng 0-100 
Ecgonine methyl ester 0.997 0.0262 1 ng / lOng 0-100 
SPE and the developed SFE methods were compared to find the existence of a 
correlation. Results showed that a correlation existed between the two methods with 
small differences observed. The percent differences between the two methods for 
cocaine in blood were 0.04, 0.09, 0.08, for benzoylecgonine 0.03 , 0, 0.05 and 
ecgonine methyl ester 0.07, 0.03, 0.03. For urine, the percent difference for cocaine 
was 0.10, 0.06, 0.02, benzoylecgonine 0.04, 0.06, 0.05 and ecgonine methyl ester 
0.09, 0.07, and 0.06 . Results fi·om both methods for blood and urine are summarised 
in Table 7. The samples results for blood lIsing SFE ranged from 0.084 - 0.2 1mg/1 
and SPE 0.11 - 0.26 mg/1. For SFE in urine the resu lt range was 0.13 - 0.29mg/1 and 
SPE 0.07 - 0.20mg/1. Figures 5 and 6 show graphs based on Table 5 for both 
methods for blood and urine, which clearly show the variation between the two 
methods. 
Table 7: Comparison of SPE and SFE results of cocaine, benzoylecgonine and 
ecgonine methyl ester in urine and blood . 
Cocaine Bcnzoylecgonine Ecgonine methyl ester 
mg/L mg/L mg/L 
SPE bid 1 0.207 0.16 0.103 
SPE bid 2 0.21 0.11 0.084 
SPE bid 3 0.18 0.17 0.093 
SFE bid 1 0.25 0.13 0.17 
SFE bid 2 0.20 0.11 0.11 
SFE bId 3 0.26 0.12 0.12 
SPE urn 1 0.19 0.10 0.08 
SPE urn 2 0.17 0.07 0.081 
SPE urn 3 0.20 0.08 0.09 
SFE urn 1 0.29 0.14 0.17 
SFE urn 2 0.23 0.13 0.16 
SFE urn 3 0.22 0.13 0.14 
Figure 5: Graph showing the comparison between the two methods for blood. 
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Figure 6: Graph showing the comparison between the two methods for urine. 
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At present, cocaine analysis from biological matrices involves a SPE method. The 
current study demonstrates that SFE can be used as a possible alternative to 
conventional methods for the isolation of drugs of abuse such as cocaine, 
benzoylecgonine and ecgonine methyl ester from blood and urine. 
Various temperatures, pressures, flow rates and modifiers were investigated during 
method development. However, the described chosen conditions proved to give the 
best results for cocaine and its metabolites. Recoveries greater than 70% were 
reported for cocaine and greater than 85% for ecgonine methyl ester. However, 
benzoylecgonine recoveries were reported to be greater than 40%, which was lower 
than cocaine and ecgonine methyl ester. A possible explanation would be because 
the benzoylecgonine analyte is a zwitterion, a closer control of the extraction pH 
would have probably increased the yields. However since the developed procedures 
produced a reproducible extraction and was optimised to maximise the recovery of 
the major metabolite (benzoyl ecgonine), further development was deemed 
unnecessary. 
SPE techniques were compared to the developed SFE techniques to find if a 
correlation existed. A correlation was observed between SPE and SFE for the 
extraction of cocaine and its metabolites. Small percent differences were observed 
between the two methods, however both methods were comparable. This developed 
SFE method for the recovery of cocaine and its metabolites has demonstrated its 
potential usage for the extraction from spiked whole blood and urine. 
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Abstract 
Drug use histories were collected from 100 subjects recruited from the "dance scene" 
in and around Glasgow, Scotland. In addition, each subject donated a hair sample 
which was analysed by gas chromatography - mass spectrometry (GC/MS) for 
amphetamine (AP), methamphetamine (MA), 3,4-methylenedioxyamphetamine 
(MDA), 3, 4-methy lenedioxymethamphetamine (MDMA) and 3,4-
methy lenedioxyethy lamphetamine (MD EA). 
The hair samples were analysed in two 6cm segments or in full, ranging from 1.5 -
12cm depending on the length of the hair. Approximately 10mg of hair was ground 
to a fine powder before treatment with ,B-glucuronidase/aryl sulphatase. A solid-
phase extraction procedure was carried out followed by derivatisation with 
pentafluoropropionic anhydride (PFP A). All extracts were analysed by gas 
chromatography/mass spectrometry (GC/MS). 
Of the 139 segments analysed, 77 (52.5%) were positive for at least one of the five 
amphetamines. The drug concentrations found in the hair were compared with the 
self-reported drug histories. A concordance of greater than 50% was found between 
the self-report data and levels detected in hair. However no correlation was found 
between the reported number of "ecstasy" tablets consumed and the drug levels 
detected in hair. An increase in the average drug levels measured was observed from 
low to high use (number of "ecstasy" tablets/month). A large number of false 
negatives and a low number of false positives were observed. 
Keywords: forensic science. hair analysis. self-report, "speed", "ecstasy", solid-
phase extraction 
Introduction 
The analysis of hair is now accepted as an alternative method for determining drug 
use. It has several possible advantages over other biological matrices (e.g. blood and 
urine), including collection of information regarding long-term drug use and 
determination of compliance with treatment programs. (1-3) Over the past few years 
there has been a substantial increase in the number of scientific papers detailing 
methods for the analysis of a variety of both prescription and non-prescription drugs 
in hair. 
Several independent laboratories in Europe, Japan and the US have confirmed the 
accumulation of drugs such as cocaine (4-6), heroin and other opiates (4,7-9), 
amphetamines (l 0-13) and phencyclidine (14,15) in the hair of drug users. Other 
studies published have reported a dose-response relationship in hair for a variety of 
drugs in controlled animal studies (16-19). Most of the studies involving human 
subjects compared self-reported drug use to hair or urinalysis. A linear relationship 
was observed between hair cotinine levels and daily nicotine intake (20), however, 
this is an exception to what is generally reported. A relationship between low and 
high use and the levels of drugs detected in hair has been observed for cocaine (21), 
heroin (22) and buprenorphine (2). The lack of a linear dose-response relationship is 
not surprising due to the number of unknown variables, such as the exact dose or 
purity of drug consumed, the accuracy of the self-report data, individual metabolism 
variations and the types and frequency of hair treatments. 
The work presented here is part of a larger study investigating the use of "speed" and 
"ecstasy" in Glasgow (23). Subjects claiming use of "speed" and "ecstasy" were 
recruited from the "dance scene" by chain referral (i.e. subjects nominated other 
subjects). They were asked to complete a detailed questionnaire of their drug use 
over the previous 12 months and to donate a hair sample for analysis. Subjects were 
compensated for samples. 
The aims of the project were to investigate the accuracy of hair analysis in 
confirming self-reported use of "speed" and "ecstasy" and to determine whether or 
not a correlation exists between the amount of drug ingested and the levels detected 
in hair. AP and MA were identified to confirm "speed" use and MDA, MDMA and 
MDEA for "ecstasy" use. 
Materials and Methods: 
Sample Collection 
100 subjects were interviewed, 51 of whom were male. Ages ranged from 15-44 
years, with a mean age of 24 years. 95% of the participants were Caucasian. 
"Ecstasy" use was recorded as the number of tablets consumed per month for each of 
the previous 12 months. "Speed" use was recorded as "ever consumed" and then 
broken down into how often they had consumed it in the previous week, month and 
year. 
The hair samples were cut close to the scalp in the vertex region, wrapped in 
aluminium foil and sealed in labelled plastic bags. The self-report "ecstasy" data was 
recorded for each month prior to interview, therefore it was possible to do segmental 
analysis on a month by month or em by em basis. Ideally 10 mg of hair is required 
for analysis, however, some of the hair samples were very small and thus, had to be 
analysed in full. Where possible, two 6 cm segments were analysed. The proximal 
6 cm was labelled the "root" sample and the distal 6cm the "tip" sample. In total, 
139 hair segments were analysed without prior knowledge of the self-report data. 
A summary of the segments analysed is shown in Table 1. The hair lengths ranged 
from 1.5-12 cm. A total of 56 samples were analysed in full. 
Summary of Drug Use History 
Of the 100 subjects questioned, 90 admitted taking "ecstasy" during the year prior to 
interview. Consumption of "ecstasy" was primarily at one of four locations (night-
clubs, licensed raves, illegal parties and private parties). Not all users consumed 
"ecstasy" on a regular basis and were classed as stable or erratic users. In contrast to 
stable users (n = 43) who consistently used the same amount of "ecstasy" each 
month, erratic users (n = 48) tended to have an irregular pattern of use which varied 
from month to month. 
The total number of "ecstasy" tablets consumed within these two groups ranged from 
1 - 144 (mean = 19, median = 10) over the previous year. In this study, the heaviest 
user consumed 144 tablets in the previous year, which translates to more than weekly 
but less than daily consumption of "ecstasy". This is in sharp contrast to heavy 
heroin users, who use heroin at least once a day. The control group (n = 9) consisted 
of individuals who participated in the dance scene, but denied ever using "speed" or 
"ecstasy". This number is low due to the difficulty in recruiting individuals who 
satisfied this criteria. 
Questions regarding use of other drugs were also answered by each subject. The 
drugs used by the respondents over the previous year are summarised in Table 2 in 
descending order of frequency of use. The majority of respondents consumed alcohol 
(96%), cannabis (95%), "speed" (84%) and tobacco (84%). 
Experimental 
Standards and Reagents 
Amphetamine (AP), methamphetamine (MA), 3,4-methylene-dioxyamphetamine 
(MDA), 3,4-methylenedioxymethamphetamine (MDMA), d3-amphetamine (d3-AP), 
lauryl sulfate (sodium dodecyl sulphate (SDS» and ,a-glucuronidase (activity = 
300,000 - 400,000 units/g solid, sulphatase activity = 15,000 - 40,000 units/g solid) 
were obtained from Sigma@ Chemical Co., (Dorset, U.K.). 3,4-methylenedioxy-
ethylamphetamine (MDEA) was manufactured by Radian International and supplied 
by Promochem, (Herts., U.K.). Pentafluoropropionic anhydride (PFPA) was 
supplied by Fluka Chemicals (Dorset, U.K.). HPLC-grade methanol, acetone, 
chloroform, deionised water and ethyl acetate chromatographic (HPLC) grade were 
obtained from Lab-Scan Analytical Sciences (Dublin, Ireland). Analytical-grade 
ammonium hydroxide and glacial acetic acid and HiPerSolv grade potassium-
dihydrogen phosphate (KH2P04) were obtained from Merck (Poole, UK). 
Stock solutions 
A combined stock standard solution (O.lmg/ml) of AP, MA, MDA, MDMA and 
MDEA was prepared in methanol. Working solutions were also prepared in methanol 
(l0, 1 flg/ml) by appropriate dilution of the stock standard. The internal standard 
(I.S.), d3-AP, was prepared in methanol to give a stock standard solution of 
O.lmg/ml. Working solutions of d3-AP (10, I ~lg/ml) were prepared by dilution of 
the stock standard with methanol. All stock and working solutions were stored in a 
freezer at -20°C. 
Gas Chromatography - Mass Spectrometry 
A Fisons model GC8000 series was used, fitted with a HP-I capillary column. The 
initial column temperature of 55°C was held for 2 minutes and then increased to 
280°C at a rate of 20°C/min. and held for a further 5 minutes. The carrier gas used 
was Helium. Injections were made in the splitless mode. 
The GC8000 was interfaced to a Fisons MD800 mass spectrometer operated in the 
electron - ionisation mode at 70e V. The ions monitored were m/z 118, 190* (AP), 
mlz 118,160,204* (MA), m/z 135,162, 190,325* (MDA), mlz 135, 162,204,339* 
(MDMA), mlz 135, 162, 190, 218, 353* (MOEA) and mlz 193* (d}-AP). The ions 
labelled "*,, were used for quantitation. 
Sample Pre-treatmellt 
Hair samples were washed once with 0.1 % SOS in deionised water and then in 
triplicate with deionised water. Euch wash step was carried out by sonicating for 15 
minutes. The hair was then rinsed with methanol and allowed to dry overnight in a 
dessicator. 
The dried hair was measured and cut to the appropriate lengths, before being ground 
to a fine powder under liquid nitrogen using a mortar and pestle. The powdered hair 
was placed in a clean vial and weighed accurately. 
Each hair sample was treated with 50 ~d of fJ-glucul'Onidase [O.lmg/ml in phosphate 
buffer (pH7.4, 0.1 M)] and 2 ml of phosphate buffer (pH7.4, 0.1 M). 100 ~ll of the 
internal standard, d3- AP (1 Ong/mg based on a 10mg hair sample) was added and the 
samples were incubated at 40°C for two hours. The samples were allowed to cool to 
room temperature, and then the supernatant was removed following centrifugation 
(2000 rpm, 5 min.). A further 2 ml of phosphate buffer was then added, centrifuged 
as before and the two supernatants combined for further analysis. 
Solid-Phase Extraction 
To separate the drugs from the hair matrix, solid-phase extraction was carried out on 
Isolute® Confirm HCX-3 (130 mg) SPE columns [manufactured by International 
Sorbent Technology LTD (Hengoed, U.K.) and supplied by Crawford Scientific 
(Strathaven, U.K.)]. 
The method used was adapted from a method previously reported for the analysis of 
methadone24 and differs only by the pH of the phosphate buffer used. The SPE 
columns were conditioned with methanol and phosphate buffer (pH7.4, 0.1 M). The 
supernatant was applied onto the column which was then washed with deionised 
water. The pH was adjusted with O.OIM acetic acid pH 3.3 and the column subjected 
to two drying steps before elution of the drugs. The first fraction (A) was eluted with 
acetone:chloroform (l : 1 v/v) and was discarded as no quantifiable levels of the drugs 
were detected. The analytes of interest were eluted into the second fraction (B) using 
2 ml of2 % ammoniated ethyl acetate. 
Der;vat;sat;on and GCIMS Analysis 
Fraction B was evaporated to dryness under a stream of nitrogen at room 
temperature. The drugs were then reconstituted using 50~Li of PFPA:Ethyl acetate 
(l : 1) sealed and allowed to derivatise at 50°C for 15 minutes. After derivatisation 
was complete, the samples were evaporated to dryness as before and reconstituted in 
SOIlI of ethyl acetate. 1 ~Ll was injected for analysis by GC/MS. 
Met/wd Validation 
Hair samples were spiked by adding a set volume of the working solution to 100mg 
of ground blank hair (washed prior to milling). The methanol was allowed to 
evaporate to dryness overnight at room temperature. The hair was then mixed 
thoroughly to ensure homogeneity of the sample. 
The developed method was validated USll1g blank hair spiked with the five 
amphetamines at three different concentrations (5, 10 and 20 ng/mg), usmg 
approximately 1 a mg of hair. 
The recoveries from the spiked hair were greater than 70 % for all five amphetamines 
and the method was linear in the concentration range 0 to 100 ng/mg. The limit of 
detection (L.D.D.) for AP and MA was O.Sng/mg and a.lng/mg for MDA, MDMA 
and MDEA. The results are summarised in Table 3. 
Spiking hair results in surface bound drugs and docs not accurately represent how 
drugs are bound in the inner layers of drug users hair. This should be taken into 
account when interpreting the validation results. 
Analysis of "ecstasy" Preparations 
Substances (n = 15) which were sold as "ecstasy" were obtained by the research 
group. A Home Office licence (Ref. No.: 93/MM/254) was obtained which 
authorised the possession of drugs specified in Schedule I and II to the Misuse of 
Drugs Regulation 1985 (As amended). The IS "ecstasy" preparations were analyzed 
by gas chromatography - flame ionisation detection (OC-FIO) and OC/MS. OC-FID 
analysis was carried out using an HP 5890 OC fitted with a CPSil 5 0.5 i.d. x 10 m 
column. The intial temperature was set at 80°C and then ramped to a final 
temperature of 200°C at a rate of 10°C/min. and held for five minutes. The injector 
and detector temperatures were set at 290°C. Confirmation was carried out by GC-
MS using a Fisons OC8000/MO 800. The initial temperature of 60°C was ramped to 
300°C at 10°C/min. and held for 10 minutes. 
Results and Discussion 
Due to the limited sample size, each hair segment (n = 139) could only be analysed 
once by the described method. The reliability of this single analysis should be taken 
into account when interpreting the results. 
Of the 139 hair segments, 73 (52.5%) tested positive for at least one of the five 
amphetamines, the remaining 66 segments were negative for all five. In general, the 
levels of AP, MA, MDA, MDMA and MOEA detected in the hair samples are in the 
same range as those reported elsewhere (10,13,25-27). 
Some exceptions to this were found where levels detected were higher than those 
previously reported. These cases were few and the median of the results was found to 
lie within the reported ranges. The results are summarised in Table 4. 
The ratio of metabolite to parent drug levels in hair has been used to determine 
whether a positive result is due to contamination or from ingestion.(28,29) This ratio 
is expected to be lower than 1.0 due to the preferential incorporation of the parent 
drug to the metabolite. Therefore, a value greater than one is thought to result from 
contamination. The Society of Hair Testing recognises set ratios for cocaine and 
heroin and their metabolites, but not as yet for amphetamines (29). 
The metabolite to parent drug ratios are summarised in Table 5. With the exception 
of the ratio MDA: MDMA, the ranges of the others were higher than those 
previously reported. This can be explained in the case of AP and MA. "Speed" can 
contain both AP and MA as the parent drug, which will effect the metabolite to 
parent drug ratio. Combining the levels of MDMA and MDEA found in individual 
hair samples was carried out to determine if a relationship exists between the 
combined levels of these parent drugs in hair and the amount of drug consumed. 
Results obtained for the ratio MDA: (MDMA+MDEA) ranged from 0.03 to 6.5 in 
contrast to those found by Rothe et al (25) (0.03 to 0.2, n=67). However, they too 
reported cases with ratios> I. A possible explanation for this would be the 
consumption of MDA as a parent drug as well as its metabolic contribution from 
MDMA and MDEA. 
To investigate this, the contents of 15 illegal "ecstasy" preparations collected at the 
approximate time of sampling were analysed. The results are summarised in Table 6. 
The amount of MDMA present was found to range from trace levels in "Emerald E" 
(which mainly consisted of AP and catTeine) to 70 % in "Madwoman" (n = 15, range: 
trace - 239mg, median = 90). MDEA was detected in only three samples (range: 
trace - 3.Smg). MDA was not detected in any of the 15 preparations. However, this 
is not a representative sample and does not eliminate the possibility that "ecstasy" 
consumed by individuals in this study contained MDA. "Ecstasy" tablets seized 
within the U.K. have been reported to contain MDA (30-31). 
Concordance between the self-reported data and the levels detected in hair was 
investigated for all 139 segments. A total of 73 segments tested positive for at least 
one of the five amphetamines with 71 of these agreeing with the self-report data. 66 
were were found to be negative. with only six agreeing with the self-report data. 
Overall, agreement or concordance was greater than 50% with a low number of false 
positives, consistent with other studies. The results of which are summarised in 
Figure 1. 
A large number of false negatives were found. There are a number of possible 
explanations for this including the method lacking sensitivity, over reporting of drug 
use by the individual and the influence of cosmetic treatment on the hair (32-34). 
Unfortunately, no information was available on previous hair treatments (e.g. perms, 
bleaching etc.) and so the contribution of this to the results could not be assessed. 
Comparing the different types of sample analysed, it was expected that root samples 
would be more accurate than tip samples as they have been subject to fewer 
environmental and cosmetic influences, which have been shown to affect the drugs 
stability in hair. In addition, the self-report data would be expected to be more 
reliable due to better recollection of drug use in recent months as opposed to 12 
months prior to interview. 
The root samples have slightly better concordance (59.3%) than the tips (51.7%) and 
full (53.6%) samples. Figure 2 summarises the concordance between self-report and 
hair analysis for each of the segment groups. Tht!se consist of roots (proximal sample 
~ 6cm), tips (distal 6cm) and full samples (> 6cm). 
When comparing the self-report data for the use of "speed" only or "ecstasy" only, 
the concordance is very low for "speed" (28.3%) but higher for "ecstasy" (57.5%). 
The results are illustrated in Figure 3. Unlike the "ecstasy" data, the "speed" data was 
not recorded for each month of the previous year and in addition. higher limits of 
detection were employed. The combination of these factors will decrease the number 
of potentially positive results. 
Of the six false positive segments where individuals denied "speed" use but tested 
positive for amphetamine and/or methamphetamine, five admitted "ecstasy" use, and 
were also positive for MDA, MDMA or MDEA. Six of the seven false positives for 
"ecstasy" admitted taking "speed" but only one case was positive for amphetamine. 
It is certainly plausible that the subjects were unaware whether they were consuming 
"speed" or "ecstasy" and this would account for some of the false positive or 
negatives. For example. one of the 15 "ecstasy" preparations consisted of mainly 
amphetamine and caffeine. with only trace levels of MDMA. 
Figure 4 illustrates the correlation between the total number of "ecstasy" tablets 
consumed and the total concentration of "ecstasy" (MDMA + MDEA) detected in 
each hair segment. There is a large scatter of results with the majority congregated 
along the axes. No linear dose-response relationship was observed (r = 0.0484, P = 
0.572). This was also the case when comparing the amount of "ecstasy" consumed 
and the total concentrations of MDMA or (MDA + MDMA + MDEA) measured. 
The results for each hair segment were separated into five groups depending on the 
average number of "ecstasy" tablets consumed each month. Each group consisted of 
approximately 20% of the segments analysed. The mean, median and range are noted 
for each group and summarised in Table 7. 
An increase in the mean and the median values for the total concentration of MDMA 
+ MDEA is observed from low to high frequency of lise. The one exception to this is 
the group where between 0.5 to 1.25 tablets were consumed each month. The mean 
value is higher due to one case which had a total concentration of 93.4 ng/mg. 
Another important point here is the high number of false negatives which are 
prevalent throughollt each of the four groups claiming "ecstasy" use. However, the 
number of false negatives did decrease from low to high use. 
The data was evaluated with respect to sex and hair colour. There was no significant 
difference between the sexes. 95% of the participants were Caucasian with the vast 
majority with hair of various shades of brown. The lack of a relationship with hair 
colour is probably indicative of this. 
Conclusion 
The described method combining enzyme extraction, SPE, derivatisation and 
GC/MS, successfully detected all five amphetamines (AP, MA, MDA, MDMA and 
MDEA) in hair samples donated by participants in the Glasgow dance scene, to 
confirm the use of "speed" and "ecstasy". 
Although concordance between self-reported data and laboratory findings was 
approximately 50%, there were a high number of false negatives (43.2%) which may 
highlight the methods lack of sensitivity in confirming low use of "speed" and/or 
"ecstasy". No con-elation was observed between the amount of "ecstasy" consumed 
and the levels detected in hair. However, there was evidence of a relationship 
existing between the level of use (measured in average "ecstasy" tablets consumed 
per month) and the levels detected in hair from low to high use. 
The results of this study have given rise to a number of key questions which need to 
be answered to realise fully the potential of hair analysis, in particular, for the 
analysis of ecstasy in hair. A combination of low concordance between self-report 
data and hair analysis results, and the high number of false negatives, raises questions 
regarding both the method sensitivity and the reliability of the self-report data. 
The method of collection of hair samples is also of utmost importance. As 
highlighted earlier in this paper, the samples obtained for this study were too small to 
be analysed more than once. In some cases, this one analysis yielded a false negative 
result as the sample size was too small to give a significant level by GC/MS. It is 
acknowledged that obtaining larger samples on a voluntary basis could be 
problematic due to the sampling area (vertex region). However it is practical to be 
able to analyse samples in triplicate in order to decrease experimental errors and thus 
increase the validity of analytical results. 
The large number of false negatives and low drug levels detected is likely to be a 
reflection on low drug consumption, with the heaviest users consuming 
approximately 1 "ecstasy" tablet per week of unknown purity. Comparing this to 
heavy heroin or cocaine users (> 1 per day), approximately 80% of "ecstasy" users in 
this study consumed less than 1 tablet per week. 
The parent drug to metabolite ratio is unusual in comparison to the studies carried out 
with heroin and cocaine, where ratios of less than one are expected. The ecstasy 
preparations analysed during this project were not a representative sample. Tablets 
seized from within the UK prior to the hair samples being collected, had high 
quantities of MDA present. With this in mind the ratios are not unusual due to the 
unknown contribution of MDA as either u parent drug and/or a metabolite. 
Large discrepancies between cases are reflected in the lack of a dose-response 
relationship for the segments analysed. Two examples are given which clearly 
illustrate this. 
One subjected reported use of 52 "ecstasy" tablets over a six month period, however 
the hair was negative for all five amphetamines. Conversely, another subject denied 
use of "ecstasy" but 0.6 ng/mg of MDMA were found in the corresponding 2 em hair 
segment. 
Determining the smallest dose detectable in hair, in combination with dose-response 
studies, would certainly help explain why in one case, where only 5 "ecstasy" tablets 
were consumed, a level of 1.1 ng/mg of MDMA was detected. However, when 50 
tablets were consumed by another subject, this only gave rise to a level of 0.5 ng/mg 
ofMDMA. 
The influence of various factors, i.e. cosmetic treatments, individual metabolism 
variations, and the uncertainty of the content and dose of the "ecstasy" tablets, are 
currently being investigated further. A wealth of information can be gained from 
studies involving consumption of known doses and subsequent hair analysis. One 
additional factor, highlighted by Rothe et al (25), is the influence of drug 
incorporation via sweat. This is of particular relevance with "ecstasy" use, where 
participants in the dance scene are known to dance for several hours in hot, humid 
conditions. 
The relationship observed between the average number of "ecstasy" tablets 
consumed per month and the total concentration of (MDMA + MDEA) detected in 
hair, gives some indication of the potential of hair analysis as an indicator of 
"ecstasy" use. This in addition to the previous points, will aid greatly with future 
interpretations of amphetamine levels in hair. 
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TABLE 1 - Lengths of hair segments analysed 
Sample Type Length (em) Total 
Roots <3cm 4 
3cm < 6cm 10 
6cm 40 
Tips 6cm 29 
Full 6.1cm< 12cm 10 
12cm 46 
Total 139 
TABLE 2 - Drugs consumed by 100 respondents over the year prior to 
interview 
Drug Yes No 
Alcohol 96 4 
Cannabis 95 5 
"speed" 84 16 
Tobncco 84 16 
LSD 67 33 
Cocnine 53 42 
*Poppers 46 50 
tMushrooms 30 67 
Temnzepam 29 68 
lather Benzos 19 75 
§Other Opiates 13 82 
Glue 7 88 
Heroin 6 86 
Temgesic 6 84 
Ketllmine 5 86 
* Alkyl nitrites 
t Hallucinogenic mushrooms 
lAll benzodiazepines with the exception of temazepam 
§All opiates with the exception of heroin 
No Response 
5 
4 
3 
3 
6 
5 
5 
8 
10 
9 
TABLE 3 - Recovery and linearity results for the extraction of amphetamines from 
hair 
Analyte* Recovery (%) ± L.O.D. t Linearity 
Std. Dev. -r (ng/mg) (r) § 
AP 70.6 ± 7.92 0.5 0.990 
MA 79.4 ± 8.68 0.5 0.993 
MDA 82.2 ± 6.26 0.1 0.993 
MDMA 87.1 ± 4.62 0.1 0.995 
MDEA 85.4 ± 2.12 0.1 0.996 
* AP: amphetamine, MA: methamphetamine, MDA: 3,4-
methy lenedioxyam phetamine, MD MA: 3, 4-methy lenedioxymethamphetamine, 
MDEA: 3 ,4-methy lenedioxyethy I-amphetamine 
tStandard Deviation 
t Limit of Detection 
§ Correlation Coefficient 
TABLE 4 - Drug concentrations detected in hair segments 
Drug No. (Range) Median Mean 
ng/mg ng/mg ng/mg 
AP 11 (0.7 - 97.7) 2.5 12.5 
MA 27 (0.6 - 32.3) 2.6 5.2 
MDA 20 (0.1 - 8.4) 1.0 1.9 
MDMA 56 (0.1 - 82.9) 0.7 4.6 
MDEA 23 (0.1 - 12.0) 0.5 2.8 
TABLE 5 - Metabolite to parent drug ratios 
Ratio No. (Range) MedhlO Mean 
AP:MA 9 (0.15 - 44.40) 0.85 7.26 
MDA:MDMA 12 (0.01 - 6.28) 0.40 0.54 
MDA: MDEA 11 (0.10 - 6.50) 0.67 1.59 
MDA: 14 (0.03 - 6.50) 0.33 0.95 
(MDMA + MDEA) 
TABLE 6 - Content of "ecstasy" preparations analysed by GC-FID and GC/MS 
Street Name 
Emerald E 
Tornado Powder 
Rhubarb + Custard 
Lemon and Lime 
Clog 
Pink Snowball 
Madm~lD 
Turbo 
Disco Biscuit 
Un-named 
Blaster 
WhitelLove Dove 
Madwoman Powder 
Super dove/robin 
Madwom~lD 
* Trace levels detected 
t Caffeine 
Form 
Capsule 
Powder 
Capsule 
Capsule 
Tablet 
Tablet 
Tablet 
Tablet 
Tablet 
Tablet 
Tablet 
Tablet 
Powder 
Powder 
Tablet 
MDMA OTHER 
MDMA (tr.)*, AP(46%), 
tCaff.( 41 %) 
MDMA(13%) 
MDMA(17%) 
MDMA(19%) MDEA (1%) 
MDMA(20%) 
MDMA(20%) 
MDMA(21%) 
MDMA(21%) 
MDMA(31%) MDEA (tr.) 
MDMA(43%) 
MDMA(46%) 
MDMA(58%) 
MDMA(65%) 
MDMA(68%) MDEA (tr.) 
MDMA(70%) 
TABLE 7 - Correlation between the number of "ecstasy" tablets consumed/month 
and the total concentration of (MDMA + MDEA) detl.!cted in hair 
No. E Tablets Frequency ng/mg in hair 
per month* 
Mean Median Range 
None 29 0.086 0.00 0-1.00 
<0.5 29 1.493 0.10 0-20.3 
0.5 -1.25 28 4.425 0.00 0-93.4 
> 1.25 - 3.5 27 1.615 0.00 0-23.9 
> 3.5 26 4.285 0.55 0-55.8 
Total 139 1.942 2.00 0-93.4 
* The average number of ecstasy tablets consumed each month. 
SELF 
Yes No 
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Introduction 
Although the results of testing hair for the presence of poisons have been accepted - at 
least in American courts - for over a century, 1 hair testing for evidence of the use of 
drugs has not yet reached that degree of full judicial acceptability,2 although there are 
various reports of quasi-judicial use.3,4,',6 
Hair testing began slowly about 20 years ago, initiated, perhaps, by Baumgartner's 
pioneering article.' Sachs suggests an erratic growth thereafter, with a "gold rush" 
period between 1986 and 1992 typified by relatively uncritical use of hair testing, 
followed by a "hang over" period between 1992 and 1996 characterised by more 
critical reflection.· It seems that a renewed "gold rush" - at least of published papers if 
not of conclusive results - began thereafter. 
Hair offers one crucial potential advantage when compared to, for example, urine as a 
medium for detection - the long time window. Whereas urine can only indicate use for 
2-3 days for opiates, cocaine and the amphetamines, hair offers the possibility of 
retrospective use examination for at least 3 months, and possibly for much longer. 
Indeed, Baumgartner, et al. claim to have tested 5 hairs, 7.6cm in length, from Keats, 
and, 167 years later, discovered the presence of opiates therein;9 and Kidwell & Blank 
report the discovery of cocaine in the hair of 1,000 year old Peruvian mummies. 10 
Specifically, hair offers the opportunity to examine evidence of drug use for each of 
the months separately, rather than merely for all of the months together. A number of 
other advantages of hair are sometimes cited (difficult to falsity, easy to store, lengthy 
shelflife, low body invasion), but for others, these apparent benefits merely offer more 
opportunity to tramel with people's civil liberties for longer periods.2•10•1I 
Previous work on MDMA (3,4-methylenedioxymethamphetamine) in hair is obviously 
of some relevance here (although Mieczkowski considers that MDMA is only 
2 
incorporated in hair to a "moderate degree", p. 60),1 and thus deserves a detailed 
review. The case reported in Moeller, et al. is almost entirely in Japanese, which we 
are unable to interpret. 12 Cirimele et al. discovered AP (amphetamine), MDA (3,4-
methylenedioxyamphetamine) and MDMA in both the fingernails and head hair of a 22 
year old male "known to be a drug user" (p. 68).13 Kikura and colleagues analysed hair 
samples from 3 rats that had been given MDMA (amongst other drugs) and also 
analysed head hair from 7 human "MDMA abusers", in whose hair, MDMA was 
indeed discovered. 14 
Kintz & Cirimele report a methodological trial involving interlaboratory comparisons 
of the analysis ofa hair sample containing MDMA, MDA and AP, and the laboratory 
comparison is discussed in a later section of this paper. IS At this point, it is merely 
worth noting that the sample came from "a male subject, aged 24 years, known to be a 
stimulant abuser and deceased from fatal methylenedioxymethamphetamine overdose" 
(p. 152). 
Rohrich & Kauert spiked drug-free hair samples with MDA, MDMA and MDEA (3,4-
methylenedioxyethylamphetamine) for calibration purposes, and subsequently tested 
"authentic hair samples from [303] individuals with suspected drug abuse" (p. 180).16 
They discovered that "28 of these samples (9.3%) contained amphetamine and/or 
methylenedioxy-amphetamine-derivatives" (p. 187). AP was detected in 23 samples, 
MDMA in 9, MDA in 6 and MDEA in 5. They conclude "Considering the increasing 
use of amphetamine and particularly of 'Ecstasy', this number of28 amphetamine-
positive samples seems remarkably low" (p. 180). 
Finally, Rothe, et al. examined (proximate 3 em length) hair samples from "20 regular 
'speed' or 'ecstasy' users of the techno scene ... who anonymously reported their drug 
history in a drugs advice centre" (pp. Ill, 113).17 While these "abusers" could report 
the number of tablets consumed, they could not comment on their relative purity 
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(another issue to be taken up later). The 20 were classified as follows: 7 "insignificant 
abusers" (up to 1 tablet per month); 5 "moderate abusers" (1-3 tablets per month); 3 
"strong abusers" (3-8 tablets per month); and 5 "very strong abusers" (over 8 tablets 
per month). The mean discovered nglmg (nanograms per microgram) levels matched 
their rank order by tablets consumed, although there was considerable variation within 
each group. For example, in the very strong abuser group, concentrations ranged from 
none detected to over 16 nglmg. Their ability to detect MDMA in the hair of subjects 
who had consumed less than 1 tablet per month persuades the authors of the sensitivity 
ofhair analysis; indeed, they suggest "in cases of ecstasy abuse the intake of 1 tablet 
may lead to a hair concentration in the order of 1 nglmg" (p. 126). However, they 
recognise considerable interindividual variation; and, separately, that participation in 
the "techno or rave" scene, and associated sweating, can lead to false positives through 
deposition, and chronological misinterpretation from sweat-assisted migration along 
the hair shaft. 
Method 
Recruitment 
Subjects were recruited for interview using a strategy which combined the use of "key 
informants" using "chain referral",11,19 as informed by a "theoretical sampling" 
strategy,20 in which subjects themselves nominate another subject (individuals well 
known in the dance scene who could introduce interviewers to a large number of 
MDMA users) coupled to 'multi-site sampling' (attempting to initiate chains in many 
separate and diverse locations). The initial criterion for inclusion in the study was that 
SUbjects had taken MDMA at least once, although not necessarily a whole tablet of 
it.21 
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The first interview took place on the 1st December 1993, and the 229th on the 9th 
June 1995 - nearly 18 months later. The 100 subjects analysed here are a sub-set of the 
229-strong main sample. 
Sample 
All respondents who reported ever taking "ecstasy" answered an array of questions 
about their lifetime use of it, and a very extensive set of questions relating to their use 
of it in the 12 months prior to interview. These included estimations of the number of 
days on which they had consumed "ecstasy" for each of the previous 12 months, 
together with an estimation of how many "ecstasy" tablets they had taken on each day 
of use. 
Users are classified in Table 1 in terms of their "ecstasy" consumption in the past 12 
months. One subject had not used in the past year, and is grouped with the 8 non 
users. The "Light" users had consumed between v.. and II tablets in the previous year 
(broadly speaking, their averaged consumption was 'less than monthly but more than 
yearly'); the "Medium" users had consumed between 12 and 47 tablets in the previous 
year (similarly, their averaged consumption was 'more than monthly but less than 
weekly')~ the "Heavy" users had consumed 48 or more tablets in the previous year 
(their averaged consumption was 'more than weekly but less than daily'). No users 
qualified as 'daily' users. 
Previous research on substance use has tended to treat self-report measures of 
quantity! frequency as sufficient, but this study also collected information on pattern of 
use. Data were obtained about "ecstasy" use during each of the twelve months 
preceding interview: specifically on how many days "ecstasy" was consumed during 
each month and for each day of use, and on how many tablets were consumed on 
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average. Measures used were mean reported number of tablets used per occasion per 
month and the mean reported number of days used per month. From these were 
derived additional measures: reported use for each month (being the number of tablets 
per occasion multiplied by the number of days of use); and reported variation in use 
per month (being the standard deviation calculated across use for each of the 12 
months). These data theoretically made it possible to distinguish 'stable' users from 
'erratic' users at each level of consumption. Essentially, a stable user was one who 
tended to use the same amount of "ecstasy" the same number of days each month, 
while an erratic user tended to have different patterns of use during different months. 
Insert Table J about here 
Hair donation 
After completing the main structured interview and various self-completion scales, all 
subjects were asked to provide some hair for laboratory testing. From those that 
agreed to donate a sample, between 30 and 50 hairs were taken from the scalp vertex. 
Cut ends were aligned, wrapped in aluminium foil for ease of identification of the root 
end, and sealed in individual plastic bags, numbered with each subject's ID code. 
Hair analysis 
This paper reports the analysis of hair from 100 of the 229 subjects (44%). Hair from a 
further 49 subjects was analysed by a commercial laboratory, and is not reported here 
as the laboratory was unable to provide sufficient technical information relating to their 
analytic procedures. Of the 80 subjects for whom a sample was not available, 12 
refused to (or could not) donate one, and 68 donated a sample which later proved to 
be of insufficient volume to pennit reliable analysis. Of the 100 remaining hair samples, 
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11 were 6 an long, and 68 were 12 em long. The remaining 21 were odd lengths 
ranging from 2 an to lOan. Donors were compensated for hair loss with 
reimbursement of expenses incurred. The 100 samples reported here were analysed at 
the Department of Forensic Medicine and Science at the University of Glasgow 
(Scotland). 
The method is reported in full e1sewhere. 21 In brief: each hair sample was washed with 
sodium dodecylsulphate and deionised water, rinsed with methanol and allowed to dry 
overnight. The methanol rinses were all analysed, and were found to be negative. The 
hair was cut and ground finely, treated with the enzyme glucuronidase in the presence 
ofpH7.4 phosphate buffer, and the internal standard, amphetamine-d3. The samples 
were then sealed and heated at 40°C for 2 hOUTS. The resultant supernatant was 
separated from the hair matrix by centrifugation. The analytes of interest were 
separated from the supernatant by solid phase extraction, and analysed by a 
combination of derivatisation and GClMS (gas chromatography/mass spectrometry). 
For MDA. MDMA and MDEA the Limit of Detection (LOD) was O.lng/mg and the 
Limit of Quantitation (LOQ) was O.Sng/mg. For AP and MA, the LOD was 0.5 ng/mg, 
and the LOQ was 1 nglmg. 
Results 
This section is divided in two. First, a discussion of the results relating to "gross 
concordance" between the self-report "ecstasy" consumption, and MDMA (or allied 
compound) ng/mg dat~ second, "net concordance", or degree of correlation between 
the number of "ecstasy" tablets reportedly consumed, and the nglmg ofMDMA (or 
related compounds) traced in the hair of each subject that self reported "ecstasy" use, 
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and in whose hair one of the five drugs tested for (MDMA, MDA, MDEA, MA, AP) 
was found. 
Gross concordaDce 
Self-repon "ecstasy" consumption data was matched to ng/mg data using the rule of 1 
an of hair growth per calendar month. For example, with a subject donating 6 cm of 
hair, self-repon data relating only to the previous 6 months was analysed. Both the 
se1f-repon tablet consumption and oglIng data were interval variables, but each was 
recoded as a nominal variable (i. e .• as a simple yes/no response) to estimate gross 
concordance using aoss-tabulation and tested using Cohen's Kappa.13 Results are in 
Table 2. 
Table 2 about here 
Overall percentage gross concordance is weak. with no cell exceeding 5~1o 
concordance. and with the Cohen's Kappa for no cell exceeding 0.08. Magura & Kang 
indicate that only Kappa values that exceed 0.8 are of interest. 24 The fourth column 
("anyxtc") is a result of a nominal version of summed data from the ng/mg output data 
for. separately. MDMA. MDA and MDEA, each of which was tested for separately. 
The seventh column ("anya") is similarly summed from the AP and MA 
(methamphetamine) ng/Ing data. The eighth column ("any") is the sum of "anyxtc" and 
"anya". Neither amphetamine consumption separately, nor amphetamine consumption 
coupled to "ecstasy" consumption (the bottom two rows of Table 2) improve 
concordance. Accordingly. data from row one column eight ("ecstasy" consumption by 
"any") is used for the remainder of this part of the paper. 
Figure 1 illustrates the breakdown of the gross concordant data, with 52% being lab 
and self positive and 7% being lab and self negative (summing to 5~1o). 
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Figure J about here 
Net concordance 
This section deals only with the 52 users that self-reported "ecstasy" use, and later 
hair-tested positive for MDMA (or related compound) use. The demographics of this 
sub-sample are in Table 3. The 52 subjects who self-confessed to "ecstasy" use and 
hair-tested positive for MDMA (or related compound) use could only be distinguished 
from the 48 who did not meet this definition on only three of 49 demographic and 
other related sociological variables. These three variables were:- whether or not they 
had taken cocaine last year, been ill in bed last year, and suffered from mood swings 
last year (all p<O.05), with those who tested positive for MDMA (or related 
compound) use being more likely to have experienced all three. Neither hair weight 
(expressed as weight per em), nor hair colour (coded as a 9-point ordinal from white 
through black) correlated with any of the nglmg data. 
Table 3 about here 
At this level (lab and self positives) correlations between interval versions of the 
variables are most appropriate, rather than the simple nominal versions used to assess 
levels of gross concordance. The results are in Table 4. 
Table 4 about here 
No correlation approaches even the lowest level of statistical significance, and no 
correlation is positive. In the latter sense, that between ng/mg ofMDMA, MDEA and 
MDA combined ("threemng" in Table 4) and number of tablets consumed comes 
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closest to a positive correlation. The degree of scatter is enormous, however, and is 
illustrated in Figure 2, in a way suggested by Marques.2' 
Figure 2 about here 
So far, when considering net concordance, the possible relationship between tablet 
consumption and ng/mg detection has been posed at the interval level, and has 
concluded that nanograms, as an "absolute dosimeter", 26 do not predict tablet 
consumption. At a weaker level, the relationship may be tested at an ordinal level 
(nanograms as a "relativistic dosimeter"21), which has proved successful elsewhere, 
and with other drugS.28,29,30,J1 Table 5 shows the results of such a test, when subjects 
are grouped by tablet consumption (pro rata by length of hair sample) using the same 
ordinal groupings as in Rothe, et 01.,17 and compared with interval nanogram data. 
Table 5 about here 
Interpretation 
Gross concordance 
From Figure I, the 5 discrepant lab positives are within the range reported elsewhere.32 
The 36 false negatives are considerably proportionately higher than those found 
elsewhere, and are probably accounted for, at least in part, by the fact that this sample 
of users were volunteers with no apparent motive to under report "ecstasy" use. 
A method of assessing the competence of hair analysis as a test for the presence of 
"ecstasy" (assuming the accuracy of self-report) is provided by Bemadt.33 An effective 
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test must have sensitivity of at least 90% (i.e., it must pick up most cases with the 
condition), and a positive predictive value of at least 40% (i.e., at least this many of the 
positive tests must be cases of the condition). Here, the test results fail at both levels: 
sensitivity is only 64%, and the positive predictive value is only 23%. 
Net concordance 
The analysis of data at this level also fails standard tests. For none of the nanogram 
data (whether separately or in summated fonn) do the means progressively increase 
with grouped reported tablet consumption, and in every case, the lowest recorded 
nanogram reading in the greatest consumption category is considerably smaller than 
the highest recorded nanogram reading in the lowest consumption category. The 
bottom row of Table 5 attempts to duplicate Rothe et al. 17 
Overall concordance 
These results do not inspire confidence in any credible individual or aggregate 
relationship between careful and unrestrained self-report on the one hand, and 
laboratory testing on the other. Analysis has relied on two sources of data which, in a . 
perfect world, should have correlated. They were: self-report "ecstasy" consumption; 
and laboratory discovered nanograms of ecstasy in the consumer's head hair. In 
principle, there are a large number of reasons why a highly correlated match was not 
achieved. In practice, all or any of them might have been in play, to some or other 
degree, on this occasion. We consider these problems in the Discussion. 
Discussion 
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Such problems are considered under two main headings, with those relating to the 
validity of self-report data considered before those relating to laboratory analysis. 
Self report data 
The most critical variable influencing putatively the quality of self report must be the 
circumstances of report itself. Confessions from those in constrained settings (arrestees 
at booking facilities, inmates of correctional establishments) may be required of 
persons in a relatively traumatised frame of mind and/or believing themselves to be at 
risk of sanction for admitting prior drug use. The first may affect memory, the second 
willingness to self-report fully. It is consequently believed that "self report may be the 
least reliable among criminal justice clients" (p. 27).34 
Since the circumstances of self-report from subjects reported here was one of 
voluntary participation with credible guarantees of confidentiality and anonymity, the 
abnonnally large number of discovered false negative gross non-concordant individual 
results begins to make some sort of sense. On the other hand, Cook et al. compared 
various types of self report with urine and hair analysis when investigating drug use 
among 928 employees at a US steel plant.32 They discovered a low false positive rate 
of 4 per cent, and a low false negative rate of 5 per cent. Although theirs was not a 
criminal justice sample, it appears not to have been a volunteer one either. 
However, unconstrained circumstances do not necessarily guarantee accurate self-
report data. Experimentation has shown both that overreporting of drug consumption 
is more common than underreporting,3' and vice versa.36 This is sometimes explained 
by reference to bravado and/or reticence, although it may be more appropriate instead 
to consider what experimental and other evidence exists related to the ability of 
memory even for those with no wish to report levels of drug use higher or lower than 
those actually experienced. 
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Hammersley has recently published a detailed review of the literature on memory 
problems which casts considerable doubt on the reliability of self-report in research 
into drug use.37 Nevertheless, complete disregard of self report (the stance adopted, 
inter alia, by Marques, et 01. who comment: "the widespread use of self report data to 
validate technical measures of drug exposure is roughly analogous to having a patient 
self report temperature in order to validate a thennometer reading" - p. 172 2') 
probably goes too far. 
Independent of these problems of truthful recall and memory difficulty. are problems of 
substance purity (only rarely referred to in the literature on hair analysis). Street 
purchased MDMA is known to vary greatly in tenns of the proportions ofMDMA and 
other inert components and/or psychoactive adulterants. Indeed, as part of the general 
research design of which hair analysis was a component, the research team obtained 15 
substances bought as "ecstasy" (the first author held a Home Office licence to be in 
possession of Class A substances at the time). The analysis of the 15 substances 
recovered this way was conducted at the same laboratory. Resulting data is in Table 6. 
Table 6 about here 
MDMA content ranged from less than 1% to a high of 70% (with a mean of 34%). A 
frequent heavy user of "Emerald Es" would probably consume less actual MDMA than 
an occasional light user of "Madwomans". Far more extensive tablet analysis 
conducted in Amsterdam (2,689 tablets, analysed during the whole of 1997) indicated 
an MDMA average content of 41 %, and a range from 24% to 61 % per month. 
Interestingly, when MDMA content was low, amphetamine content was high, and vice 
versa.38 Purity is clearly an issue deserving more sustained attention. 
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Laboratory analysis 
Turning now to problems associated with laboratory analysis, perhaps the main one is 
an unswerving belief in the validity of laboratory data, which, when produced by 
GeIMS, is often "assumed to be virtuaIly 100 percent accurate" (p. 20).34 However, 
laboratory analysis of hair for the presence of drugs is not unproblematic. Relevant 
problems faIl into one of two types: problems relating to hair, and problems relating to 
its analysis. 
First, rates of hair growth. A norm currently is to assume a growth rate of I cm/month 
(the assumption on which the technical analysis in this paper was based). Not so long 
ago, however, the American assumption was half an inch/month. Twelve cm is the 
equivalent of four and three-quarter inches. On the current assumption, this would 
indicate 12 months of hair growth: on the earlier one, nine and a half months. In 
addition, rates of hair growth are believed to vary individuaIly from, by one estimate, 
from 0.6-3.36 cm/month.39 For an individual at the low end of this scale, 12 em of hair 
would reflect 20 months of hair growth; for one at the high end, 12 cm of hair would 
imply just over three and a half months of hair growth. This is a major, yet typically 
unaddressed problem. 
These latter are only averages: the situation for individuals is more complex as hair 
growth varies by the length of the individual's hair (with "in general, the longer the hair 
is, the longer the growing phase is", p. 306)40; by race (Causcasian hair grows faster 
than Asian hair); by sex (scalp hair in women grows faster than in men); age (hair 
growth generaIly decreases with age); by position on the scalp (hair grows faster in the 
vertex region than elsewhere); by general location (compared to scalp hair, pubic hair 
grows more slowly, and beard hair more slowly still); by hair colour (darker hair is 
more likely to reveal substances or their metabolites); and possibly by hair texture 
(whether "coarse" or "fine"). In addition, a certain proportion of head hair - usually 
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estimated at 15 per cent of it - is donnant at anyone time, and could not, thus, be any 
sort of calendrical record of consumption. 
It is further the case that "hair is a very complex part of the anatomy whose biology is 
only partially understood" (p. 9).39 This leads to two more problems. First, rates of 
incorporation of substances into hair are believed to vary by many of the dimensions 
that affect rates of hair growth as noted above. Kidwell & Blank suggest that cocaine 
incorporation ratios for Afiicans:Whites are 2.9: 1, and for Koreans:Whites, 6.8: 1. 10 
Second, here is the more immediately relevant difficulty: the problem of the possibility 
of external contamination ofhair.41 Harkey comments: "the hair shaft is exposed 
directly to sebaceous secretions before it emerges from the skin. Scalp hair is also 
exposed to sweat secretions as well as contaminants in air, water, or dust" (p. 16).39 
However, most drugs can be delivered by a variety of different methods, and might be 
consumed differently by one individual on different occasions. Tablets, such as those of 
MDMA (which is also available in powdered - as well as capsule and tablet - form, and 
has been known to be injected) are generally handled by those not wearing surgical 
gloves, who may thereafter run their hands through their own, or somebody else's, 
hair. IfMDMA is consumed in hot dance venues, which is typical in the UK, then the 
problem of sweat contamination is presumably greater than it may be in cooler drug 
consumption environments. On the other hand, handling (and subsequent hair-
fondling) has been challenged by Mieczkowski who refers to his work with undercover 
narcotics officers "who are chronically exposed to cocaine", but who, even after 
"several thousand" exposures, have "near-zero levels of contamination [and] are 
readily differentiated from cocaine users" (p. 62).1 
The effects of the differential regularity and frequency of individual non-experimental 
washing, dyeing, perming and otherwise cosmeticising hair are unknown, but cannot 
be dismissed. Jurado, et al. examined the hair of those with similar drug consumption 
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histories, and concluded that "in all cases the drug content in hair that had undergone 
cosmetic treatment decreased in comparison to untreated hair" (p. 159).42 They also 
conclude that shampooing may not have much effect on drug retention, but that 
bleaching, dyeing and streaking all do: albeit with different individual variations. 
Skopp, et al. appear to disagree. Their analysis of bleaching indicates that: "in general, 
the drug concentrations in virgin hair were slightly lower compared to cosmetically 
treated hair" (p. 47).43 
As for laboratory analysis, first, there are problems of comparison. Hair preparation 
procedures adopted prior to testing itselfvary widely, and new ones are developed 
with a regularity unjustified by citation of conclusive evidence of superiority. 
Subsequent laboratory tests selected are from a variety of different options which are 
known to vary in their ability to detect the presence of various substances. Further, 
cut-off points, which crucially determine the ratio of false positives to false negatives, 
are not always reported, and when they are, they are not always similar. 
Next, there are occasionally problems of credibility. Of the five English language 
reports of laboratory testing for MDMA use, one analysed hair from somebody 
"known to be a drug user", a second analysed hair posted from overseas where it had 
been harvested from alleged "MDMA abusers", and a third analysed a sample from 
somebody "known to be a stimulant abuser". Only the samples used by Rohrich & 
Kauert,16 and Rothe, et al. 17 come anywhere near sizes or sampling techniques that 
would permit any acceptable generalisations. 
Post-harvesting wash procedures are designed to eliminate traces on the external 
surface of the hair. The extent to which they do so is clearly related to the reagents and 
to thoroughness and frequency of washing, with Baumgartner, et al. indicating that 
washing has a variable effect with, in one case, removal of 88 per cent of cocaine from 
a hair sample, and in another, 41 per cent.9 It is sometimes believed that tracing drug 
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metabolites (rather than the drugs themselves) in hair is indicative of consumption 
rather than of contamination, but Kidwell & Blank offer evidence that metabolites have 
been traced in street samples. 10 
The washing problem is akin to the cut-off problem noted above. Too much washing 
might lead to too many false negatives: too little, too many false positives. It has been 
noted, by Blank & Kidwell that, even after "substantial washing" by one method, two 
cocaine spiked samples still retained 211 ng of cocaine or its metabolitesl10mg hair. 44 
This is equivalent to amounts found in the hair of those classified as heavy cocaine 
users. Finally, the degree of external contamination will relate to the mechanism and 
context of original drug delivery. Drugs which are smoked or chased will, presumably, 
stand a greater chance of externally contaminating hair than those which are consumed 
orally or by injection. 
In the introduction to this paper, reference was made to Sachs' distinction between a 
"gold rush" phase for hair analysis, followed by a "hang over" one.8 One implication is 
that, in brief, during the "gold rush" era, hair was believed to possess the probable 
potential to be an "absolute dosimeter" for drug consumption. The period of retreat 
typifying the subsequent "hang over" era has forced a stocktaking, and a revision of 
expectations down to hoping that hair may offer what Baumgartner & Hill latterly have 
referred to as a chronometrically operating "relativistic dosimeter".31 
That even this has not proved possible in the analysis presented above does not 
necessary mean a further retreat is called for. Instead, improved research protocols 
might well be more appropriate, and it is to this that the Recommendations attend. 
Recommendations 
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Whilst the analysis of the materials presented here offers no obvious source of 
optimism for the future of hair analysis in the confirmation ofMDMA (or related 
compound) use, the failure to generate impressively positive results may well be due to 
the failure of self report anellor laboratory analysis. How could faith in each be 
enhanced? 
Self report would seem to be more reliable ifsamples are large, voluntary, and not 
derived from criminal justice populations. Self report could be more credible if it were 
contemporaneous (perhaps as diary record) rather than retrospective, and limited, 
perhaps, to a three month period. The issue of the consumption of variously 
adulterated complicates matters further. Until sampled users can be permitted to return 
samples of substances along with their self reported consumption details, little impact 
on this key issue will be possible. An alternative is for the sort of controlled dosage 
studies that Mieczkowski. et al. have called for, although these may be harder to 
organise. 45 
Laboratory analysis would, in principle, be surprisingly easy to check for reliability, 
and if a high degree can be demonstrated to exist, then the need for research into self 
report itself declines. There would appear to be room for improvement in laboratory 
analysis, and this would be facilitated if considerably larger hair samples were 
harvested in future. This would enable double testing of samples: something which 
should become the norm rather than merely an ideal. Another part of the problem is the 
proliferation of different washing procedures, assays, etc., on which, Mieczkowski 
comments (p. 68):1 
"There is not yet a universal standard for washing the specimens, conducting the 
assay or establishing quantitative outcomes which are readily extrapolated to 
consumption levels. Systematic comparison of hair analysis values will require a 
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standardised assay method, and be greatly facilitated by a standard system of 
reporting outcomes. " 
The establishment of a single method for washing, assaying and reporting could be the 
basis of a sound interlaboratory and intralaboratory research programme. This has been 
tried, in part, but only with small samples of rather dubious authenticity, or with 
possibly flawed sample spiking. Welsh, et al. conducted two exercises with "hair from 
suspected drug users" and "drug-free hair".46 In the first exercise, 8 laboratories were 
sent 8 powdered samples, and 7 laboratories returned quantitative results. Ninety four 
per cent correctly identified positives, and all correctly identified negatives. However, 
"scatter in quantitative results was high" (p. 295). In a second exercise, ten laboratories 
were sent eight hair segments rather than powder. The qualitative results were not as 
good (78% correctly identified positives, 94% correctly identified negatives), and they 
comment "quantitatively, the results were more scattered for the second exercise when 
the hair was in form of short segments. " 
Mieczkowski, et al. report the despatch of cocaine positive hair samples from 141 
individuals to two laboratories.47 The two laboratories used different assay methods 
(one RIAH, the other GeIMS) and different cut-offs. None of those deemed negative 
by GeIMS were deemed positive by RIAH, but 16 of those deemed positive by 
GeIMS were deemed negative by RIAH. Finally, Kintz & Cirimele sent a hair sample 
spiked with AP, MDA and MDMA to 16 different laboratories. IS The laboratories all 
used GeIMS (but used a variety of washing procedures) and were asked to test for 
AP, MA, MDA and MDMA. Two laboratories detected MA (with which the samples 
were not spiked), three failed to detect AP, two failed to detect MDA and three failed 
to detect MDMA. For the remainder, the scatter in the concordant set was: for AP (13 
positive results) 3.3-17.5; for MA (2 positive results) 0.8-1.8; for MDA (14 positive 
results) 2.5-19.S~ and for MDMA (14 positive results) 3.3-100.00. 
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Such interlaboratory testing for MDMA (and related compound) use as has been 
conducted so far does not inspire confidence, but divergent results may be because of 
insufficient sample size,46 different assay methods,47 different washing procedures, l' 
and/or because some amphetamines are notoriously volatile in the testing process 
itself. 48. Clearly, if the first can be boosted, the middle two standardised, and the latter 
overcome, then an appropriate level of faith in hair analysis might be calibrated. 
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Table 1: Sample demographics; and % reporting having used various drugs at 
least once in year prior to interview 
ex- light light medium medium heavy heavy 
users stable erratic stable erratic stable erratic 
n= 9 20 27 12 15 11 6 
% % % % % % % 
% female 67 40 48 50 67 36 33 
% aged 14-19 11 15 15 8 53 18 16 
% aged 20-24 56 40 44 42 40 46 83 
% aged 25+ 33 45 41 50 7 36 
-
cannabis 67 100 100 92 100 100 83 
alcohol 89 100 96 92 100 100 83 
ecstasy - 90 100 100 100 100 100 
tobacco 67 90 89 75 80 82 100 
amphetamine 56 80 82 100 93 91 83 
LSD 22 70 70 83 73 55 83 
cocame 11 26 63 55 75 82 100 
nitrites 44 45 39 64 64 55 20 
mushrooms 11 26 37 33 43 20 33 
temazepam - 30 19 25 57 50 33 
benzodiazepine 11 20 15 8 42 33 17 
other opiate - 10 11 25 27 10 17 
heroin 
-
11 4 17 9 
- -
temgesic - 5 4 9 18 11 -
solvent 
-
10 12 8 8 
- -
ketamine - - 8 9 - 22 -
Note: all rows do not sum to 100. None of the dlfferences 10 sample demographlcs 
are statistically significant; neither are most of the prior year drug consumption 
differences. except for cannabis and cocaine (at p<O.OOl). Drugs listed in descending 
order by prevalence in whole sample. "Light" users report using between 1,4 and 11 
tablets in the previous year; "medium" users between 12 and 47 tablets in the 
previous year, and "heavy" users 48 or more tablets in the previous year. At each 
level of use. "stable" users tended to use the same amount of "ecstasy" the same 
number of days each month. and an "erratic" user tended to have different patterns 
of use during different months. 
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ALL 
100 
% 
49 
20 
46 
34 
95 
96 
90 
84 
84 
67 
56 
48 
31 
30 
20 
14 
7 
7 
7 
6 
Table 2: Gross concordance between "ecstasy" (and/or related compounds) 
reportedly consumed, and nglmg found (n=100). 
% concordant rndma rndea rnda anyxtc ap rna anya 
p 
Cohen'sK 
"ecstasy" 43% 33% 27% 55% 22% 32% 34% 
consumption - - - - - - -
0.05 0.07 0.03 0.09 0.03 0.05 0.05 
amphetamine 37% 31% 27% 51% 24% 32% 34% 
consumption 
- - - - - - -
-0.07 0.01 -0.01 -0.01 0.02 0.02 0.02 
"ecstasy" and/or 41% 25% 21% 55% 14% 24% 26% 
amphetamine - - - - - - -
consumption 0.05 0.02 0.02 0.08 -0.00 -0.00 -0.00 
22 
any 
59% 
-
0.08 
55% 
-
0.01 
59% 
-
0.06 
Fagan 1: Gross concordance and non-concordance (% & n = 100) 
LAB 
Yes 
Yes 52 
SELF (+) 
No 5 
(-ive) 
No 
36 
(+ive) 
7 
(-) 
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Table 3: Demographics of those who confess to "ecstasy" use and who also test 
positive for at least one of the fIVe methamphetamines or amphetamines; and 0/0 
reporting using various drugs at least once in year prior to interview 
ex- light light medium medium heavy heavy 
users stable erratic stable erratic stable erratic 
n= 13 13 6 7 9 4 
% % % % % % % 
% female 
-
46 46 67 71 33 50 
% aged 14-19 - 15 8 - 4 2 -
% aged 20-24 - 46 46 33 29 44 100 
% aged 25+ - 39 46 67 14 33 -
alcohol - 100 100 100 100 100 75 
-
92 100 100 100 100 100 
cannabis - 100 100 83 100 100 75 
amphetamine - 77 85 100 86 89 75 
tobacco - 85 77 83 86 78 100 
LSD - 85 62 100 86 67 100 
cocaine 
-
42 92 20 67 78 100 
nitrites - 46 31 80 83 67 25 
te am - 39 23 33 67 50 25 
mushrooms - 33 39 33 43 25 25 
benzodiaze~ine - 23 31 - 60 29 -
other opiate - 15 8 33 60 13 -
heroin - 17 8 17 - - -
solvent - 15 15 - - - -
temgesic - 8 - - 20 14 -
ketamine - - 15 - - 14 -
. 
. . Note: all rows do not sum to 52. None of the differences IS statistIcally slgmflcant • 
Drugs listed in descending order by prevalence in whole sample. "Light" users report 
using between 1,4 and 11 tablets in the previous year; "medium" users between 12 and 
47 tablets in the previous year, and "heavy" users 48 or more tablets in the previous 
year. At each level of use, "stable" users tended to use the same amount of "ecstasy" 
the same number of days each month, and an "erratic" user tended to have different 
patterns of use during different months. 
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ALL 
52 
% 
50 
17 
46 
37 
98 
98 
96 
85 
83 
79 
67 
52 
38 
34 
25 
18 
9 
8 
7 
6 
Table 4: Net coacordaace betweea "ecstasy" consumed, and nglmg discovered 
(a=5%) - aD Peanoa's' coefficients. 
Pearson's r mdma mdea mda three ap ma two 
(n) og ng ng mng ng ng ang 
p 
-ecstasy-
-.1022 -.1739 -.2744 -.0518 -.1236 -.2016 -.1392 
consumption (36) (20) (16) (52) (8) (19) (52) 
.553 .463 .304 .715 .771 .408 .325 
five 
mng 
-.1008 
(52) 
.477 
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Table 5: Net concordance between "ecstasy" reportedly consumed, and nglmg 
found (n=52) - means and ranges for ordinal groups 
Mean(*) 0=23 2=14 n=7 n=8 N=52 
range ofng <1 tab 1-3 tabs 3-8 tabs 8+ tabs 
mdmang 2.7 (9) 15.3 (6) 1.1(1) 10.8 (-) 7.0 (16) 
0.1-13.7 0.1-82.9 0.5-3.3 0.3-55.8 0.1-82.9 
mdeang 3.8 (14) 3.1 (9) 2.4 (5) 2.4 (4) 3.2 (32) 
0.2-15.0 0.1-10.5 0.9-3.9 0.1-8.9 0.1-15.0 
mdang 3.2 (14) 0.9 (12) 0.2 (5) 1.0 (5) 2.1 (36) 
0.1-8.6 0.8-1.0 0.1-0.2 0.5-1.4 0.1-8.6 
threemng 4.4 (-) 9.9 (-) 1. 7 (-) 12.4 (-) 6.8 (-) 
0.0-30.4 0.0-93.4 0.1-7.2 0.3-57.2 0.0-93.4 
apng 5.0 (19) 51.5 (12) - (7) 6.4 (6) 16.9 (44) 
1.2-13.3 5.2-97.7 
- - -
2.4-10.4 1.2-97.7 
mang 7.4 (12) 7.1 (8) - (7) 0.7 (6) 6.6 (33) 
0.6-32.3 0.6-28.0 
- - -
0.6-0.7 0.6-32.3 
twoang 4.4 (-) 10.4 (-) - (7) 1.8 (-) 5.0 (-) 
0.0-32.3 0.0-99.9 
- - -
0.0-11.1 0.0-99.9 
fivemng 8.8 (-) 20.3 (-) 1.7(-) 14.2 (-) 11. 7 (-) 
0.0-59.5 0.0-193.3 0.1-7.2 0.3-59.6 0.0-193.3 
mdmang+ 4.3 (6) 17.2 (6) 2.7 (-) 12.0 (-) 8.1 (12) 
mdeamg 0.1-21.8 0.1-93.4 0.5-7.5 0.3-55.8 0.1-93.4 
• Figure in parenthesis • no. of negative cases 
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Table 6: Analysis of 15 substances, bought as "ecstasy" 
street name type believed actual % other active substances 
contents MDMA 
clog tablet MDMA 20 
madman tablet MDMA 21 
white dove tablet MDMD+ S8 
heroin 
pink snowball tablet MDMA+ 20 
rhubarb and capsule MDMA 17 
custard 
emerald E capsule MDMA,LSD trace· 46% Amphetamine; 
Amphetamine, 41% Caffeine 
turbo tablet MDMA 21 
blaster tablet MDMA 46 
madwoman tablet MDEAor 70 
MDA 
madman powder MDMA 68 
disco biscuit tablet MDMA 31 trace ofMDEA 
tablet MDMA 43 
super dove tablet MDMA 68 trace ofMDEA 
white tornado powder MDMA 13 
lemon and lime capsule MDMA 19 I%MDEA 
Avera2e 34 
• = less than 1% 
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THE USE OF SUPERCRITICAL FLUID EXTRACTION FOR THE 
DETERMINATION OF AMPHETAMINES IN HAIR 
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ABSTRACT 
A laboratory study interested in the analysis of human hair for drugs of abuse was 
conducted to determine if drugs could be detected and quantified from hair. 
Supercritical fluid extraction (SFE) techniques followed by GC/MS analysis were 
applied to extract amphetamines from hair. The group of amphetamines included 
methylenedioxyamphetamine (MDA), methylenedioxymetamphetamine (MDMA), 
methylenedioxyethylamphetamine (MDEA) and internal standard mephentermine (MP). 
To validate information on an1phetamine use in hair, powdered hair samples free from 
drugs were collected and soaked in a known amphetamine standard solution. Authentic 
fortified case hair samples taken from known drugs users known to have consumed 
amphetamines were also analyzed for amphetamine. 
Results from this study show that amphetamine use can be detected in spiked and 
authentic fortified human hair using SFE techniques for qualitative and quantitative 
reproducible results. 
Key Words: Hair analysis, Supercritical fluid extraction, methylenedioxy-amphetamine, 
methylenedioxyethylamphetamine, methylenedioxymethamphetamine 
* Corresponding author 
INTRODUCTION 
Most of the literature written dealing with the detection of amphetamine in hair has 
come from Japanese researchers. This is mainly because of the vast amphetamine 
consumption in the East that has prompt increase analytical research. In the past, target 
drugs have been amphetamine (AP) and methamphetamine (MA), however, more 
recently MDA derivatives like MDMA are of particular interest. 
Nakahara published a detailed review in 1995 on the detection of amphetamines in 
hair. I Techniques published before 1990 used acid or alkaline hydrolysis or a 
combination of hydrochloric acid and methanol followed by SPE or LLE and 
derivatised. Recently Rohrich and Kauert developed a screening procedure for the 
simultaneous detection of AP. MA. MDA. MDMA and MDEA based on methanol 
sonication with methaqualone used as the internal standard.2 Kintz and Cirimele 
compared four different procedures for AP, MDA and MDMA (methanol sonication 
and acid, alkaline and enzymatic hydrolysis) where alkaline hydrolysis was determined 
. . 3 
to give greatest recoveries. 
The detection of amphetamine and ecstasy in hair is becoming of growing interest in the 
forensic laboratory. Since Moeller el (II first identified MDMA in human hair, it has 
become one of the most frequently identified, especially in Europe.4 Therefore, it is 
included in all screening procedures. 
There are various techniques used for the extraction of drugs from hair. Conventional 
techniques such as solid-phase extraction have been a popular choice, along with 
alkaline or acid hydrolysis and enzymatic digestion techniques. However, more recent 
techniques such as supercritical fluid extraction has been applied for the extraction of 
drugs of abuse from human hair. 
Supercritical fluid (SF) is a substance that is above its critical temperature and pressure. 
Supercritical extraction depends on the ability of the SF to selectively dissolve various 
amounts of nonvolatile substances.5 The favorable mass transport properties and ability 
to vary the temperature and pressure of the SF, changes the solvent properties to be able 
to extract substances from various matrices. For these reasons researchers have 
investigated the use of SFE as an alternative to conventional methods for drug analysis 
in hair. b.7 
Although, the analysis of amphetamine and its analogues (e.g. MDMA. MDEA and 
MDA) have been detected in hair using several extraction techniques. there is no present 
literature on the extraction of hair for amphetamines by SFE. It was Sachs and Uhl II 
and Sachs and Raff 9 that demonstrated for the first time the use of supercritical fluids in 
the extraction of drugs in hair. Sinc\;! then there has been studies fur the extraction of 
. d .. h' 10 II opIates an cocame III air. . 
The purpose of this study was to investigate the use of SFE for the detection of MDA. 
MDMA and MDEA in human hair. Second. to optimize a method that would extract 
and identify the selected amphetamines. Also. to determine if this method can be used 
for the extraction of authentic case samples. 
Experimental 
Materials 
Chloroform and Isopropyl alcohol AnalaR grade were supplied by Merck (Poole. UK). 
Ethyl Acetate chromatographic (HPLC) grade (Analytical Sciences Lab-Scan Dublin. 
Ireland). Pentafluoropropionic anhydride (PFPA) was supplied by Fluka Chcmika. 
C0 2 Air Products (Walton-on-Thames, UK). SFE vials 6ml Hypovial™ (Pierce. Oud-
Beyerland, The Netherlands), Butyl rubber septa (Pierce and Warner. Chester. UK) and 
columns for SFE were 3cm x 4.6 mm i-d. stainless steel tubing. 
Stock solutions 
Drug and internal standard stock solutions were prepared in methanol (1 ~lg Iml and 
10~g Iml). 
Sample Conditions and Prcp~,ration 
It is necessary to wash the hair to remove any exogenous contaminates. prior cosmetic 
treatments and grease that can interfere with analysis or create false positives. The 
samples are first washed with sodium dodecyl sulfate (detergent) followed by a 
dichloromethane wash, a methanol wash and a tinal wash with distilled water. Each 
stage was repeated twice followed a 15 minute sonication at room temperature and dried 
at room temperature. 
After being washed and dried, blank hair samples were finely cut and weighed out into 
50 mg samples. The blank sample was spiked with 10 ng/mg of drug standards (e.g. 
MDA, MDMA and MDEA) in a glass vial. To ensure the hair was coated sufficiently, 
3 ml of MeOH was added to the vial, sealed and sonicated for 15 minutes then opened 
and left overnight to dry at room temperature. The internal standard for all drugs was 
added to the hair during hair spiking preparation or after extraction for recovery 
purposes. 
It is possible that this method of spiking is not the most ideal, as most drugs coat the 
surface of the hair and possibly do not incorporate into the hair structure. However, it is 
accurate enough for estimation of exact concentration levels and is the only way to 
spike hair samples with known concentrations. 
SFE Parameters 
A Gilson 308 "master" pump, which controlled a 306 "slave" pump and regulated the 
pressure, CO2 amount, modifier and flow rate was used. A Gilson 811 B dynamic mixer 
combined the solvent with CO2 and a Gilson 821-pressure regulator controlled by the 
308 pump regulated the pressure. 
Placed in-line between the 811B mIxer and the extraction cell, an HPLC 7125 
Rheodyne valve was housed inside an 831 Gilson temperature regulator (oven), for the 
application of the gas and modifier to the cell. A second valve located below the 7125 
valve, was used to switch the extraction from static to dynamic (continuous) mode. 
SFE pressure conditions were set at 3800 psi with the flow rate at set 2ml Imin and 
temperature 70° C. Modifier was Chloroform and Isopropyl alcohol (90: 1 0 v/v) pumped 
at 10 % in 90 % C02 in dynamic extraction mode for 30 minutes. Derivatise by adding 
50~1 ofPFPA: Ethyl acetate (1:1v/v) and analyzed using GC/MS. 
GCIMS Parameters 
A Hewlett-Packard gas chromatography model 5890 fitted with a VG Analytical VG70-
250S mass spectrometry was used for analysis. The GC was fitted with a HP-5 X- link 
5 % PH Me silicone capillary column 30 111 x 0.25 ~l1n, 0.88~l111 film thickness. 
The selected ions were monitored in the electron ionization mode at 70 e V and the trap 
current was set at 200 ~A. The initial temperature was 55° C held for 2 minutes and 
final temperature was 2800 C held for 5 minutes. The oven rise was at a rate of 20 
Celsius 0 per min. The ions monitored were m/z 218 mephentermine (internal 
standard), mlz 325 MDA, m/z 339 MDMA and mJz 353 MDEA. 
Results and Discussions 
Under the developed SFE parameters from amphetamines, hair samples were extracted 
and analyzed using GC/ MS. At lOng /mg hair samples produced recoveries at an 
average of 84 % for MDA. 71 % for MDMA and 77 % for MDEA. These results are 
summarized in Table I. 
For the linear calibration of each drug, the method proved linear over a concentration 
range of 0 to 20ngl mg of hair was investigated. The limit of detection for MDA was 
0.02nglmg and O.lng/mg for MDMA and MDEA. Table 2 shows the method validation 
for MDA. MDMA and MDEA. 
The reproducibility of this method was investigated and was found to be relatively 
reproducible from sample to sample extraction. The results are summarized in Table 3. 
Intra and inter-day reproducibility produced comparable results from sample to sample 
and day to day. Tables 4 and 5 shows the peak area ratios produced for day one and day 
two for MDA, MDMA and MDEA. 
For 10ng/mg MDA, MDMA and MDEA for day one, the standard deviation was 0.595, 
0.200 and 0.148, the mean 2.102, 1.804 and 0.692 and the RSD 28 %, II % and 21 %. 
For MDA, MDMA and MDEA for day two, the standard deviation was 0.507, 0.565 
and 0.214, the mean 2.5022, 2.1318, 1.2960 and RSD 20 %, 26 % and 16 %. 
There was some variation between the two days but comparable. MDEA for day one is 
much lower than for day two. A possible explanation for this could be because of the 
spiking of the blank hair. Spiking blank hair with a drug does not incorporate into the 
hair as fortified hair samples, therefore not all the time will there be precise consistency 
from batch to batch. However, it is accurate enough for estimation of exact 
concentration levels and is the only way to spike hair samples with known 
concentrations. Also the sensitivity of the GC/MS from day to day can be a possible 
contributory factor. 
Hair samples taken from subjects participating in the self-report study for amphetamine 
use which were analyzed under SFE conditions. The samples were too small to be 
separated into segments of root or tip so they were analyzed in bulk or Full. Before 
analysis, the hair samples were washed and dried under the aforementioned wash 
conditions and the colour, weight and length were applicable of each hair sample were 
recorded. Table 6 lists twenty cases analyzed for MDA, MDMA and MDEA. 
Out of the 20 samples analyzed, 5 were positive for MDA, MDMA and MDEA, 4 were 
positive for MDMA only, 2 were positive for MDA and MDMA only, 1 was positive 
for MDMA and MDEA only and 8 were not found to contain drugs. Samples that were 
not detected may have contained drugs below the limit of detection. Below in Figure 2 
are the result summarized for the case samples positive overall for all three drug. 
Samples that were listed as not detected are not included. There were 7 overall MDA 
positives, 11 MDMA positives and 6 MDEA positives. 
The self-report data was compared to the SFE findings from the hair samples to find if a 
correlation existed. It was found that some of the subjects that reported no use or little 
use (e.g. half an ecstasy tablet monthly) over the past 12 months were found to be 
negative and others found positive with low levels detected. Figure 3 summarizes the 
results of the self-report data to the hair findings. Out of the 20 hair samples analyzed, 
11 (55 %) were positive for all or either MDA, MDMA or MDEA and said yes to 
consuming ecstasy. 3 (15 %) were also positive but disagreed with having taken any 
ecstasy and 6 (30 %) were negative for MDA, MDMA or MDEA, but agreed with 
having consumed ecstasy in the past 12 months. There was no one that claimed to be 
negative and was found to be negative. 
CONCLUSION 
Supercritical fluid extraction is a good technique that can be used as an alternative 
extraction method to conventional techniques. Among its many advantages, SFE is fast, 
inexpensive and produces less solvent waste. The use of SFE for the extraction of hair 
has been reported in various studies. Despite the controversial aspects of hair testing, 
the use of hair analysis is rapidly expanding. 
The aim of this study was to determine if amphetamines. MDA, MDMA and MDEA. 
could be extracted from hair samples using SFE, optimize a method for extraction and 
its application to authentic hair samples. The results demonstrate that MDA, MDMA 
and MDEA can be extracted from hair under the developed SFE conditions. Recoveries 
better than 84 %, 71 % and 77% were produced for MDA, MDMA and MDEA. Based 
on spiked hair samples, the method was found to be linear of a concentration range of 
0.02 to 20 ng/mg of hair. The correlation coefficient (r2) for MDA, MDMA and MDEA 
was 0.9703, 0.9775 and 0.9938 showing the linearity of the method. The method was 
also found to be reproducible from sample to sample and on a day to day basis. 
It has also been demonstrated that by the application of a polar modifier directly 
through the system providing better extraction conditions for the drugs of interest. By 
varying the temperature and pressure for optimal conditions increased the extraction 
potential. Temperature and pressure are the two main parameters that effect SFs. An 
increase in pressure at a constant temperature, increasing the density and mass transfer 
of the SF to allow more polar and higher molecular weight analytes of interest to be 
eluted. 
Authentic hair samples taken from subjects participating in a self-report study were 
analyzed using developed SFE techniques. Out of the 20 samples analyzed, 7 overall 
were positive for MDA, 11 for MDMA and 6 for MDEA, Samples were positive for 
either MDA or MDMA or a combination of MDA, MDMA and MDEA. Samples that 
were not detected may not have been negative, but had levels too low to detect using 
this method. The results from the hair analysis were compared to the self-report data 
collected to find if a correlation existed between the two. It was found that with some 
of the subjects, a correlation did exist between what they had reported consumption 
from month to month and hair findings and others it did not. The accuracy of the self-
report data was questionable because of the possibility of under or over reporting of 
consumption and whether or not what was taken contained MDA, MDMA or MDEA. 
It can be concluded that, SFE IS an appropriate method for the extraction of 
amphetamines in hair. It is fast (30 minutes), reproducible and can be applied to 
authentic hair samples with results comparable to those generally observed in hair 
analysis. 
REFERENCES 
1. Y. Nakahara, Detection and Diagnostic Interpretation of Amphetamines in Hair, 
Forensic Science International, 70, (1995), 135 
2. J. Rohrich and G. Kauert, Determination of Amphetamine and Methylene-
dioxyamphetamine derivatives in Hair. Forensic Science International, 84, (1997). 
179 
3. P. Kintz and V. Cirimele, Interlaboratory Comparison of Quantitative Determination 
of Amphetamines and Related compounds in Hair Samples. Forensic Science 
International, 84, (1997), 151-156 
4. M. R. Moeller, H. H. Maurer, M. Roesler in: Tnagata (editor), Proceedings of the 
30th TIAFT Meeting, Fukuoka, October 1992, Yoyodo Printing, Kaisha, (1992), 347 
5. W. B. Streett, Phase Equilibria in Fluid and Solid Mixtures at High Pressure, in 
Chemical Engineering at Supercritical Fluid Conditions, Eds. M. E. Paulaitis, J .. M. 
L. Penninger and R. D. Gray, P. Davidson, Ann Arbor Science, An Arbor MI, 
(1983),3 
6. C. Staub, P. Edder and J. Veuthey, Importance of Supercritical fluid Extraction 
(SFE) in Hair Analysis. Drug Testing in Hair, Ed, P. Kintz, CRC Press. Inc. Boca 
Ration, Florida, (1996), 121-149 
7. R. J. Maxwell and J. F. Morrison, Handbook of Analytical Therapeutic Drug 
Monitoring and Toxicology; S. Wong, I. Sunshine, Eds.; CRC Press, Inc.; Boca 
Ration, FL (1997), Chap 5 
8. H. Sachs and M. Uh1, Opiat-Nachweis in Haar-extrakten mit Hilfe von GC/MS/MS 
und Supercritical Fluid Extraction (SFE), Toxichem. Krimtech., 59, (1992), 114-120 
9. H. Sachs and I. Raff, Comparison of Quantitative results of Drugs in Human Hair by 
GCIMS, Forensic Science International, 63, (1993), 207-216 
10. P. Edder, C. Staub, J. Veuthey, I. Pierroz and W. Haerdi, Subcritical Fluid 
Extraction of Opiates in Hair of Drug Addicts, Journal of chromatography B., 658, 
(1994), 75-86 
11. J. F. Morrison, W. A. MacCrehan and C. M. Selavka, Evaluation of Supercritical 
Fluid Extraction for the Selective Recovery of Drugs of Abuse from Hair, 2nd 
International Meeting on Clinical and Forensic Aspects of Hair Analysis, national 
Institute on Drug Abuse. Special Publication, submitted, (1995) 
Figure 1 Chromatography of a 10 ng/ mg hair sample of MDA, MDMA and MDEA 
extracted using supercritical fluid extraction. 
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Table 1 The average recovery of amphetamines from hair 
DRUG %AVG UN EXTRACTED PAR RANGE 
RECOVERY STDPAR 
MDA 84.2 1.6722 1.0976 - 1.5090 
MDMA 71.2 0.7352 0.4071 - 0.7345 
MDEA 77 0.3785 0.2294 - 0.3690 
Table 2 Method validation for amphetamines in hair. 
DRUG Correlation Cone. range LOD Intercept SLOPE 
coefficient (r2) ng/mg ng/mg B A 
MDA 0.9703 0.02 - 20 0.02 0.4736 0.085 
MDEA 0.9775 0.02 - 20 0.1 0.3535 0.0106 
MDMA 0.9938 0.02 - 20 0.1 0.2870 0.0581 
Table 3 Reproducibility of amphetamines in hair at 2ng/mg. 
DRUG MEAN RANGE StdDev %RSD 
MDA 1.2761 1.2309-1.3241 0.038 ±3 
MDMA 1.1079 0.9470-1.2779 0.165 ± 14 
MDEA 0.6522 0.577-0.7230 0.059 ±9 
Table 4 Day one reproducibility of each drug 
DRUG UNEXTSTD 1 2 3 4 5 
MDA 2.119 1.913 1.1897 2.7397 2.2025 2.4690 
MDMA 2.0746 2.068 1.788 1.939 1.6371 1.5929 
MDEA 2.0549 0.456 0.677 0.855 0.7037 0.7699 
Table 5 Day two reproducibility of each drug 
DRUG UNEXTSTD 1 2 3 4 5 
MDA 3.3182 2.1934 2.1173 2.6670 3.3232 2.2103 
MDMA 2.5970 1.7711 1.8597 1.9111 3.133 1.9840 
MDEA 2.0833 1.1376 1.2789 1.1837 1.6681 1.2103 
Table 6 Case samples analyzed for MDA, MDMA and MDEA 
CASE # MDA ng/mg MOMAng/mg MOEA ng/mg Length em Weight mg 
A99-A 0.255 0.638 0.396 11 60 
A99-B 0.125 0.288 0.067 4 30 
A99-C 0.252 0.153 0.171 11 40 
A99-0 NO 0.117 ND 11 70 
A99-E NO 0.659 0.286 11 19 
A99-F NO NO ND 12 78 
A99-G NO NO NO 11 60 
A99-H 0.274 0.53 0.11 5 35 
A99-1 0.061 0.336 0.082 4 20 
A99-J NO NO NO 11 53 
A99-K NO 3.88 ND 11 60 
A99-L NO NO ND 11 21 
A99-M 0.059 1.15 ND 12 10 
A99-N NO NO NO 11 40 
A99-0 ND ND ND 2 66.5 
A99-P NO NO NO 2 7 
A99-Q 2.14 6.44 NO 8.5 10 
A99-R NO 0.71 NO 11 9 
A99-S NO l.62 ND 11 10 
A99-T NO NO NO 11 52.5 
NO = Not detected 
Figure 2 Chart of overall po iti cas s 
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Figure" elf-report data ompur d to hair analysis for MDA, MDMA and MDEA 
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